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Native and bioprosthetic aortic valve diseases are an increasingly common clinical 
challenge as a consequence of the ageing demographic and the expansion of new valve 
technology. In both conditions, there remains substantial scope to broaden our 
understanding of the pathophysiology, improve diagnostic sensitivity and accuracy, 
and develop new markers of disease activity with which to measure therapeutic effect. 
Computed tomography (CT) and positron emission tomography (PET) are non-
invasive imaging assessments that combine high resolution anatomical detail with 
real-time functional information about disease activity, and as such are ideally suited 
to complement echocardiography in the investigation of native and bioprosthetic aortic 




Volunteers with aortic stenosis (n=143) across a range of severity underwent 
echocardiography, CT aortic valve calcium scoring and contrast-enhanced CT 
angiography. Aortic valve fibrosis and calcification were quantified to produce two 
novel measures: the fibro-calcific ratio and fibro-calcific burden. From the same study 
population, a subset of 15 volunteers underwent hybrid 18F-fluoride PET/CT on two 
separate occasions and we investigated different methods of image analysis to optimise 




Explanted degenerated bioprosthetic valves (n=16) were examined ex vivo using 
histopathology and preclinical 18F-fluoride PET/CT. Patients with bioprosthetic aortic 
valves (n=78) were then recruited into two cohorts, with and without prosthetic valve 
dysfunction, and underwent in-vivo contrast-enhanced CT angiography, 18F-fluoride 




Contrast-enhanced CT calcium volume correlated closely with conventional CT 
calcium score in the aortic valve (r=0.86, p=<0.001). Fibrosis dominated in mild aortic 
stenosis while calcification dominated in severe stenosis (fibro-calcific ratio: 1.33 
[0.91-2.4]) versus 0.53 [0.35-1.05] respectively; p=0.001).  Males exhibited more 
calcium than fibrosis, with the reverse true for females (fibro-calcific ratio: 0.89 [0.45-
1.54] versus 1.49 [0.82-5.74] respectively; p=0.001). The fibro-calcific burden 
demonstrated the strongest correlation with peak aortic-jet velocity (r=0.71, p<0.001), 
especially in women (r=0.77, p=0.001) where it outperformed CT calcium score 
(p=0.027). In our investigation of 18F-fluoride-PET/CT, contrast-enhanced, ECG-
gated PET/CT provided superior spatial localisation of 18F-fluoride uptake. Scan-
rescan reproducibility was markedly improved using enhanced analysis techniques 
leading to a reduction in variability from 25% to <10%.  
 
Bioprosthetic Valves  
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In degenerated bioprosthetic valves ex vivo, calcification was the most prevalent 
pathological feature (87%), whilst thrombus (40%) and pannus overgrowth (47%) 
were other common findings. All valves exhibited 18F-fluoride uptake on PET, with a 
strong positive correlation between 18F-fluoride uptake and calcium volume (r=0.73, 
p=0.0031). 18F-Fluoride uptake was highest in regions of leaflet calcification but also 
localised to regions of organised thrombus, fibrosis and features of matrix degradation 
on histopathology.  
 
In the cohort study of patients with bioprosthetic aortic valves, all those with 
recognised valve dysfunction exhibited abnormalities on CT and high 18F-fluoride 
uptake. In the 71 patients without valve dysfunction, 20% had leaflet pathology on CT 
and 34% had increased 18F-fluoride uptake (target-to-background ratio 1.55 [1.44-
1.88]). Patients with increased 18F-fluoride uptake exhibited more rapid deterioration 
in valve function than those without (annualised change in peak transvalvular velocity: 
0.30 [0.13-0.61] versus 0.01 [-0.05-0.16] ms-1/year, p<0.001). 18F-Fluoride uptake 
correlated with deterioration in all echocardiographic measures of valve function (e.g. 
change in peak velocity, r=0.72; p<0.001) and, on multivariable analysis, was the only 
independent predictor of future bioprosthetic dysfunction.  
 
Conclusions 
In both native aortic valve disease and bioprosthetic valve disease, CT and 18F-fluoride 
PET afford valuable insights into disease mechanisms, inform patient risk 
stratification and prognosis, and provide biomarkers of disease activity that may be 




Heart valve disease and the disease of artificial heart valves are health challenges that 
share key features and have become increasingly common as a result of the increased 
life expectancy in developed countries and the availability of new approaches to valve 
replacement for people who may not previously have been eligible. Computed 
tomography (CT) uses X-rays to build a detailed 3-dimensional image of all or part of 
the human body. Positron emission tomography (PET) involves injection of a 
substance called 18F-fluoride which binds to chalk-like material (calcium) often found 
in the heart valves and blood vessels. PET/CT then allows the areas in the body where 
18F-fluoride has attached to calcium to be identified and the strength of signal can be 
measured. In this thesis, we investigate the use of CT and PET to build a greater 
understanding of the factors that cause heart valve disease, to improve our ability to 
identify these problems, and to establish measurements that can be used to test if new 
treatments are working.  
 
Volunteers (143 people) with a narrowing of the main outlet valve of the heart (aortic 
valve), called aortic stenosis, underwent testing with an ultrasound scan and two 
different types of CT scan, one of which involved injection of an iodine-based ‘dye’ 
to light up the circulating blood. The CT scan was used to measure the amount of scar 
tissue (fibrosis) and chalk-like material (calcium) in the aortic valve. These new 
measurements were compared to standard measurements of the severity of valve 
narrowing. From the same group of volunteers, 15 people underwent PET scans using 
an identical method on two separate occasions within 3 months. We then used the 
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information from these scans to work out the best technique to make our measurements 
as accurate and repeatable as possible.  
 
In our study of artificial heart valves, we first examined 16 artificial heart valves, 
which were no longer working satisfactorily and had been removed from patients at 
the time of an operation, under a microscope and with a miniaturised form of PET/CT. 
In addition, a total of 78 volunteers with artificial heart valves participated in a study 
during which they received a PET/CT scan and annual ultrasound scans over 2 years.  
 
The results of our work in people with a narrowed heart valve (aortic stenosis) 
demonstrated that scarring (fibrosis) is particularly important in the early stages of the 
condition, and also appears to be a more significant factor in women than men. Our 
unique combined measurement of scar tissue (fibrosis) and chalk-like material 
(calcium) in the valve seemed to offer a better test of the severity of valve narrowing 
than the current widely used test to measure calcium alone.  
 
In the same condition (aortic stenosis), we experimented with different methods to 
improve measurements obtained from PET/CT. We successfully showed that using 
iodine ‘dye’ during the CT scan and taking steps to account for movement of the 
beating heart resulted in major improvements in the quality of our images and 
measurements. Also, using average rather than maximum measurements of PET signal 
in the valve resulted in much improved repeatability.  
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In our study of failing artificial heart valves that had been removed from patients, we 
found heavy build of chalk-like material (calcium) in a large majority, and evidence 
of clotted blood and scar tissue less commonly. PET/CT identified abnormalities in all 
of the failed valves and findings suggested that blood clot and scar tissue may be early 
events which eventually lead to the formation of calcium. In patients with artificial 
heart valves, we discovered that PET/CT can be used to detect valves with early stages 
of disease, long before any symptoms might develop, and to predict worsening 
performance of the artificial valve over time.  
 
In summary, CT and PET scans can be used to increase our understanding of how heart 
valves and artificial heart valves fail, to monitor progression of these conditions over 














Aortic valve disease presents a growing clinical problem, with the incidence of severe 
aortic stenosis in developed countries predicted to double over the next 30 years 
(Osnabrugge RL et al, 2013). Advances in our understanding of aortic stenosis 
pathogenesis increasingly point towards a closely regulated process that is ultimately 
dominated by calcification (Pawade TA et al, 2015). However, there are gaps in our 
knowledge of disease pathways and we have not adequately accounted for the 
subgroup of patients who develop aortic stenosis with severe fibrotic cusp thickening 
rather than calcification (Shen M et al, 2016). With no medical therapies currently 
proven to alleviate the progression of aortic stenosis, the only treatments options for 
patients with symptomatic severe aortic stenosis are aortic valve replacement or 
palliation of symptoms.  
 
Modern techniques in computed tomography (CT) allow detailed tissue 
characterisation whilst 18F-fluoride positron emission tomography-computed 
tomography (PET-CT) is a functional imaging modality with the ability to quantify 
and localise calcification activity (Irkle A et al, 2015). CT and PET-CT therefore hold 
promise in both elucidating the mechanisms of aortic stenosis and monitoring disease 
activity, providing an early measure of the efficacy of novel medical therapies to 
attenuate calcification.  
 
Aortic valve replacement may be performed via a surgical or transcatheter procedure, 
and the significant majority of valves implanted are now bioprosthetic. Bioprosthetic 
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aortic valves themselves are associated with long term complications including the 
risk of endocarditis, systemic embolism and finite durability due to structural valve 
degeneration (Rodriguez-Gabella T et al, 2017). Though the pathophysiology of 
bioprosthetic valve degeneration is not well understood, calcification again appears to 
be a central feature (Siddiqui RF et al, 2009). However, non-invasive methods for 
detecting this process have been lacking and current care relies on serial 
echocardiography to identify the valve dysfunction that occurs towards the end stages 
of the degeneration process.  
 
Here, we firstly explore the use of micro-18F-fluoride PET-CT and histological 
examination of degenerated explanted valves to illuminate the mechanisms of 
structural valve degeneration. We then assess the application of 18F-fluoride PET-CT 
in patients with bioprosthetic valves to identify structural valve degeneration and 








1.2 NATIVE AORTIC VALVE STENOSIS 
 
Epidemiology of Native Valve Aortic Stenosis 
Valvular heart disease is a common pathology, with a recent U.K. study identifying 
clinically significant (moderate or severe) undiagnosed valvular disease in 6.4% of 
individuals aged 65 years and over, in combination with 4.9% of the study population 
who had pre-existing valve disease giving a total prevalence of 11.3% (d’Arcy et al, 
2016).  Aortic stenosis is the most common clinically significant heart valve pathology 
in the developed world, characterised by progressive fibro-calcific remodelling and 
thickening of the aortic valve cusps which ultimately restricts cardiac output (Lindman 
et al, 2016). In a North American population with mean age 60 years, the annual 
incidence of new cases of aortic stenosis was ~5 per 1,000 and the prevalence of aortic 
stenosis at age 65 years was 5%. In a meta-analysis of studies conducted in Europe, 
the U.S.A. and Taiwan, the prevalence of aortic stenosis in people aged 75 years and 
over was 12.4%. Consistent with these observations, there is a significant increase in 
the prevalence of aortic stenosis with advancing age. It can therefore be anticipated 
that, with the changing population demographics of developed nations, aortic stenosis 
is set to become an increasingly common clinical challenge and place a growing 
burden on healthcare resources. Indeed, the incidence of aortic stenosis in Scotland 
increased from 246 cases per million population in 1997 to 365 per million in 2005 
(Berry C et al, 2013) and the number of people with severe aortic stenosis in Europe 
and North America is projected to double by 2050 (Osnabrugge RL et al, 2013). Whilst 
advanced age is the central feature, important sex differences are also apparent in the 
clinical presentation of aortic stenosis. The overall incidence of aortic stenosis is 
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similar in men and women, although women are more likely to present later in the 
disease trajectory, at older age and with greater frailty, renal dysfunction and evidence 
of heart failure (Kong et al, 2017).  
 
Anatomy of the Native Aortic Valve 
Under normal circumstances, the aortic valve is composed of three cusps that are 
named according to their anatomic relationship to the coronary arteries, termed the 
right coronary, left coronary and non-coronary cusps. Each cusp has a trilaminar 
structure comprising the fibrosa, spongiosa and ventricularis. The central spongiosa 
layer contains a loose matrix of glycosaminoglycans, the fibrosa with its dense 
connective tissue forms the aortic layer and the pliable ventricularis forms the 
ventricular layer. The fibrosa is primarily composed of circumferentially orientated 
type 1 and III fibrillar collagen whilst the ventricularis is composed of radially 
orientated elastin fibres, permitting greater compliance and allowing apposition of the 
free edges of the cusps to prevent regurgitation of blood flow (Schoen FJ, 2008). The 
cellular composition includes endothelial cells covering the aortic and ventricular 
surfaces of the valve, smooth muscle cells residing at the base of the ventricularis, and 
valve interstitial cells which constitute the majority of the cell population (Taylor PM 
et al, 2000).  
 
Pathophysiology of Native Aortic Valve Stenosis 
Each aortic valve cusp is a thin (<1 mm), smooth, flexible and mobile structure. In 
aortic stenosis, these cusps become thickened with fibrosis and calcification resulting 
in increasingly restricted cusp movement and valvular obstruction. Aortic stenosis has 
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conventionally been considered a degenerative “wear and tear” condition driven by 
mechanical stress and progressive valve disruption leading to tissue injury and 
calcification. However, emerging evidence supports a more complex and closely 
regulated pathophysiology. There is postulated to be an early initiation phase of lipid 
deposition and inflammation with similarities to atherosclerosis, followed by a later 




Similar to atherosclerosis, endothelial injury is triggered by high mechanical stress and 
reduced sheer stress. This at least partly accounts for the more rapid development of 
aortic stenosis in patients with congenital abnormalities of the aortic valve. A bicuspid 
aortic valve, for example, is the commonest form of congenital heart disease with a 
population prevalence of 0.5-0.8%. The two cusp structure results in less effective 
dissipation of mechanical stress, accelerated endothelial damage and disease 
progression, with a mean age under 50 years at the time of aortic valve replacement 
surgery (Pachulski et al, 1993; Coffey et al, 2016). Aortic stenosis and atherosclerosis 
also share important risk factors with large studies demonstrating an association 
between the incidence of aortic stenosis and age, cigarette smoking, diabetes mellitus 
and hypertension (Thanassoulis et al, 2010; Stewart et al, 1997; Stritzke et al, 2009). 




Endothelial injury is accompanied by early histological changes including deposition 
of low-density lipid predominantly within the fibrosa (Otto et al, 1994). A variety of 
lipids have been associated with aortic stenosis including total cholesterol, low-
density-lipoprotein (LDL) cholesterol, oxidised LDL cholesterol, lipoprotein(a), 
apolipoprotein B, triglycerides and proprotein convertase subtilisin/kexin type 9 
(PCSK9). Lipoprotein(a) is an LDL-like particle that carries apolipoprotein B-100 and 
is the main transporter of oxidised phospholipids. Oxidised phospholipids are a key 
driver of vascular inflammation and atherosclerosis, with substantial evidence of an 
adverse role in ischaemic heart disease, cerebrovascular disease, peripheral arterial 
disease and risk of cardiovascular death (Capoulade et al, 2015). Circulating plasma 
levels of both lipoprotein (a) and oxidised phospholipids are associated with incident 
aortic stenosis, haemodynamic progression of aortic stenosis, need for aortic valve 
replacement and cardiovascular death (Zheng et al, 2019; Tsimikas S et al, 2012). 
Levels of lipoprotein (a) are almost entirely genetically determined, and a single 
nucleotide polymorphism of lipoprotein (a) has been identified as the only single 
nucleotide polymorphism to reach genome-wide significance for the presence of aortic 
valve calcification (Thanassoulis et al, 2013).  
 
During the early phase of aortic stenosis, endothelial disruption, infiltration and 
oxidisation of lipid particles drives translocation of immune cells into the valve and 
production of pro-inflammatory cytokines. The early inflammatory response is 
histologically characterised by increased presence of non-foam cell macrophages and 
foam cell macrophages (macrophages that have engulfed lipid), T lymphocytes and 
small numbers of alpha-actin-positive cells. These features become more marked as 
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aortic stenosis progresses (Otto et al, 1994). Endothelial damage results in 
upregulation of cell adhesion molecules such as ICAM-1 and VCAM-1 which triggers 
an influx of leucocytes, principally monocytes (Sucosky P et al, 2009). Monocytes 
differentiate into macrophages and these cells release cytokines such as TNF-alpha, 
TNF-beta and IL-1 beta which stimulate the inflammatory response (Steiner I et al, 
2012). Gene expression profiling in aortic stenosis confirms the upregulation of 
various chemokines and chemokine receptors (Bosse et al, 2009).  
 
The adaptive immune system is also implicated in the pathogenesis of aortic stenosis. 
Elevated numbers of T lymphocytes are found in the peripheral blood and aortic valves 
of people with aortic stenosis, in particular multiple oligoclonal CD4+ and CD8+ T 
cells (Wu HD et al, 2007; Winchester R et al, 2011). T lymphocyte proliferation may 
occur not only in lymphoid tissue but also in the valve itself where these cells secrete 
further pro-inflammatory cytokines. B lymphocytes are not normally found in cardiac 
valves, however, CD20+ B cells and CD138+ plasma cells infiltrate the subendothelial 
layer on the aortic surface of diseased aortic valves. B lymphocytes can be activated 
by macrophage-secreting cytokines, such as B cell-activating factor belonging to the 
TNF family (BAFF). There is a positive correlation between the number of BAFF 
receptor-positive B cells and disease severity in aortic stenosis (Natorska et al, 2016).  
 
Furthermore, mast cells exhibit an increase in number in valve tissue in aortic stenosis, 
again mainly localising to the subendothelial space of the aortic surface of the valve 
and associating with macrophages. When activated, mast cells release cathepsin G 
which causes elastin degradation in the disease valve (Helske S et al, 2006). The other 
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significant mast cell effect is to promote angiogenesis in valve tissue via production 
of vascular endothelial growth factor (VEGF). And tryptase, which inhibits levels of 
the angiogenesis inhibitor endostatin (Syvaranta S et al, 2010).  
 
Propagation Phase 
Microcalcification is observed histologically even in the early lesion of aortic stenosis, 
colocalising with regions of lipid infiltration (Otto et al, 1994). It is likely that early 
calcification in the form of hydroxyapatite is mediated by cell death and release of 
apoptotic bodies containing calcium and inorganic phosphate. Thereafter calcification 
is thought to become the fundamental and self-perpetuating mechanism by which 
aortic valve stenosis progresses in severity.  
 
In the context of inflammation, valve interstitial cells (VIC) can differentiate into 
myofibroblasts and osteoblast-like cells. A number of cytokines have been shown to 
facilitate this, including interleukin (IL)-1beta, IL-6, IL-8, insulin-like growth factor 
(IGF)-1, tumour necrosis factor (TNF)-alpha and tissue growth factor (TGF)-beta (Jian 
B et al, 2003; New SE, et al, 2011). Myofibroblasts are capable of absorbing lipid and 
producing pro-inflammatory cytokines and chemokines. Myofibroblasts also produce 
extracellular collagen and tenascin-C resulting in changes to the composition of the 
extracellular matrix and tissue fibrosis. This collagen matrix provides a structural 
template upon which calcification may develop (Heinz B, 2007). Osteoblast-like cells 
secrete bone morphogenic protein 2 (BMP-2) and osteopontin which stimulate 
mineralisation, and express runt-related transcription factor 2 and osterix which 
encourage further osteoblastic differentiation (Yang X et al, 2009 a). The 
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inflammatory and pro-calcific functions of valve interstitial cells are closely 
associated, with in vitro activation of inflammatory processes correlating strongly with 
valvular calcification (Yang X et al, 2009 b).  
 
As mineralisation advances, it develops a more organised crystalline structure with 
features of lamellar bone (Pawade et al, 2015). Interestingly, valve ossification is 
contingent upon angiogenesis and the role of mast cells in this regard is described 
above. In established aortic valve disease, osteoblastic differentiation is maintained by 
mechanisms including Notch, Wnt and receptor activator of nuclear factor kappa B 
(RANK), receptor activator of nuclear factor kappa B ligand (RANKL) and 
osteoprotegerin (OPG) pathways. Notch cell surface receptors are widely expressed in 
the aortic valve and a Notch-1 loss-of-function mutation predisposes to potent 
osteoblastic differentiation via the action of BMP-2 (Nigam V et al, 2009). This 
mutation has been identified in families with premature vascular and aortic valve 
calcification (Garg et al, 2005). Wnt binds to LDL receptor-related proteins to activate 
the Wnt/beta-catenin pathway that again drives osteoblastic differentiation. TGF-beta1 
is stimulated by mechanical stress and further promotes Wnt signalling, thus 
establishing a perpetual cycle of increasing morphological disruption and 
haemodynamic turbulence (Chen et al, 2011). In bone marrow stromal cells, RANKL 
binds to RANK and induces osteoclastic differentiation and activity, resulting in 
demineralisation of bone. This is regulated by OPG which is a competitive inhibitor 
of RANK. By contrast in the aortic valve and vasculature, RANKL promotes 
osteoblastic differentiation and upregulation of BMP-2. VICs adopt an osteoblastic 
phenotype resulting in greater expression of alkaline phosphatase and osteocalcin, 
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increase in matrix mineralisation and formation of calcific nodules. The contradictory 
effects of RANK/RANKL in bone marrow and valve tissue may in part be due to the 
presence of a pre-osteoclast population of cells in bone which favours pro-osteoclastic 
activities, whereas no such pool exists in the vasculature and pro-osteoblastic effects 
prevail. The paradox is exemplified in OPG-deficient mice that suffer from 
osteoporosis but also exhibit accelerated vascular calcification (Bucay N et al, 1998). 
In stenotic aortic valves, there appears to be reduced OPG expression and increased 
levels of RANKL (Kaden JJ et al, 2004) 
 
Ectonucleotide pyrophosphate 1 (ENPP1) is manufactured by VICs in order to regulate 
extracellular production of inorganic phosphate. ENPP1 is highly upregulated in 
calcific aortic valve disease and a polymorphism to this effect is found in diseased 
valves. ENPP1 results in the hydrolysis of adenosine triphosphate (ATP) and 
production of inorganic phosphate. Depletion of ATP induces cell apoptosis and 
further stimulates ENPP1 production in a positive feedback loop. This may be another 
important mechanism by which the cycle perpetuates such that ‘calcium begets 
calcium’ (Cote N et al, 2012) 
 
Fibrosis 
Fibrotic remodelling is a consistent finding in histological studies of aortic stenosis 
and leads to increased stiffening of the valve cusps, escalation of adverse mechanical 
stress and contributes to calcification of the valve (Lindman BR et al, 2016; Otto et al, 
1994). Under the influence of cytokines, integrin expression and TGF-beta 1, activated 
myofibroblasts in the diseased aortic valve increase production of collagen, alpha-
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smooth muscle actin and extracellular matrix proteins such as tenascin-C and 
proteoglycans. Angiotensin converting enzyme is also believed to play an important 
role. It is delivered to the valve tissue by LDL, where chymases and cathepsin G 
(produced by mast cells) promote conversion of angiotensin I to angiotensin II. The 
latter is a potent driver of vascular inflammation and fibrosis. Recent studies have 
further implicated altered expression of regulating proteins including Klotho and 
plasminogen activator inhibitor in directing this process (Chen J et al, 2018; (Chen J 
et al, 2016).  
 
The relationship between aortic valve calcification and haemodynamic stenosis is 
imperfect, and there are patients in whom significant aortic stenosis develops in the 
absence of notable calcification. This has been observed, in particular, in younger 
female patients and those with bicuspid aortic valves. Fibrosis may therefore be an 
important but under-appreciated mechanism in the pathogenesis of aortic stenosis that 





Proposed mechanisms in the pathogenesis of aortic stenosis 
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BMP = bone morphogenetic protein; ENPP1 = ectonucleotide pyrophosphate 1; LDL = low-density lipoprotein; 
RANK = receptor activator of nuclear kappa B; RANKL = receptor activator of nuclear kappa B ligand; VIC = 




Clinical Imaging in Native Aortic Valve Stenosis 
 
Doppler echocardiography, computed tomography (CT) and more recently positron 
emission tomography (PET) have all been employed to help characterise native aortic 
valve stenosis. Together these imaging modalities have informed our understanding of 
disease aetiology, underpin the assessment of disease severity, and help us to predict 
both haemodynamic progression and clinical outcomes.  
 
Echocardiography  
Echocardiography is well established as a mainstay of routine clinical assessment in 
aortic stenosis. Doppler ultrasound can be used to examine the jets of stenotic valves 
and to measure the peak and mean aortic valve gradient with good reproducibility. 
These values demonstrate good agreement with invasive haemodynamic 
measurements (Holen et al, 1976) and offer strong prediction of the need for 
intervention and adverse cardiovascular outcomes (Otto et al, 1997; Bohbot et al, 
2017). Additionally, echocardiography can provide helpful anatomic detail about 
aortic valve morphology, severity of fibro-calcification, the structure of the aorta and 
the left ventricular response to aortic stenosis. Furthermore, it is widely available, 
inexpensive, non-invasive and does not utilise radiation.  
 
Current guidelines recommend the assessment of aortic valve stenosis based upon peak 
velocity, mean gradient, and aortic valve area. Whilst peak aortic jet velocity may offer 
superior reproducibility, both peak jet velocity and mean gradient are intrinsically 
dependent on flow status. Derived aortic valve area (calculated by the continuity 
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equation) is independent of flow status, however, is subject to inconsistencies in 
measurement of the left ventricular outflow tract with even minor differences resulting 
in significant discrepancy.  
 
In light of the above, there is often disagreement between echocardiographic 
measurement of disease severity, in around one third of patients (Clavel et al, 2013). 
This is seen in patients with impaired left ventricular ejection fraction, termed ‘low-
flow, low gradient’ aortic stenosis, in whom the peak velocity and mean gradient may 
be below the threshold for severe stenosis (<4 et al and <40 mmHg respectively), but 
the calculation of aortic valve area suggests severe stenosis (<1 cm2). In this setting, 
augmenting left ventricular function with an intravenous infusion of dobutamine and 
repeating the echocardiographic assessment can be helpful. Nonetheless, a significant 
proportion of patients with discordant echocardiographic parameters have normal flow 
status and this makes interpretation of disease severity problematic.  
 
Computed Tomography Aortic Valve Calcium Scoring 
Aortic valve calcification is the dominant macroscopic feature of aortic stenosis 
resulting in valvular obstruction. Echocardiography may be used to provide a 
subjective quantification of aortic valve calcification, although this is limited by 
suboptimal reproducibility. Computed tomography (CT) aortic valve calcium scoring 
has therefore emerged as a complementary tool in the assessment of aortic stenosis 
that is accurate, highly reproducible and independent of flow status (Messika-Zeitoun 
D, et al, 2004). 
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Employing a similar protocol as that developed for CT coronary artery calcium 
scoring, a non-contrast and ECG-gated acquisition can be used to quantify calcium 
using the Agatston technique. This provides information with respect to the volume, 
mass and weighted density of calcium. With the recognition of the need for sex-
specific thresholds to determine severe stenosis (Aggarwal et al, 2013), CT aortic 
valve calcium scoring correctly classifies severe aortic stenosis with a sensitivity 
>86% and specificity >79% (Clavel et al, 2013). These thresholds have been validated 
in a multicentre cohort of over 900 patients (Pawade et al, 2018). Furthermore, CT 
aortic valve calcium score independently predicts clinical events including aortic valve 
replacement and cardiovascular death (Tastet L et al, 2017). Although CT aortic valve 
calcium scoring is not currently recommended for disease surveillance in the clinical 
setting, recent European Society of Cardiology guidelines advocate its use to 
adjudicate disease severity in patients with discordant echocardiographic findings and 
normal flow (Baumgartner H et al, 2017). 
 
CT aortic valve calcium scoring does have several important limitations. First, non-
contrast CT imaging offers little detail about valve morphology and is unable to 
localise the anatomical distribution of calcium in the valve and surrounding structures. 
Second, it is unable to detect or quantify fibrosis, an important contributor to valve 
stenosis, and may therefore misclassify disease severity, particularly in young women 
and those with bicuspid valves (Shen et al, 2016; Simard et al, 2016). Third, it 
demonstrates only a moderate correlation with haemodynamic severity on 
echocardiography and different severity thresholds are required in the two sexes, with 
women consistently demonstrating lower calcium burden for a given degree of 
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valvular stenosis even after correction for body size (Clavel et al, 2013; Clavel et al, 
2014; Pawade et al 2018).  
 
Contrast CT angiography is widely used to assess and to quantify both calcific and 
non-calcific plaques in the coronary vasculature (Dweck et al, 2016). It may therefore 
be possible to apply a similar approach to the aortic valve, allowing evaluation of aortic 
valve calcium burden and also fibrotic leaflet thickening. The development of such a 
technique would have potential to provide novel insights into the pathogenesis of 





Contrast-enhanced computed tomography in the assessment of aortic stenosis:   
 
 
 Figure 1.2. Doppler echocardiography assessment of the aortic valve demonstrating 
moderate aortic stenosis (A), non-contrast CT axial image of the aortic valve 
showing only minor calcification (B), contrast-enhanced CT en-face image (C) and 
long axis image of the aortic valve illustrating significant non-calcific thickening of 




Positron Emission Tomography 
Positron emission tomography (PET) is a novel imaging technique in the assessment 
of aortic stenosis. PET is a functional imaging modality which utilises administration 
of a radioactive ligand to detect and quantify metabolic processes in the body. In 
combination with computed tomography (CT), PET-CT provides information about 
disease activity allied with detailed anatomical localisation.  
 
Radiolabeled sodium fluoride has long been used as a radioactive tracer in the skeleton 
but has more recently been employed successfully to assess vascular calcification 
(Dweck MR et al, 2012 b; Forsythe RO et al, 2018; Joshi NV et al, 2014). 18F-Fluoride 
exchanges hydroxyl groups in hydroxyapatite to produce fluoroapatite, and thus 
detects calcification. Availability of hydroxyl binding sites is greatest in immature 
nanocrystalline forms of calcium phosphate and as such 18F-fluoride has higher affinity 
for regions of newly developing microcalcification (Irkle A et al, 2015). In clinical 
studies, 18F-fluoride binding is increased in the aortic valves of patients with aortic 
stenosis when compared to a healthy population, and measures of 18F-fluoride uptake 
correlate positively with echocardiographic measures of disease severity (Dweck et al, 
2012). Interestingly, 18F-fluoride binding in the aortic valve was often spatially distinct 
from calcium deposits apparent on CT, and new macroscopic calcification later 
became apparent in these regions on 1 and 2-year follow-up CT. This suggests that 
18F-fluoride PET offers information about calcification activity beyond the resolution 
of CT and that it has the potential to predict disease progression. Accordingly, 18F-
fluoride uptake has been found to correlate closely with change in aortic valve calcium 
score over time and moderately with the haemodynamic progression of aortic stenosis. 
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After almost 5 years of follow-up, 18F-fluoride emerged as an independent predictor 
of aortic valve replacement and cardiovascular mortality (Jenkins et al, 2015).  
 
Whilst 18F-fluoride PET holds promise as a sensitive marker of disease activity, it is 
not likely to find a major role in routine clinical practice due to the limited provision 
of PET imaging facilities, the relative expense when compared to echocardiography 
and CT aortic valve calcium scoring, and the accompanying radiation exposure. The 
most advantageous application of PET-CT in aortic stenosis is therefore likely to be 
within a research setting to provide an early measure of the efficacy of novel 
treatments. Indeed, in bone imaging, significant changes in 18F-fluoride uptake can be 
detected after ~1 month of bisphosphonate treatment (Installé J et al, 2005). However, 
before 18F-fluoride PET-CT can be employed as an outcome measure of therapeutic 
efficacy in randomised controlled trials, the methodology for image acquisition and 




18F-Fluoride PET-CT predicts new aortic valve calcification in aortic stenosis  
 
 
Figure 1.3. Baseline CT calcium scores (left) for patients 1 and 2 (top and bottom). Fused 
coaxial 
18
F-fluoride PET-CT scans (middle) show fluoride uptake in red and yellow. The 1-
year follow-up (right) suggests that the baseline PET signal predicts the spatial distribution of 
subsequent macrocalcification. (Dweck et al, 2014) 
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1.3 BIOPROSTHETIC VALVE DISEASE 
 
Epidemiology of Bioprosthetic Valves  
Patients with valvular heart diseases are living longer and with a better quality of life 
than at any time in the past as a result of advances in the design of prosthetic heart 
valves and related clinical care. Prosthetic valves may be categorised as either 
mechanical or bioprosthetic, and these differ from one another in terms of longevity, 
thrombogenicity and haemodynamic performance (Bloomfield PB et al, 1991). In the 
present era, it is estimated that between 300,000 and 400,000 heart valve replacements 
are performed each year worldwide (Fiedler AG et al, 2018). There has been a 
significant transformation in practice over recent decades such that the majority of 
implanted valves are now bioprosthetic rather than mechanical. For example, 
bioprosthetic valves accounted for 43.6% of surgically implanted aortic valves in 
North America in 1997, rising to 78.4% in 2006 (Brown et al, 2009). The use of 
bioprostheses has perhaps increased due to a combination of patient preference (opting 
for improved durability allied to the lower risk of bleeding complications), the 
increasing prevalence of valve disease in the ageing population, and the emergence of 
transcatheter aortic valve replacement (Iung B et al, 2011; Nkomo VT et al, 2006). 
Consequently, more patients with bioprosthetic valves are under surveillance and 




Classification of bioprosthetic heart valves 
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History of Bioprosthetic Valves 
Bioprosthetic valves can be composed of either human tissue (allografts and 
autografts) or animal tissue (xenografts). Xenograft bioprosthetic valves are 
manufactured from either bovine pericardial or porcine tissue and can be stentless or 
mounted on a stent. The first xenograft replacement aortic valve was successfully 
implanted in 1965 in Paris by Carpentier and his team. However, the early porcine 
valves suffered from a high rate of failure with ~45% functioning well at 1 year 
(Carpentier A et al, 1969). Whilst there were some technical surgical reasons for valve 
failure, there was also histological evidence of an immune response. Subsequent work 
identified glutaraldehyde to be effective in reducing, although not eliminating, the 
antigenicity of xenograft valves. This led to improvements in valve durability, from 
~45% to ~82% functioning well at 1 year (Carpentier A et al, 1969). The success of 
glutaraldehyde-fixed bioprosthetic heart valves resulted in commercialisation and 
increasingly widespread use.  
 
Modern xenograft surgical valves are predominantly of the stented type, comprising 3 
porcine or bovine pericardial tissue leaflets mounted on a stent frame made from alloy 
or polymer, and a circular fabric-covered external sewing ring that provides an anchor 
to the aortic annulus. Stentless valves constitute a preserved porcine aortic valve and 
aortic root removed en block that can be individually tailored to each patient for sub-
coronary implantation, a mini-root or full root replacement. In theory, the absence of 
an external sewing ring in stentless valves offers a greater effective orifice area and 
superior haemodynamic performance. The most commonly used transcatheter valves 
to date have been the Edward’s Sapien and Medtronic Corevalve series. The Edwards 
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Lifesciences Sapien consists of bovine pericardial leaflets sutured within a balloon-
expandable cobalt chromium stent frame, whereas the Medtronic Corevalve consists 
of porcine pericardial leaflets sutured in a supra-annular position to a self-expanding 
nitinol stent frame.  
 
Diagnosis and Definition of Bioprosthetic Valve Degeneration 
Structural valve degeneration is a gradual process leading to valve dysfunction 
secondary to prosthetic valve stenosis (40%), regurgitation (30%), or a combination 
of both (30%) (Cote N et al, 2017). Historically, most surgical studies have associated 
valve degeneration with the need for reoperation, but without specific criteria to define 
structural valve degeneration. Given that reoperation does not necessary imply 
structural valve degeneration, and that patients with structural valve degeneration are 
often not suitable for redo-surgery, one would expect an underestimation of the true 
incidence if defined only on the basis of reoperation. A systematic assessment of 
prosthetic valve morphology and function may more accurately describe the true 
prevalence of structural valve degeneration.  
 
Despite the considerable experience reported with different types of surgical 
bioprostheses, there are widely ranging definitions of structural valve degeneration 
and varying criteria have been suggested based upon evaluation of haemodynamic 
performance by Doppler echocardiography. One proposed definition for bioprosthetic 
structural valve degeneration according to echocardiographic criteria included 
increase in the transvalvular aortic gradient with mean gradient ≥30 mm Hg associated 
with an effective orifice area ≤1 cm2, or prosthetic aortic regurgitation grade ≥3 
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(Senage T et al, 2014). Another contemporaneous study defined structural valve 
degeneration of aortic surgical bioprostheses as severe aortic stenosis with mean 
gradient >40 mm Hg, or severe prosthetic regurgitation (Bourgignon T et al, 2014). 
Alternatively, one group recommended structural valve degeneration be recognised by 
an increase in mean gradient ≥20 mm Hg with a concomitant decrease in effective 
orifice area and/or a progression of intraprosthetic regurgitation by at least 1 grade 
(Mahjoub H et al, 2013). The more recent European Association of Cardiovascular 
Imaging guidelines suggest defining structural valve degeneration using the following 
criteria: (i) an increase in mean gradient ≥10 mm Hg (possible valve degeneration) or 
≥20 mm Hg (significant valve degeneration) during follow-up, with a concomitant 
decrease in effective orifice area and abnormal valve leaflet morphology and mobility; 
and/or (ii) new onset or worsening transprosthetic regurgitation (Lancellotti P et al, 
2016). Structural valve deterioration was defined upon quite similar criteria by the 
European Association of Percutaneous Cardiovascular Interventions, with severe 
structural valve deterioration identified by any of mean transprosthetic gradient 
≥40 mm Hg, an increase in mean transprosthetic gradient  ≥20 mm Hg from baseline, 
and new or worsening severe intraprosthetic regurgitation (Capodanno D et al, 2017).  
 
An alternative definition of bioprosthetic valve degeneration and dysfunction has been 
proposed in a recent expert consensus statement, and for the first time, references the 
complementary role of computed tomography in the detection of early degenerative 
changes. Stage 1 is characterised by morphological abnormality (detected on 
echocardiography or computed tomography) in the absence of haemodynamic 
changes; stage 2 is characterised by the presence of either moderate valve obstruction, 
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moderate regurgitation or both; and stage 3 is characterised by the presence of either 
severe valve obstruction or regurgitation. Central to this definition is a dynamic 
change, for example, new valve obstruction should be accompanied by a change in 
mean gradient >10 mmHg associated with a decrease in Doppler velocity index and 
effective orifice area (Dvir D et al, 2018).  
 
In light of the above definitions of bioprosthetic valve degeneration, a robust 
assessment of valve morphology and function at baseline is therefore fundamental 
along with ongoing interval surveillance. This is reflected in international guidelines 
which strongly recommend an initial transthoracic echocardiogram for evaluation of 
valve haemodynamics following prosthetic valve implantation (Otto C et al, 2021; 
Baumgartner H et al, 2017). At follow-up, guidelines suggest echocardiography in 
response to any change in clinical symptoms or signs suggesting valve dysfunction, 
with routine annual echocardiography recommended by the European Society of 
Cardiology (Baumgartner H et al, 2017), and echocardiography at 5 years then 
annually from 10 years post-implantation by the American College of Cardiology / 
American Heart Association (Otto C et al, 2021). Depending on approach, it is 
possible that subclinical changes in prosthetic valve hemodynamic performance go 





Expert consensus statement: Definition of structural valve degeneration and 
clinical approach to patients with bioprosthetic valves 
 
 
*Structural valve degeneration excludes endocarditis, valve thrombosis and isolated 
patient-prosthesis mismatch. (Adapted from Dvir et al, Circulation 2018)  
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Durability of Bioprosthetic Valves 
Finite durability is the chief limitation of bioprosthetic valves when compared to 
mechanical prostheses. There are several inherent challenges when assessing the long 
term performance of contemporary valves. First, reporting of valve durability often 
relates to specific models of prosthesis, and the progress of valve technology is such 
that data about outcomes 15-20 years after implantation are published when newer 
models have already superseded them in clinical practice. Moreover, the duration of 
follow-up and criteria for defining valve dysfunction vary widely and so make direct 
comparisons very difficult.  
 
Surgically Implanted Bioprosthetic Valves 
Bioprosthetic valve degeneration is generally slow, gradual and time dependent 
(Bloomfield P et al, 2001). After implantation of 1,315 first generation Carpentier-
Edwards porcine bioprosthetic valves in the aortic and mitral positions, <1% 
demonstrated dysfunction within 5 years, 20-30% within 10 years, and >50% failed as 
a consequence of structural valve degeneration with 12-15 years (Jamieson W et al, 
1995). In a rare prospective study of 1,134 patients who underwent aortic valve 
replacement with the Medtronic Hancock II second generation porcine stented 
bioprosthesis, ~98% were free from structural valve deterioration (defined by 
echocardiography or need for reoperation) at 10 years, ~87% at 15 years and ~63% at 
20 years (David TE et al, 2010). 
 
In a more contemporary study of 12,569 patients undergoing aortic valve replacement 
with a Carpentier-Edwards Perimount stented bovine pericardial valve, the rate of 
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explant for structural valve deterioration was 1.9% at 10 years and 15% at 20 years. 
The rate of explant does not, however, take account of patients with earlier stages of 
valve dysfunction or who were unsuitable for reoperation, and in this study ~3.3% of 
patients had structural valve deterioration without reoperation (Johnston DR et al, 
2015). In slight contrast, another study of the same valve type implanted in 2,405 
patients of similar age reported freedom from valve reoperation at 10 years of ~96% 
and at 20 years of ~67%. Despite discrepancies, these data on the long term 
performance of modern bioprostheses are generally encouraging.  
 
Within surgically implanted bioprostheses, stented models most commonly fail as a 
result of late calcification and stenosis. Stentless valves display similar rates of 
structural degeneration to stented valves but with a predilection to develop valvular 
regurgitation over stenosis (Dvir D et al, 2012). Complications of degenerating 
stentless grafts can also include aortic wall calcification and stenosis, aortic dilatation 
or a nidus for systemic embolism (Siddiqui RF et al, 2009). Allografts tend to be used 
in select clinical scenarios, such as the setting of endocarditis or complex aortic 
anatomy, and often in younger patients. In one study of 353 patients undergoing aortic 
valve replacement with an allograft, with mean age 45 years, the rate of reoperation 
for structural valve deterioration over 12 years follow-up was ~28% (Arabkhani B et 
al, 2016).  
 
Transcatheter Bioprosthetic Valves 
Potential differences in the long term durability of transcatheter valves in comparison 
to surgical bioprostheses have been a source of extensive speculation. It has been 
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hypothesised that crimping of the valve cusps during transcatheter delivery may result 
in disruption of collagen structure and so accelerate valve degeneration (Alavi SH et 
al, 2014). The commissural cusp attachment to a rigid stent frame in transcatheter 
valves rather than the flexible stent post in stented surgical valves might also 
negatively impact on dissipation of mechanical stress. Furthermore, severe 
calcification of the native aortic valve cusps and annulus may lead to suboptimal 
deployment and paravalvular leaks after transcatheter valve implantation, with a 
negative impact on long term durability (Arsalan M et al, 2016). Alternatively, there 
has been early evidence that transcatheter valves produce superior haemodynamic 
results to surgical valves and thus lower rates of patient-prosthesis mismatch, which is 
known to affect longevity (Pibarot P et al, 2014).  
 
The long term durability of transcatheter valves is particularly difficult to assess for a 
number of reasons. Transcatheter valve delivery was until recently a novel technology 
in the hands of inexperienced operators, with both valve technology and operator 
expertise having progressed rapidly since FDA approval in 2011. Moreover, the 
patient population is generally elderly with multiple-morbidities and so there is a 
scarcity of patients available for long term follow-up. Nonetheless, data up to 5 years 
from the PARTNER trials with the Edwards SAPIEN valve demonstrate comparable 
haemodynamic performance to surgical bioprostheses, other than a higher rate of 
paravalvular regurgitation, and the absence of structural valve degeneration (Mack MJ 
et al, 2015; Kapadia SR et al, 2015; Daubert MA et al, 2017). In the NOTION trial, 
randomising low risk patients to either surgical aortic valve replacement or 
transcatheter valve implantation with the Medtronic Corevalve self-expanding valve, 
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there was no difference in the composite primary endpoint of all-cause mortality, 
stroke or myocardial infarction (36.3 versus 38.0% respectively, p=0.86), though the 
transcatheter cohort suffered higher rates of moderate/severe aortic regurgitation and 
requirement for permanent pacing (Thyregod HGH et al, 2019).  Analysis of the 
FRANCE-2 Registry suggested the incidence of severe structural degeneration to be 
2.5% and of moderate/severe structural degeneration to be 13.3% at 5 years (Didier R 
et al, 2018).  Data from the UK TAVI Registry, with a mean follow-up of 5.8 years, 
demonstrated an incidence of 0.4% for severe structural valve degeneration  and 8.7% 
for moderate structural valve degeneration (Blackman D et al, 2019).  
 
Pathophysiology of Bioprosthetic Valve Degeneration 
Calcification 
Unfortunately, the pathophysiology of bioprosthetic valve degeneration is 
incompletely understood, largely because of the difficulty in obtaining tissue 
specimens in early disease. Nonetheless, calcification is the dominant histological 
feature of explanted degenerated valves. In one series of explanted porcine 
bioprostheses, more than 50% demonstrated calcific deposits within 3 years of 
implantation with a preponderance for the commissural and basal regions of the valve 
cusps, where mechanical stress is greatest (Butany J et al, 2001). Calcification may 
lead to valve stenosis as a consequence of progressive cusp immobility or lead to 
regurgitation as a consequence of cusp tears, perforation or commissural dehiscence 
(Schoen F et al, 1987; Allard M et al, 1995).  
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Bioprosthetic valve calcification is believed, at least in part, to occur as a consequence 
of pre-treatment with glutaraldehyde which results in cross-linking of collagen and 
availability of free aldehyde groups. Phosphorus on free aldehyde groups then interacts 
with circulating calcium after implantation to initiate calcium phosphate aggregates 
(Schoen F et al. 1999). Devitalisation of tissue during glutaraldehyde fixation also 
releases calcium and membrane-associated phospholipids from damaged cells which 
form the nidus for further nucleation of calcium phosphate within the valve cusps. 
Over time these deposits expand and coalesce, ultimately resulting in valve 
dysfunction.  
 
Manufacturers have appreciated the less favourable effects of glutaraldehyde fixation 
and explored alternative cross-linking pre-treatments, such as dye-mediated 
photofixation and carbodiimide-based fixation. These show promise in the prevention 
of tissue calcification but have not translated into clinical use (Simionescu DT et al, 
2004). Instead, most current generation bioprostheses are now treated with anti-
mineralisation preparations such as ethanol or alpha-oleic acid. Alpha-oleic acid 
covalently bonds to residual aldehyde groups and so reduces the binding of calcium 
(Chen W et al, 1994). Intriguingly, observations suggest that some anti-mineralisation 
treatments protect the valve cusps from calcification but not the aortic wall of stentless 
valves. This may be because elastin is the principal substrate for calcification in the 
aorta (Schoen FJ et al, 2005).  
 
Beyond the passive initiation of calcification via interaction of circulating calcium and 
the components of devitalised xenograft tissue, bioprosthetic valve calcification is 
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thought to be actively mediated by atherosclerotic-like pathways including infiltration 
of oxidised lipid. Accordingly, the development of structural valve degeneration has 
been associated with higher levels of plasma low-density lipoprotein-cholesterol and 
apolipoprotein B (Mahjoub H et al, 2013). Bioprosthesis calcification is, furthermore, 
thought to become orchestrated in a fashion similar to the physiological mineralisation 
of bone. For example, the regulatory proteins osteopontin, tissue growth factor-alpha 
and tenascin-C have been demonstrated in calcified porcine bioprostheses as well as 
in stenotic native aortic valves (Srivasta SS et al, 1997).  
 
Other factors predisposing to bioprosthetic valve calcification are thought to be 
dysregulation of calcium-phosphate metabolism, such as that found in chronic renal 
disease or parathyroid tumours, and increased valvular mechanical stress, as in the 
setting of arterial hypertension or patient-prosthesis mismatch (Butany J et al, 2001). 
Small prosthesis size and the aortic position are both associated with greater 
mechanical stress and accelerated mineralisation (Reul Jr GJ et al, 1985). Likewise, 
various valve design features which result in suboptimal distribution of haemodynamic 
stress have been found to profoundly affect valve durability. For example, one low 
profile porcine bioprosthesis had a reduced free edge angle rendering it less effective 
in dissipating mechanical stress and was discovered to suffer from premature 
calcification and failure (Vesely I et al 2003).  
 
Immune Reaction 
A number of studies have presented evidence of a pathway involving immune 
rejection, inflammation and ultimately calcification of bioprosthetic valves. Whilst 
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glutaraldehyde fixation reduces xenograft antigenicity, it does not wholly eliminate it 
(Pibarot et al, 2009). Animal model studies show that xenogeneic implants, even when 
pre-treated with glutaraldehyde, are associated with greater histological evidence of 
adventitial inflammation, and humoral and cellular immune infiltrates when compared 
to syngeneic implants. The subsequent extent of calcification correlated with the 
immune cell infiltrate (Manji RA et al, 2006). Similarly, in humans, the role of the 
immune system response to xenografts is highlighted by histological evidence of 
accumulation of IgM and IgG, incursion of macrophages, cytokine release, collagen 
breakdown and tissue calcification (Konakci K et al, 2005).  
 
Galactose-alpha1,3-galactose (Gal) has long been considered the most important 
antigen in porcine tissue with respect to stimulating xenograft rejection in humans. Gal 
antigens are present on commercially available porcine bioprosthetic valves and after 
implantation are associated with an increase in circulating anti-Gal host antibodies 
(Bloch O et al, 2011). The Gal-related immune reaction is also linked to calcification. 
One study compared implantation of pericardium from Gal knock-out pigs and wild 
type pigs in rats, with the pericardium from Gal knock-out pigs calcifying less than 
that from wild-type pigs (Lila N et al, 2010). The anti-Gal IgM and IgG responses are, 
however, lower when grafts have undergone fixation and decellularisation (Lim HG 
et al, 2013). Ultimately, elimination of Gal antigens has not been sufficient to prevent 




Although contentious, if an immune response were implicated in degeneration of 
porcine and bovine valves, this would help to account for the accelerated structural 
valve degeneration observed in younger patients, who are more immunologically 
active. Certainly, the incidence of bioprosthetic valve calcification appears to be 
strongly associated with age (Reul Jr GJ et al, 1985). In those over the age of 65 years, 
<10% of bioprosthetic valves failed within 10 years whereas in those under the age of 
35 years, valve failure was almost uniform by 5 years (Siddiqui RF et al, 2009). Higher 
haemodynamic stresses in more physically active young people and the greater 
competence of the immune system in young people are both speculated to contribute 
(Milano A et al, 1998).  
 
The counter argument to the role of the immune system in valve degeneration cites 
experiments in which xenograft valve tissue has been implanted in athymic mice and 
in filter chambers that prevent host cell contact but allow free diffusion of extracellular 
fluid. The resulting pattern and extent of calcification in xenograft tissue is no different 
from that seen when implanted directly into wild-type mice (Levy RJ et al, 1983). 
Antibody infiltrates could therefore be a secondary response to valve damage rather 
than a cause of degeneration.  
 
Pannus 
Bioprosthetic valves undergo rapid endothelialisation after implantation, which helps 
to protect them from leaflet thrombosis. Pannus refers to the proliferation of host 
endothelial, fibroblast and myofibroblast cells from the anastomotic margins at the 
suture line over the prosthesis. This occurs almost invariably to a degree, usually 
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covering part of the sewing ring of stented valves. However, when pannus spreads 
over the stent posts and valve cusps themselves this is considered an over-exuberant 
reaction and can result in prosthesis dysfunction. As the process underlying pannus 
progresses, collagen deposits mature and lead to thickening, increased stiffness and 
retraction of tissue. Depending on the pattern of pannus overgrowth, it can therefore 
impede opening of the cusps resulting in stenosis, cause retraction of one of more cusps 
resulting in progressive valvular incompetence, or cause adverse redistribution of 
mechanical stress and consequent cusp tears resulting in acute valvular incompetence 
(Butany J et al, 2001) 
 
Bioprosthetic Valve Thrombosis 
Overt prosthetic valve thrombosis is unusual in the case of both patients with 
bioprosthetic valves and mechanical valves receiving therapeutic anticoagulation, with 
a reported incidence of 0.1-5.7% per patient year (Freeman R et al, 2005). The risk is 
highest during the first 3 months after implantation, greater when the prosthesis is 
implanted in the mitral position, and in those patients with atrial fibrillation, severe 
left ventricular systolic impairment and a history of thromboembolism (Vongpatanasin 
W et al, 1996). Clinically, prosthetic valve thrombosis may present as left ventricular 
failure, cardiogenic shock or systemic embolism.  
 
Closer scrutiny over the past decade, peaked by the emergence of transcatheter aortic 
valve implantation and development of 4-dimensional computed tomography, has 
increased our appreciation of valve thrombosis in bioprosthetic valves. Recognition of 
bioprosthetic valve thrombosis by transthoracic echocardiography alone is very 
 57 
limited, detecting only ~13% of cases (Egbe et al, 2015). To improve detection, it has 
been proposed that the combination of a 50% increase in transvalvular gradient from 
baseline, cusp thickness >2 mm and abnormal cusp mobility on echocardiography are 
suggestive of valve thrombosis (Egbe et al, 2015).  
 
The incidence of thrombosis of transcatheter aortic valves is likely to be at least 0.6%, 
with the majority occurring within the first year. Around two thirds of patients 
presented with progressive breathlessness whilst the remaining third were 
asymptomatic. Most developed valve thrombosis despite dual antiplatelet therapy 
although the introduction of oral anticoagulation was almost universally successful in 
restoring normal valve function (Cordoba-Soriano JG et al, 2015).  
 
Under normal circumstances, the intact vascular endothelium appropriately regulates 
vessel tone and favours an antithrombotic state. However, the presence of a foreign 
biomaterial leads to adhesion of plasma proteins which promotes adhesion and 
activation of platelets, thrombin generation and activation of the pro-thrombotic 
complement system (Jaffer IH et al, 2015). Altered flow dynamics are also associated 
with endothelial damage and thrombosis. High wall shear stress conditions trigger 
platelet activation, whilst the complex interplay of altered flow patterns and blood 
stasis around the prosthetic valve predisposes to localised thrombosis (Kopanidis A et 
al, 2015). Wall shear stress is greater in the setting of patient-prosthesis mismatch, and 
this has been noted to alter simultaneously the configuration of circulating von 
Willebrand factor and activate the coagulation cascade, promoting both bleeding and 
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thrombosis. In surgical bioprostheses, patient-prosthesis mismatch has been associated 
with early stenosis-type structural valve degeneration (Flameng W et al, 2010).  
 
The incidence of clinically overt bioprosthetic valve thrombosis has been estimated at 
~1.46-1.99% (Puri R et al, 2017). Recently, 4-dimensional computed tomography has 
emerged as a valuable tool for the characterisation of bioprosthetic valves with the 
ability to detect hypoattenuated leaflet thickening and restricted leaflet motion as 
evidence of valve thrombosis. In a study of 405 patients following transcatheter valve 
implantation, hypoattenuated leaflet thickening was observed in 7%, and the majority 
of these cases were asymptomatic. Of note, valve thrombosis was associated with 
larger valve size (29 mm) and the absence of oral anticoagulation. In combined studies 
of surgical and transcatheter bioprostheses within the first 3 months after implantation, 
the incidence of valve thrombosis was 13-14% in transcatheter valves and half this at 
4-7% in surgical valves. There was, however, no difference in haemodynamic 
measures of valve function and the only clinical correlate was an increased incidence 
of ischaemic cerebrovascular events in those patients with hypoattenuated leaflet 
thickening (Makkar RR et al, 2015; Chakravarty T et al, 2017). Another study 
suggested that transprosthetic gradients increased more rapidly during follow-up in 
those with CT features of subclinical valve thrombosis (Rashid HN et al, 2018). 
Subclinical leaflet thrombosis might then be a trigger of inflammation and fibrocalcific 
remodelling of valve cusps ultimately leading to structural valve degeneration, 





Macroscopic photography of explanted bioprosthetic valves illustrating 




Schematic of the mechanisms of bioprosthetic structural valve degeneration 
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Clinical Imaging of Bioprosthetic Valves 
Echocardiography 
Transthoracic Doppler echocardiography is the central tool in the assessment of 
bioprosthetic valves. International guidelines recommend a thorough evaluation be 
undertaken at baseline and updated in the setting of any new relevant symptoms or 
clinical signs.  Routine surveillance transthoracic echocardiography should then be 
considered at 5-10 years after valve implantation. Whilst echocardiography is readily 
accessible and economical, unfortunately image quality is often limited by patient 
factors and acoustic shadowing from the prosthetic valve. Transoesophageal 
echocardiography is the next imaging modality of choice when there is reason to 
suspect prosthetic valve dysfunction or infection. This allows clearer visualisation of 
the valve cusps and is particularly helpful for localising regurgitant jets. 
Transoesophageal echocardiography may be able to differentiate infected vegetations 
from thrombus.  
 
A recent report from the European Association of Cardiovascular Imaging offers 
recommendations for the assessment of prosthetic valves. First, determining the cause 
of prosthesis dysfunction is critical and assessment with transthoracic and 
transoesophageal echocardiography are the mainstays of imaging. Complementary use 
of computed tomography, fluoroscopy and magnetic resonance imaging should also 
be considered. Second, echocardiography should include interrogation with Doppler, 
colour Doppler and in certain instances the use of 3-dimensional echocardiography to 
better examine cusp pathology and the origin of regurgitant jets. The authors highlight 
the challenge of assessing the more complex haemodynamics of prosthetic valves, 
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particularly in some types of mechanical valve, and the potential inaccuracies of 
estimating the effective orifice area, such as measurement of the left ventricular 
outflow tract. The Doppler velocity index (peak left ventricular outflow tract velocity 
/ peak aortic jet velocity) is proposed as a particularly helpful measure of prosthetic 
valve function as there is a linear relationship between the velocity in the outflow tract 
and implanted valve size. Algorithms are described for the classification of prosthetic 




Computed tomography is not performed in the routine clinical evaluation of patients 
with bioprosthetic valves but may provide incremental information to 
echocardiography when there is a suspicion of valve dysfunction. ECG-gated 
computed tomography can be undertaken with or without intravenous iodinated 
contrast medium using a similar protocol to that for computed tomography coronary 
angiography. If data are acquired throughout the cardiac cycle, then images can be 
reconstructed during different phases and used to assess motion of the prosthetic valve. 
Computed tomography may therefore be used to examine the structural integrity of 
prosthetic valves, to detect leaflet pathology such as calcification, thrombosis or 
pannus, and to assess the anatomy of the adjacent aorta. Four-dimensional imaging 
may be used to assess mobility of the valve leaflets, to measure the geometric valve 
orifice area, and to detect pathological motion of the sewing ring as might suggest 
dehiscence (Chenot F et al, 2010; Lancellotti P et al, 2016).  
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Computed tomography has recently emerged as being of particular value in the 
assessment of leaflet abnormalities in bioprosthetic valves. Characterisation of tissue 
density can help to discriminate between pannus and relatively low-density thrombus, 
with a suggested threshold of 200 Agatston units (Lancellotti P et al, 2016). Four-
dimensional computed tomography has also contributed greatly to our understanding 
of leaflet thrombosis in bioprostheses, wherein the combination of >2 mm leaflet 
thickening and restricted leaflet motion support the diagnosis (Makkar RR et al, 2015; 
Pache G et al, 2016). 
 
The limitations of computed tomography include the exposure to ionising radiation 
and iodine contrast dye, with potential for nephrotoxicity and allergy. Depending on 
the composition, images may also be degraded by artefact from high density materials 
present in the construct of a prosthetic valve.  
 
Positron Emission Tomography 
Positron emission tomography using the 18F-fluorodeoxyglucose radioisotope has 
been described in the assessment of suspected prosthetic valve endocarditis and may 
provide a useful discriminator when other investigations are inconclusive (Nuvoli S et 
al, 2018).  
 
In contrast, 18F-fluoride remains unexplored in the assessment of bioprosthetic valves 
to date. As described previously, 18F-fluoride positron emission tomography has 
recently been used to image vascular calcification activity in a range of cardiovascular 
diseases (Dweck MR et al, 2012 b; Forsythe RO et al, 2018; Joshi NV et al, 2014). It 
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preferentially signals regions of nascent microcalcification associated with 
inflammation or tissue degeneration and can be detected before macrocalcification is 
apparent on computed tomography (Irkle et al, 2015). Given that calcification is 
considered the key pathological process underlying bioprosthetic valve degeneration, 
we hypothesised that increased 18F-fluoride uptake may identify early subclinical 
structural valve degeneration before it is visible on either echocardiography or CT and 




1.4 SUMMARY  
 
The evolution of aortic stenosis is dominated by progressive valve calcification in the 
majority, though not all patients. Despite this, the underlying triggers of this process 
are incompletely understood. There is therefore a mandate for non-invasive 
assessments that can help to characterise disease mechanisms and evaluate the efficacy 
of novel therapeutics.  
 
Aortic valve replacement alleviates the bleak prognosis of untreated symptomatic 
severe aortic stenosis, however, the durability of bioprosthetic valves is finite. The 
pathogenesis of bioprosthetic valve degeneration is likely to be multi-faceted with 
calcification as a common end-point but is again not well understood. The natural 
history of bioprosthetic valve degeneration is such that patients often present late in 
the disease with acute decompensation. There is therefore an important rationale for 
assessments that can identify early valve degeneration and predict clinical outcomes.  
 
Novel approaches to contrast-enhanced CT and 18F-fluoride PET-CT will be applied 
to the assessment of native and bioprosthetic aortic valves to contribute to the 
understanding and management of aortic stenosis and the structural degeneration of 





1.5 AIMS AND HYPOTHESES 
 
The aims of this thesis are:  
 
1. To investigate the novel use of computed tomography angiography in the 
assessment of patients with native aortic stenosis and thereby to investigate the 
relative roles of fibrosis and calcification in the pathogenesis of aortic stenosis 
(Chapter 3). 
 
2. To establish a methodology for the use of 18F-fluoride PET-CT in the 
assessment of aortic stenosis and to assess the reproducibility of this technique 
(Chapter 4). 
 
3. To explore the mechanisms of bioprosthetic valve degeneration in explanted 
degenerated bioprosthetic valves by assessment with histology and micro-
computed tomography/positron emission tomography (Chapter 5). 
 
4. To investigate the utility of 18F-fluoride PET-CT in the detection and prediction 
of bioprosthetic valve degeneration in a cohort of patients with surgically 






The hypotheses of this thesis are: 
 
1. Computed tomography angiography can detect both calcification and fibrosis 
of the aortic valve, and thereby highlight the contribution of fibrosis and 
calcification in the pathogenesis of aortic stenosis (Chapter 3).  
 
2. 18F-Fluoride positron emission tomography and computed tomography can be 
established as an accurate and reproducible technique to assess disease activity 
in aortic stenosis (Chapter 4).  
 
3. Assessment of degenerated bioprosthetic valves with micro-18F-fluoride 
positron emission tomography and computed tomography, and correlating 
tissue histology will provide novel insight about the mechanisms of 
bioprosthetic valve degeneration (Chapter 5).  
 
4. 18F-Fluoride positron emission tomography/computed tomography can be 
applied to the assessment of bioprosthetic aortic valves to detect and predict 



















The design and methodology of each study is described in detail within the relevant 
chapters. The following section provides an overview of the patient populations and 




2.2 STUDY POPULATIONS 
 
Two prospectively recruited patient populations form the basis for the work described 
herein. First, a group of patients with native valve aortic stenosis underwent multi-
modality imaging assessment as part of the SALTIRE 2 double-blinded, randomised, 
placebo-controlled trial. The SALTIRE 2 trial was designed to investigate the ability 
of calcium modulators, denosumab and alendronic acid, to modify disease progression 
in aortic stenosis. The primary endpoint was change in CT aortic valve calcium score 
(CT-AVC) at 2 years and an exploratory secondary endpoint was uptake of 18F-
fluoride as assessed by positron emission tomography-computed tomography (PET-
CT) at 1 year. A substudy was firstly performed to optimise and establish the 
reproducibility of 18F-fluoride PET-CT in the assessment of aortic stenosis. An 
additional group of patients with native aortic valve disease were recruited to an 
observational imaging study at a collaborating centre (University of Laval, Quebec, 
Canada). A number of these patients proceeded to aortic valve replacement surgery 
and donated aortic valve tissue for histological validation.  
 
Second, a group of patients with surgically implanted bioprosthetic aortic valves were 
recruited at a range of time-points following valve implantation and underwent multi-
modality imaging assessment as part of the 18F-FAABULOUS observational cohort 
study. A cohort of patients with failing bioprosthetic aortic valves undergoing redo-
aortic valve replacement surgery donated explanted bioprosthetic valve tissue for 
micro-PET/CT and histological analysis.  
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The SALTIRE 2 and 18F-FAABULOUS research studies were approved by the South-
East Scotland Research Ethics Committee and the Administration of Radioactive 
Substances Advisory Committee (ARSAC) of the United Kingdom. SALTIRE 2 is a 
clinical trial of an investigational medicinal product and was therefore considered and 
approved by the Medicine and Healthcare products Regulatory Agency (MHRA) of 
the United Kingdom. Both SALTIRE 2 and 18F-FAABULOUS were registered on the 
clinicaltrials.org website (NCT 02132026 and NCT 02304276 respectively) and the 
conduct was overseen by NHS/University of Edinburgh sponsors. Participants 
provided prior written informed consent and all studies were performed in accordance 
with the Declaration of Helsinki.  
 
Recruitment 
Patients under the care of the cardiology or cardiothoracic clinical teams at 
participating centres were firstly identified as potentially suitable study participants 
and approached by their usual clinical care team. Those who agreed were contacted by 
the research team and provided with an approved written participant information sheet 




2.3 STUDY ASSESSMENTS 
 
Study visits were primarily undertaken at the Edinburgh Clinical Research Facility at 
the Royal Infirmary of Edinburgh. At the first visit, the process of obtaining written 
informed consent was performed, and the study inclusion and exclusion criteria were 
confirmed prior to further study involvement. The criteria for each study are detailed 
below. 
 
SALTIRE 2 Study Eligibility Criteria  
For inclusion in the study, participants needed to fulfil the following criteria: 
• Age >50 years 
• Aortic stenosis with peak aortic jet velocity of  >2.5 m/s on Doppler 
echocardiography  
• Grade 2-4 calcification of the aortic valve on echocardiography  
 
Participants did not enter the study if any of the following exclusion criteria were 
fulfilled:  
• Anticipated or planned aortic valve surgery in the next 6 months  
• Life expectancy <2 years  
• Inability to undergo scanning  
• Treatment for osteoporosis with bisphosphonates or denosumab 
• Long-term corticosteroid use 
• Abnormalities of the oesophagus or conditions, which delay 
oesophageal/gastric emptying  
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• Inability to sit or stand for at least 30 minutes 
• Known allergy or intolerance to alendronate or denosumab, or any of their 
excipients  
• Hypocalcaemia  
• Regular calcium supplementation  
• Dental extraction within 6 months  
• History of osteonecrosis of the jaw  
• Major or untreated cancers  
• Poor dental hygiene  
• Women of child-bearing potential who have experienced menarche, are pre-
menopausal, have not been sterilised or who are currently pregnant 
• Women who are breastfeeding 
• Renal failure (estimated glomerular filtration rate of <30 mL/min) 
• Allergy or contraindication to iodinated contrast  
• Inability or unwilling to give informed consent 
• Likelihood of non-compliance to treatment allocation or study protocol  
 
18F-FAABULOUS Study Eligibility Criteria 
For inclusion in the study, participants must meet the following criteria: 
• Ability to give informed consent 
• Over 40 years of age 
• Cohort 1: patients with a surgically implanted bioprosthetic aortic valve who 
are due to undergo redo-aortic valve surgery or valve-in-valve transcatheter 
valve implantation for bioprosthetic valve failure 
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• Cohort 2: patients with a surgically implanted bioprosthetic aortic valve, 
implanted 1 month, 2 years, 5 years or 10 years prior to study recruitment and 
without known evidence of valve dysfunction or degeneration.  
 
Participants did not enter the study if any of the following exclusion criteria were 
fulfilled:  
• Inability to give informed consent 
• Pregnancy  
• Breastfeeding 
• Claustrophobia 
• Allergy to iodinated contrast 
• Liver failure 
• Chronic kidney disease (with estimated glomerular filtration rate <30 
mL/min/1.73 m2) 
• Paget’s disease  
• Metastatic malignancy 
• Inability to tolerate the supine position  
 
Clinical History 
Anonymised participant data was entered into case record forms with demographic 
details including date of birth, sex and ethnicity. Participants were then asked 
questions in relation to their current symptoms, in particular their experience of 
breathlessness (according to the New York Heart Association classification), ankle 
swelling, angina (according to the Canadian Cardiovascular Society classification), 
 75 
palpitation, pre-syncope and syncope. Details of significant past medical history were 
recorded with particular reference to history of cardiac disease, details of previous 
cardiac surgery or procedures, history of hypertension, dyslipidaemia, diabetes, 
respiratory disease, renal disease, liver disease, cerebrovascular disease or 
malignancy. Participants were also asked to provide information about smoking habit 
and alcohol intake. Current medication and history of adverse or allergic medication 
reactions were documented.  
 
Clinical Examination 
Each participant had their height and weight recorded, which was then used to 
calculate body mass index and surface area. Heart rate and blood pressure (by 
automated sphygmomanometry) were measured. A standardised cardiovascular 
clinical examination was performed in each case with the participant positioned at 45 
degrees in a semi-reclined position. The rate, regularity, volume and character of the 
pulse, the height and characteristics of the jugular venous pressure, the location and 
character of the left ventricular apex beat, and fluid status were assessed. Heart sounds 
were evaluated by auscultation with additional sounds and murmurs being noted. The 
lung fields were auscultated for evidence of inspiratory crepitations which might 
signify pulmonary oedema.  
 
Venesection 
Venesection was performed at stipulated points according to study protocol and 
undertaken in conjunction with peripheral venous cannulation where this was required. 
Up to 40ml of venous blood was withdrawn and samples used to measure the full blood 
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Participants were all assessed with a 12-lead electrocardiogram (ECG), which was 
printed and filed in the case record. The ECG was examined for features consistent 
with arrhythmia, conduction disease, ischaemia, left ventricular hypertrophy and left 
ventricular strain. Left ventricular hypertrophy was diagnosed using the Romhilt-Estes 
criteria (5 points diagnostic; 4 points probable): any one of R or S in limb leads >20 
mm, S in V1 or V2  > 30 mm, R in V5 or V6  > 30 mm = 3 points; ST-T vector opposite 
to QRS without digoxin = 3 points or ST-T vector opposite to QRS with digoxin = 1 
point; negative P wave in V1 > 1 mm depth and > 0.04 s = 3 points; left axis deviation 
(axis -30o or more) = 2 points; QRS duration > 0.09 s = 1 point; delayed intrinsicoid 
deflection V5 or V6 > 0.05 s = 1 point. Left ventricular strain was diagnosed if there 
was ST depression and T wave inversion in the anterolateral chest leads.  
 
One study comparing ECG-based approaches for the diagnosis of left ventricular 
hypertrophy has suggested that the Romhilt-Estes criteria, using a threshold of 4 
points, has a sensitivity of 11.9% (95% confidence interval 5.3-22.2%) and specificity 
of 96.7% (95% confidence interval 88.5-99.6%) for the detection of left ventricular 
hypertrophy as defined by echocardiography when left ventricular mass is corrected 
for body surface area and sex-specific thresholds are employed. (Morrison I et al, 





Physics of Echocardiography 
The first clinical application of ultrasound was in diagnostic brain imaging in the 
1930s, whereby a separate transmitter and receiver were used to detect transmission 
of ultrasound waves through the head. Modern day cardiac ultrasound is based upon 
detection of the reflection of ultrasound waves by a single transducer (both transmitter 
and receiver) and originated in 1953 in Sweden, later being termed echocardiography. 
Ultrasound refers to sound waves with a frequency >20 kHz and in echocardiography 
transducers work using the piezoelectric effect. Piezoelectric crystals change shape 
when an electrical voltage is applied and can be made to oscillate rapidly by applying 
an alternating voltage, thereby generating ultrasound. As ultrasound travels through 
the body, each tissue has a different acoustic impedance which results in varying 
degrees of reflection as ultrasound waves meet tissue boundaries. Returning 
ultrasound waves will then cause the piezoelectric crystals to oscillate and so generate 
an electrical voltage which can be detected.  
 
The Doppler effect describes how an observer perceives a difference in the wavelength 
or frequency of a sound wave depending on movement of the source relative to them. 
For example, if a source is moving towards the observer then the sound wave 
wavelength shortens and frequency increases, with the converse also being true. The 
difference in frequency between the transmitted and returning ultrasound beams is 
used to calculate the Doppler shift. By this principle, Doppler echocardiography allows 
characterisation of the direction and velocity of blood flow in the heart and great 
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vessels, which is fundamental to the assessment of valve function. The Doppler effect 
can also be used to measure movement of the myocardium (tissue Doppler imaging) 
and help in the assessment of left ventricular systolic and diastolic function. 
 
Image Acquisition  
Transthoracic echocardiography is the principal non-invasive imaging method for 
assessment of aortic valve heart disease. Standard echocardiographic assessment 
involves the use of ultrasound to produce 2-dimensional images in a number of 
anatomical planes with high spatial and temporal resolution. In addition, the use of 
colour flow, pulsed and continuous wave Doppler facilitates a detailed assessment of 
native and prosthetic valve function. The aortic jet velocity can be measured from 
continuous wave Doppler aligned to blood flow through the aortic valve, which can 
be used to derive the peak and mean aortic valve gradients. The estimated aortic valve 
area can also be calculated from the continuity equation (aortic valve area = [left 
ventricular outflow tract velocity-time integral x left ventricular outflow tract area] / 
aortic valve velocity-time integral).  
 
Comprehensive transthoracic echocardiography was performed at intervals in all study 
participants. Echocardiography was performed by a single experienced British Society 
of Echocardiography-accredited sonographer using a single scanner (Affiniti 70, 
Philips Medical Systems, The Netherlands) according to international guidelines 
(Lancelloti P et al, 2016) (Zoghbi W et al, 2009). Left ventricular outflow tract 
diameter was measured from the inner edge of the septal endocardium to the inner 
edge of the anterior mitral valve leaflet in mid-systole. Left ventricular outflow tract 
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velocity-time integral was measured in the apical 5-chamber view using pulsed-wave 
Doppler positioned just proximal to the aortic valve. Aortic valve peak gradient, mean 
gradient and peak aortic jet velocity were calculated from the aortic valve velocity-
time integral, measured using a continuous wave Doppler. The aortic valve velocity-
time integral was sampled from the apical, suprasternal and right parasternal position 
using both the standard phased array probe and standalone pencil probe. Mean values 
were taken from 3 measurements when subjects were in sinus rhythm and from 5 
measurements if atrial fibrillation was present. This was the approach used in the 
assessment of both native aortic valve and prosthetic aortic valve function.  
 
Aortic valve regurgitation was graded as mild, moderate or severe according to 
guideline recommendation on the basis of visual appraisal of colour flow mapping in 
multiple acoustic planes. In addition, the pressure half time (ms), vena contracta width 
(cm), regurgitant volume (mL), regurgitant fraction (%), regurgitant jet width/left 
ventricular outflow tract diameter, and evaluation of aortic flow reversal in diastole 
were all used as appropriate to help guide severity assessment.  
 
Reproducibility 
Echocardiography in the assessment of aortic valve disease is highly reproducible 
when performed by experienced observers. In a study of 150 patients with moderate 
aortic stenosis, the intra-observer variation and reproducibility coefficients were 
1.88% and 0.16 et al respectively for peak aortic jet velocity, and 2.08% and 0.14 et al 
for LVOT velocity/peak aortic jet velocity, whilst inter-observer variation and 
reproducibility coefficients were 2.00% and 0.14 et al for peak aortic jet velocity, and 
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2.08% and 0.14 et al for LVOT velocity/peak aortic jet velocity (Moura L et al, 2011, 
Rev Port Cardiol). It appears to be more reproducible to measure the peak of a Doppler 
trace rather than the velocity time integral, so peak aortic jet velocity and the ratio of 
left ventricular outflow tract velocity to peak aortic jet velocity offer the best 
variability and reproducibility amongst measures of aortic stenosis severity. In another 
study, 25 observers independently reviewed Doppler tracings from 20 patients with 
aortic stenosis and demonstrated the superior reproducibility of measuring peak 
velocity rather than velocity time integral (coefficient of variation 10.1% vs. 18.0% 
for LVOT pulsed wave Doppler, p<0.001) (coefficient of variability 4.0% vs. 10.2% 
for peak aortic jet velocity continuous wave Doppler, p<0.001) (Sacchi S et al, 2018). 
We have also previously demonstrated excellent reproducibility of echocardiography 
in the assessment of aortic stenosis specifically in our centre, which can be enhanced 




FIGURE 2.1.  
Transthoracic echocardiography in the assessment of aortic stenosis. 
Figure 2.1. Images from a transthoracic echocardiogram of a patient with aortic 
stenosis showing severe fibrocalcific thickening of a trileaflet aortic valve in the 
parasternal short axis (A) and parasternal long axis (B), and a continuous wave 
Doppler profile aligned to the aortic valve in the apical 5-chamber view with 
measurements consistent with severe aortic stenosis (C).    
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2.5 COMPUTED TOMOGRAPHY  
 
Physics of Computed Tomography 
X-ray, or Rontgen radiation, is a highly penetrative form of electromagnetic radiation 
emitted when accelerated electrons collide with a target anode. Conventional clinical 
radiography is the product of an X-ray photon beam being attenuated to varying 
degrees depending on the density of tissue through which it passes, and results in a 2-
dimensional projection of a 3-dimensional structure. Computed tomography (CT) is 
based upon the principle of conventional radiography that different tissues can be 
distinguished by their relative ability to absorb photons (attenuation coefficients). 
However, the detectors of a CT scanner do not produce an image but rather measure 
the passage of a thin (1-10 mm) X-ray beam through the body. In modern CT scanners, 
one or more X-ray photon beams and detector rays are mounted on a rapidly rotating 
gantry and the information from the intersection of beams is used to generate cross-
sectional (tomographic) images. The cross-sectional area created by the intersection 
of 2 beams is referred to as a pixel and is multiplied by slice width to produce voxels, 
producing a matrix of up to 1024 x 1024 voxels. The attenuation coefficient is 
calculated for each voxel and converted to Hounsfield scale (HU). Cross-sectional 
images are then digitally ‘stacked’ to create a 3-dimensional reconstruction of the 
scanned volume. Thus, CT can provide a detailed anatomical assessment of the 





Participants were imaged using a hybrid 128-slice PET/CT scanner (Biograph mCT, 
Siemens Medical Systems, Erlangen, Germany). If the resting heart rate prior to 
scanning was > 60 /min, medication (usually betablockade) was administered as 
appropriate to suppress the heart rate with a view to optimising image quality and 
limiting radiation exposure. Participants were asked to lie supine with both hands 
above the head and attached to a 3-lead ECG monitor. Non-contrast CT was centred 
on the aortic valve and acquired with electrocardiogram-gating during held expiration 
(40 mAs/rot [CareDose], 120 kV tube voltage, pitch 0.24, field of view 210 mm). 
Contrast-enhanced CT angiography was timed to obtain peak arterial enhancement in 
the aortic root, with a 20-mL test bolus of contrast given to determine the appropriate 
trigger delay and, depending on body mass index, 80-100 mL of contrast (400 mgI/mL; 
Iomeron, Bracco, Milan, Italy) administered for the acquisition. This was performed 
with either prospective (heart rate <60 /min) or retrospective (heart rate >60 min) 
electrocardiogram-gating during held expiration (330 ms rotation time, 100-120 kV 
tube voltage, 160-245 mA tube current and 3.8 mm/rotation table feed).  
 
All scans were supervised by experienced radiographers and a medical practitioner. 
Patient radiation exposure was recorded and periodically reviewed by the medical 
physics department. Patients were observed for at least 5 min after scanning for 
evidence of contrast-related reactions before their venous cannula was removed and 
they were released from the department. All scans were reported by a consultant 
radiologist and incidental findings were acted upon as appropriate.  
 
 84 
Aortic Valve Calcium Scoring 
Image Reconstruction 
Non-contrast CT images in the scanned volume were reconstructed in diastole in the 
axial plane with a 3-mm slice thickness, using a B35f kernel and standard filtered back 
projection reconstruction algorithm.  
 
Image Analysis 
Aortic valve calcification was assessed using the dedicated CT VscoreTM application 
within the Vitrea Advanced analysis software (Vitrea Advanced, Vital Images, 
Minnetonka, USA). Aortic valve calcification was manually selected on 3-mm axial 
slices through the valve and surrounding structures. Beginning at the base of the valve, 
careful attention was paid to distinguish calcification of the aortic valve from that of 
other structures including the mitral annulus, left ventricular outflow tract and 
coronary arteries. If confluent calcification extended into the ascending aorta, the 
ostium of the left coronary artery was used as the anatomical limit beyond which 
calcification was excluded. Calcification was defined on the Hounsfield scale as at 
least 3-4 adjacent pixels with a radiodensity ≥ 130 HU. The calcium score was 
calculated in Agatston Units (AU) by applying an arbitrary weighted density score 
(130-199 HU = 1; 200-299 HU = 2; 300-399 HU = 3 and ≥ 400 HU = 4) and then 
multiplying by the area (mm3). Aortic valve calcium volume and CT-aortic valve 
calcium score (CT-AVC) (Agatston Units, AU) were recorded.  
 
The measurement of CT-AVC in patients with aortic stenosis is repeatable, with very 
good inter-observer reproducibility (median CT-AVC 1207 AU, mean difference 0%, 
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[limits of agreement -6 to 5%]) and intra-observer scan-rescan reproducibility (median 
CT-AVC 1149, mean difference 2% [limits of agreement -12 to 16%]) (Jenkins WSA 
et al, 2018). This has similarly been demonstrated for measurement of aortic valve 
calcium volume (correlation coefficient r=0.99, median interscan variability 7.9%, 
repeatability coefficient 237.8 mm3, limits of agreement −393 to 559 mm3). As 
expected, proportional bias is evident whereby scan-rescan differences are greater in 
patients with higher calcium burden (Messika-Zeitoun D et al, 2004). 
 
CT Angiography  
Image Reconstruction 
Contrast-enhanced CT images in the scanned volume were reconstructed in diastole 
with a 1 mm slice thickness, using a B35f kernel and standard filtered back projection 
reconstruction algorithm.  
 
Image Analysis 
Analyses were performed using an OsiriX workstation (OsiriX version 8.0.3 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). The diastolic sequence offering the 
best image quality was selected and a 3-dimensional multi-planar reconstruction was 
re-oriented to the short axis plane of the aortic valve. This allowed measurement of the 
dimensions of the aortic valve annulus and assessment of valve pathology such as 
leaflet calcification or non-calcific leaflet thickening. In the evaluation of patients with 
bioprosthetic aortic valves, CT scans were determined to be abnormal if there was 
evidence of circumferential pannus extending into the valve cusps, spotty leaflet 
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calcification (<3 mm) (Motoyama S et al, 2007), large leaflet calcification (≥3 mm) or 
non-calcific thickening (≥2 mm) (Figure 2.2).  
 
In the evaluation of patients with native aortic valve stenosis, quantification of aortic 
valve calcium volume and non-calcific leaflet volume were quantified using 
SliceOmatic (Tomovision, Magog, Canada). Using re-oriented short axis images, the 
region-growing tool was employed to select voxels within a defined range of 
attenuation values. The lower threshold for detection of calcium was 3 standard 
deviations of the Hounsfield units within the blood pool region of interest above mean 
blood pool attenuation. For non-calcific leaflet tissue, a fixed lower threshold of 30 
HU was employed to exclude artifact (e.g. photon starvation adjacent to dense 
calcification). The upper threshold for non-calcific tissue was calibrated to blood pool. 
Using these thresholds, areas of calcium and non-calcific leaflet thickening were 
assessed and quantified. Each adjacent 3-mm slice was assessed so that the whole 
volume of the valve was covered, with care to avoid regions of calcification in the 





CT to detect leaflet pathology in the assessment of bioprosthetic valves. 
 
Figure 2.2. CT can be used to identify bioprosthetic valve leaflet pathology in vivo, 
for example, normal appearance of a bioprosthetic valve (A), an isolated calcific 
nodule (B), hypoattenuation leaflet thickening implying leaflet thrombosis (C) and a 
circumferential rim of low attenuation consistent with pannus (D).  
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2.6 18F-FLUORIDE POSITRON EMISSION TOMOGRAPHY / 
COMPUTED TOMOGRAPHY 
 
Physics of Positron Emission Tomography  
Positron emission tomography (PET) is a non-invasive medical imaging technique that 
permits the detection and quantification of active metabolic processes in the human 
body. The positron is released by unstable positron-emitting nuclei, such as 18F-
fluoride, following radioactive decay of a proton to a neutron (beta decay). The 
positron travels a short distance (millimetres) before colliding with an electron, 
resulting in annihilation of both particles and the release of two photons directed at 
nearly 180º degrees to one another with a fixed energy of 511 keV. That the origin of 
these tangential photons may be localised to a ‘line of coincidence’ using a ring of 
detectors encircling a patient forms the basic principle of clinical PET imaging. From 
the accumulation of events detected over a period of time, the originating point of these 
collisions can be computed, and a 3-dimensional image reconstructed.  
 
Radioactive PET tracers comprise a positron emitter and a molecular vehicle selected 
to interact with a metabolic process of interest. The tracer is injected into an individual 
and the PET scanner detects emitted radiation to localise and to quantify the 
pathophysiological process in question. The resolution of clinical PET imaging is 
restricted by the distance that the emitted positron travels before annihilation, with 
modern clinical PET cameras achieving a resolution of ~2.36 mm (Moses et al, 2011) 
which compares with ~0.5 mm for modern CT scanners. We have combined PET with 
CT imaging by using a hybrid scanner where both technologies are incorporated in the 
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same gantry and scanning modalities can be performed sequentially with the patient 
lying in the same position. This allows an attenuation correction CT scan to be 
performed in order to adjust PET data according to the density and volume of tissue 
through which photons have travelled. Hybrid scanning also permits co-registration of 
PET and CT images so that functional data from PET tracer uptake can be combined 
with detailed anatomical information from CT. Radiation exposure is greater by virtue 
of performing both imaging modalities but remains modest, in the region of 5 





FIGURE 2.3.  





Figure 2.3. 1. 18F-Fluoride binds to hydroxyapatite in the cardiovascular system and 
skeleton. 2. Beta decay of 18F-fluoride results in release of a positron. 3. After 
travelling a short distance (millimetres), the positron collides with its anti-particle, an 
electron, which results in an annihilation reaction. 4. The annihilation reaction releases 
two photons with a fixed energy of 511 keV in opposite directions (180 degrees) to 
one another. 5. This activity is sensed by a ring of detectors which convert the signal 
into an electronic pulse. Two electronic pulses detected in coincidence confirms the 
presence of an annihilation reaction somewhere along the line of response. 6. This data 




18F-Fluoride was synthesised in the on-site cyclotron in the Edinburgh Imaging facility 
at the University of Edinburgh by radiochemistry staff. 18F-Fluoride is produced 
primarily by proton irradiation of 18Oxygen, a stable naturally occurring isotope of 
oxygen, in aqueous H218O. Radioisotope was produced on the day of administration 
and quality assurance checks were satisfied prior to approval for human use. 
 
Image Acquisition 
As already described, participants’ height and weight were measured to facilitate 
correct setup of the scan, and a peripheral venous cannula was inserted. If the resting 
heart rate prior to radioactive tracer injection was > 60 /min, 25-50 mg oral metoprolol 
was administered where safe and appropriate to suppress the heart rate. Participants 
were transferred to a lead-lined uptake room under video surveillance where a target 
dose of 125 MBq of 18F-sodium fluoride was administered intravenously by PET-
trained radiographers, with an expected effective radiation dose of 3 mSv. 
Pharmacokinetic modelling has previously demonstrated that 60 min post-
administration provides optimal vascular tissue contrast resolution (Irkle et al, 2015). 
Therefore, on approaching 60 min following tracer administration, participants were 
asked to empty their bladder in dedicated facilities and transferred to the scanner. They 
were asked to lie supine with both hands above their head and were attached to a 3-
lead ECG monitor.  
 
18F-Fluoride PET/CT of the thorax was performed using a hybrid 128-slice PET/CT 
scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany). An 
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attenuation correction CT scan was performed initially (without contrast enhancement, 
120 kV, 50 mA, slice thickness 5 mm, increment 3 mm). PET data was then acquired 
in 3-dimensional list mode over a single 30-min bed position centred over the aortic 
valve. A simultaneously acquired ECG allowed segregation of PET data into 4 phases 
according to the R-R interval. Immediately after the PET scan, an ECG-gated, 
contrast-enhanced CT angiogram was performed for co-registration with PET. The 
acquisition protocol for CT has been described above.  
 
Image Reconstruction 
Static PET images were reconstructed with correction applied for attenuation, dead 
time, scatter and random coincidences, using an optimised iterative reconstruction 
algorithm (Siemens Ultra-HD; TrueX + time of flight, matrix 200, zoom 1; Gaussian 
filter).   
 
Image Analysis 
Analyses were performed using an OsiriX workstation (OsiriX version 8.0.3 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). In order to counteract the significant 
motion during the cardiac cycle, ECG-gated contrast-enhanced CT images were 
reconstructed in diastole using 1-mm slices. For this purpose, list mode PET data was 
also configured to the ECG and used to reconstruct at 25% intervals of the cardiac 
cycle with diastolic data determined as that acquired between 50 and 75% of the R-R 
interval. Diastolic PET and CT reconstructions were reoriented to the short axis plane 
of the aortic valve (native or bioprosthetic), fused and carefully co-registered in all 3 
planes using the 2-D orthogonal tool. Key points of reference for co-registration were 
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the sternum, vertebrae, blood-pool in the left ventricle (based upon the high 18F-
fluoride activity in the blood relative to the surrounding myocardium), the ascending 
aorta and the aortic arch.   
 
Regions of interest in the native or bioprosthetic aortic valve were manually selected 
to generate maximum and mean standardised uptake values (SUV). The SUV is the 
decay-corrected tissue concentration of a tracer divided by the injected dose per body 
weight; each image voxel represents a SUV that is derived during image 
reconstruction. SUVs were corrected for residual blood pool activity, measured with a 
2 cm2 region of interest drawn on 3 contiguous slices in the right atrium from the level 
of the right coronary ostium, to produce a tissue-to-background ratio (TBR). 
Cardiovascular PET imaging may be hampered by both cardiorespiratory motion and 
proximity to the blood pool. These factors amount to potential sources of error when 
quantifying the radiotracer signal within a cardiovascular tissue of interest, making the 
use of TBR quantification preferential over SUV alone. Both a ‘whole valve’ approach 
and a ‘most diseased segment’ (MDS) approach to measuring tracer activity in the 
tissue of interest were explored, and the refinement of this technique is described in 
Chapter 4.  
 
The reproducibility of the quantification of 18F-sodium fluoride in the aortic valve has 
previously been examined, optimised by the reorientation of PET/CT images into the 
short axis plane of the valve and by the use of mean TBR values. Using this method, 
good repeatability has been demonstrated with narrow limits of agreement (±0.20) and 
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intraclass coefficients for both intra-observer and inter-observer reproducibility > 0.95 




FIGURE 2.4.  
Methodology for co-registration of positron emission tomography and contrast 
computed tomography in bioprosthetic aortic valves. 
 
 
Figure 2.4. Careful alignment of PET tracer uptake in the cardiac blood pool with 
contrast-enhanced CT images (already re-orientated into the short axis of the aortic 
valve) was performed in 3 planes (left). This was possible because of high 18F-fluoride 
activity in blood pool compared to the myocardium.  Subsequently PET tracer uptake 
in the ascending aorta and aortic arch (centre) was aligned with the CT and final 
refinement of co-registration was performed according to landmarks around the aortic 




2.7 MICRO-18F-FLUORIDE POSITRON EMISSION 
TOMOGRAPHY / COMPUTED TOMOGRAPHY 
 
Micro-PET/CT describes the use of a pre-clinical scanner for molecular or functional 
imaging of biochemical processes on a miniaturised scale.  This facilitates imaging of 
anaesthetised small animal subjects or ex-vivo tissue. The fundamental resolution of a 
pre-clinical PET scanner (0.67 mm full width at half maximum) is superior to that of 
a clinical PET scanner (1.83 mm full width at half maximum). Micro-PET/CT was 
performed to explore the mechanisms of bioprosthetic aortic valve degeneration, 
allowing correlation between high resolution images and histological analyses.  
 
Explanted degenerated aortic valve bioprostheses were obtained with written consent 
from patients undergoing repeat surgical aortic valve replacement for bioprosthetic 
valve failure. Valves were weighed, photographed and their macroscopic features 
documented. Ex-vivo micro-PET/CT was performed with a nano-PET-CT scanner 
(Mediso, Hungary) before undergoing histological evaluation. A series of scans using 
variations in acquisition parameters and scanning mediums were undertaken to arrive 
at the optimal method. Explanted valves were incubated with 2 MBq 18F-fluoride for 
20 min and PET data were acquired over a 30-min bedtime using 1:5 coincidence 
mode. A micro-CT was then acquired (semi-circular full trajectory, maximum field of 
view, 720 projections, 70 kVp, exposure 300 ms and 1:1 binning) for attenuation 
correction and anatomical co-registration. PET data were reconstructed using 
Mediso’s iterative Tera-Tomo 3D algorithm and the following settings: 4 iterations, 6 
subsets, full detector model, normal regularization, spike filter on, voxel size 0.6 mm, 
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400-600 keV energy window. Analysis was performed using PMOD (PMOD 
Technologies, Switzerland) to localise and quantify 18F-fluoride activity and 




2.8 HISTOLOGICAL VALIDATION  
 
To characterise the pathophysiology underlying the imaging observations made in 
these investigations, excised native aortic valve tissue and bioprosthetic valve tissue 
was obtained for histological examination. All patients provided prior written 
informed consent. These analyses were performed by collaborating groups at the 
University of Laval (Quebec, Canada), the University of British Columbia 
(Vancouver, Canada) and the CVPath Institute (Gaithersburg, Maryland, USA).  
 
In patients undergoing aortic valve replacement, the aortic valve (native or 
bioprosthetic) was excised at the time of surgery and the integrity of the valve structure 
was preserved wherever possible. Explanted valve specimens were fixed in 10% w/v 
buffered formalin phosphate (Fisher Chemical SF100-20) pending histological 
analysis. Heavily calcified samples were treated with fixative decalcifier to facilitate 
sectioning (Fisher Chemical, Cal-Ex II, CS511-1D). Leaflets were detached from the 
base of the valve and marked with tissue dye fixed with acetic acid to maintain 
orientation. Each leaflet was processed then sectioned into 2-4 mm sections and 
embedded in paraffin sequentially to yield 7-8 tissue cross-sections per leaflet. Paraffin 
sections (4 µm) were used for histology and immunohistochemistry (IHC). Tissue was 
sectioned and stained for architecture (haematoxylin and eosin, Movat pentachrome, 
Verhoeff-van Gieson), calcium phosphate (von Kossa, Alizarin red), thrombus and 
fibrosis (Movat Pentachrome), and collagen (Picrosirius red). Visual assessment was 
performed by experienced pathologists and reported.  
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Histology Tissue Staining Protocols 
Haematoxylin and Eosin: Eosin is an acidic dye which stains basic structures pink, 
such as cytoplasm or extracellular fibres. Haematoxylin is a basic dye which stains 
acidic structures, such as nuclei, a purple-blue colour. Tissue sections were 
deparaffinised using heat and immersion in xylene. Sections were then hydrated by 
passing through decreasing concentrations of alcohol before firstly being stained with 
haematoxylin for 3-5 min. Sections were washed under running water for several 
minutes, treated in 1% hydrochloric acid alcohol, washed, treated in ammonia and then 
washed again prior to staining with eosin for 10 minutes. Finally, tissue sections were 
washed in running water, dehydrated in increasing concentrations of alcohol, cleared 
in xylene and mounted in mounting media ready for microscopy.  
 
Movat Pentachrome: This is a five-colour stain which highlights the constituents of 
connective tissue, with nuclei and elastin staining black, collagen staining yellow, 
mucin staining blue, fibrin staining bright red and muscle staining red. Tissue sections 
were deparaffinised and hydrated as above. Tissue was subject to a Bouins mordant, 
heated in a microwave and rested for 10 min. After washing in cold running water, 
sections were treated in sodium thiosulphate for 5 min then again washed and stained 
with 1% Alcian Blue for 20 min. After a wash, sections were placed in preheated 
alkaline alcohol for 10 min, again rinsed then treated in Movat’s Weigerts for 1 hour. 
A further wash was followed by treatment in Crocein scarlet/acid fuchsin for 1 minute, 
a rinse, treatment in 5% phosphotungstic acid for 5 minutes, transfer to 1% acetic acid 
for 5 min, a rinse, dehydration in increasing concentrations of alcohol and then 
treatment in alcoholic saffron for 20 min. A final rinse with 2 changes was performed 
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in 100% ethanol before clearing in xylene and mounting in mounting media for 
microscopy.  
 
Verhoeff-van Gieson: This method stains collagen red, nuclei blue, erythrocytes and 
cytoplasm yellow, and elastin blue/black. Tissue sections were deparaffinised and 
hydrated to distilled water, then stained in Verhoeff’s solution for 1 hour. After a tap 
water rinse, sections were differentiated in 2% ferric chloride for 1-2 min then washed 
in several changes of tap water to stop differentiation. Sections were treated in 5% 
sodium thiosulphate for 1 min, rinsed in tap water, then counter-stained with van 
Gieson’s solution for 3-5 min. Finally, sections were dehydrated through increasing 
concentrations of alcohol, cleared in xylene and mounted in mounting medium.  
 
Von Kossa: Silver ions bind phosphate ions and undergo photochemical degradation 
to visualise silver deposits as a metallic silver colour on microscopy. Tissue sections 
were deparaffinised and hydrated as above, then immersed in 5% aqueous silver 
nitrate. Sections were then exposed to ultraviolet light for 20 min, washed in distilled 
wated then treated with 2% sodium thiosulphate for 2 min. After rinsing, sections were 
counter-stained with 1% neutral red for 2 min. They were then dehydrated in alcohol, 
cleared in xylene and mounted in mounting medium.  
 
Alizarin Red: This stain binds calcium to form a lake pigment that is orange-red in 
colour. Mounted tissue sections were deparaffinised and hydrated. Sections were 
stained with the Alizarin red solution for up to 5 min under microscope observation 
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then dried and blotted. Sections were dehydrated in acetone, then acetone-xylene, 
cleared in xylene and mounted in mounting medium.  
 
Picrosirius Red: In bright field microscopy this stains collagen red and nuclei, 
cytoplasm and muscle fibres yellow. Tissues sections were deparaffinised and 
hydrated. Nuclei were stained with Weigert’s haematoxylin for 8 min, then thoroughly 
rinsed in running water. Sections were stained with picrosirius red for 1 hour then 
washed in 2 changes of acidified water and dried. Finally, slides were dehydrated, 





2.9 STATISTICAL ANALYSIS 
 
Baseline characteristics are reported as number (percentages) for categorical variables 
and mean ± standard deviation or median [interquartile range] for continuous variables 
depending on whether variables were normally distributed. Categorical data were 
compared using chi-squared or Fisher’s exact tests. Continuous variables were 
transformed where not normally distributed. The point-biserial correlation coefficient 
was used to measure the strength and direction of the association between one 
dichotomous variable and one continuous variable. One-way ANOVA was used to 
compare continuous data across multiple factors, with post-hoc analysis using the 
Bonferonni test where appropriate. The Student’s t-test or Mann-Whitney U test were 
used to compare continuous outcomes between two independent groups depending on 
whether they were or were not normally distributed, respectively. The Student’s t-test 
or Wilcoxon signed-rank test were employed to compare paired variables. Two-tailed 
Pearson’s correlation analysis was performed to investigate the strength of linear 
relationship between two variables, for example, between 18F-fluoride uptake and 
echocardiographic measures of valve function. Multivariable analysis was performed, 
for example, to assess the predictors of deterioration in bioprosthetic valve 
dysfunction. Reproducibility was analysed and presented using Bland-Altman 
analyses and intraclass correlation coefficients (ICC). Statistical analysis was 
undertaken using IBM SPSS Statistics 23 or Graph Pad Prism 6 (GraphPad Software 
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Computed tomography (CT) aortic valve calcium scoring is an emerging marker of 
disease severity in patients with aortic stenosis but ignores the substantial contribution 
of valvular fibrosis.  
 
Objectives 
To assess aortic valve fibro-calcific burden using contrast-enhanced CT in patients 
with aortic stenosis. 
 
Methods  
Patients with and without aortic stenosis (38 normal, 39 mild, 78 moderate, 26 severe) 
underwent echocardiography, CT aortic valve calcium score and contrast-enhanced 
CT. Volumes of calcific and non-calcific (fibrosis) valve tissue were quantified and 
indexed to annulus area, using Hounsfield unit thresholds calibrated against blood-
pool radiodensity. The fibro-calcific ratio assessed the relative contributions of valve 
fibrosis and calcification. The fibro-calcific burden (sum of indexed non-calcific and 
calcific volumes) was determined and validated against ex-vivo valve weight.  
 
Results 
Contrast-enhanced CT calcium volumes correlated closely with CT calcium score 
(r=0.86, p=<0.001), and moderately with peak aortic-jet velocity on echocardiography 
(r=0.57 p<0.001). Non-calcific leaflet volumes were similar to calcific volumes in 
patients with aortic stenosis (79 [52-100) versus 75 [40-138] mm3/cm2, p=0.209). 
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Fibrosis predominated in mild stenosis while calcification dominated in severe disease 
(fibro-calcific ratio: 1.33 [0.91-2.4]) versus 0.53 [0.35-1.05] respectively; p=0.001).  
Males exhibited more valve calcium than fibrosis, with the reverse true for females 
(fibro-calcific ratio: 0.89 [0.45-1.54] versus 1.49 [0.82-5.74] respectively; p=0.001). 
The fibro-calcific burden demonstrated the strongest correlation with peak aortic-jet 
velocity (r=0.71, p<0.001), especially in women (r=0.77, p=0.001) where it 
outperformed CT calcium score (r=0.27, p=0.216) (p=0.027). The fibro-calcific 
burden correlated closely with ex vivo valve weight (r=0.88, p<0.001), providing a 
closer association than CT calcium score, especially in women.  
 
Conclusions 
Aortic valve fibrosis is a major contributor to the evolution of aortic stenosis 
particularly in women. Fibro-calcific burden outperforms aortic valve calcium score 
as a measure of disease severity and could add value in patients with discordant 






The pathogenesis of aortic stenosis involves an initiation phase characterised by 
mechanical injury, lipid deposition and a localised inflammatory response, followed 
by a propagation phase wherein progressive valve fibrosis and calcification promote 
worsening valvular stenosis (Pawade TA et al, 2015).  
 
Recent guidelines have recommended non-contrast CT calcium scoring of the aortic 
valve (CT-AVC) as an additional method of assessing aortic stenosis severity when 
echocardiographic measurements are discordant (Baumgartner H et al, 2017). This 
recommendation is based upon data demonstrating the diagnostic accuracy of CT-
AVC and its powerful prediction of both disease progression and clinical events 
(Clavel MA et al, 2013; Clavel MA et al, 2014; Pawade TA et al, 2018). However, 
CT-AVC has several important limitations. First, it offers little detail about valve 
morphology and is unable to localise the anatomical distribution of calcium in the 
valve and surrounding structures. Second, CT-AVC cannot quantify fibrosis, an 
important contributor to valve stenosis and can therefore misclassify disease severity, 
particularly amongst young women and those with bicuspid valves (Shen M et al, 
2016; Simard L et al, 2016). Third, it demonstrates only moderate associations with 
hemodynamic severity on echocardiography and different severity thresholds are 
required in the two sexes, with women consistently demonstrating lower calcium 
burden for a given degree of valvular stenosis, even after correction for body size 
(Clavel MA et al, 2013; Clavel MA et al, 2014; Pawade TA et al, 2018).  
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Contrast CT angiography is widely used to assess and to quantify both calcific and 
non-calcific plaques in the coronary vasculature (Dweck MR et al, 2016). In the 
present study, we aimed to apply a similar approach to the aortic valve, allowing 
evaluation of the aortic valve calcium burden but also non-calcific leaflet thickening 
as a marker of valve fibrosis. We hypothesised that this technique would provide novel 
insights into the pathogenesis of aortic stenosis and improve the quantification of 







Individuals over the age of 50 years with mild, moderate and severe aortic stenosis 
were prospectively recruited from the Edinburgh Heart Centre. This was a substudy of 
the SALTIRE 2 randomised controlled trial of novel drug treatments in aortic stenosis 
(NCT 02132026) and patient eligibility was defined by the inclusion and exclusion 
criteria for this study, detailed below. Written informed consent was obtained from all 
participants. The study was approved by the South East Scotland Research Ethics 
Committee, the Medicine and Healthcare products Regulatory Agency (MHRA) of the 
United Kingdom and conducted in accordance with the Declaration of Helsinki. 
Volunteers without clinical or imaging evidence of aortic valve disease were recruited 
from a coronary heart disease population to provide a control cohort (NCT 02110303).  
 
Study Patient Selection Criteria 
Inclusion Criteria  
For inclusion in the study, participants should fulfil the following criteria:  
Age > 50 years; peak aortic jet velocity >2.5 m/s on Doppler echocardiography; grade 
2-4 calcification of the aortic valve on echocardiography. 
 
Exclusion Criteria  
Participants will not enter the study if any of the following exclusion criteria are 
fulfilled:  
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Women of childbearing potential who are premenopausal, have not been sterilised or 
who are currently pregnant; women who are breastfeeding; renal failure (estimated 
glomerular filtration rate of <30 mL/min); inability to undergo scanning; allergy or 
contraindication to iodinated contrast; inability or unwilling to give informed consent; 
likelihood of non-compliance to treatment allocation or study protocol; anticipated or 
planned aortic valve surgery in the next 6 months; life expectancy less than 2 years; 
treatment for osteoporosis with bisphosphonates or denosumab; known allergy or 
intolerance to alendronate or denosumab, or any of their excipients; abnormalities of 
the oesophagus or conditions, which delay oesophageal/gastric emptying; inability to 
sit or stand for at least 30 minutes; hypocalcaemia; regular calcium supplementation; 
dental extraction within 6 months; long term corticosteroid use; history of 
osteonecrosis of the jaw; poor dental hygiene.  
 
Study Assessments and Data Collection  
Potential participants with aortic stenosis were approached by the clinical team and 
attended for an initial visit with clinical evaluation and Doppler echocardiography to 
assess the severity of aortic stenosis. Participants fulfilling the eligibility criteria were 
then invited to undergo baseline clinical assessment, electrocardiography (ECG), non-
contrast CT-AVC and contrast-enhanced CT angiography. Randomization to 
investigational treatment or placebo was undertaken at a subsequent visit outwith the 





A comprehensive echocardiographic assessment was performed at baseline by a single 
experienced British Society of Echocardiography (BSE)-accredited sonographer using 
a standardised protocol (Bushra R et al, 2012). The principal measure of hemodynamic 
aortic stenosis severity was the peak aortic-jet velocity but mean gradient, aortic valve 
area (calculated using the continuity equation) and indexed aortic valve area were also 
recorded. Aortic valve Doppler measurements were routinely assessed from the apex, 
suprasternal notch and right sternal edge.  Mean values were taken from 3 
measurements when subjects were in sinus rhythm and from 5 measurements when in 
atrial fibrillation.   
 
Computed Tomography 
Baseline CT imaging was performed on a 128-detector CT scanner (Biograph mCT, 
Siemens). Electrocardiography (ECG)-gated non-contrast CT-AVC and contrast-
enhanced CT angiography were performed in diastole and held expiration. Prior to 
scanning, participants were given 25 mg of oral metoprolol if their resting heart rate 
was >65 beats/min in the absence of any contraindication. 
 
All CT analyses were performed blinded to the echocardiographic assessments of 
aortic stenosis severity. CT-AVC was quantified by an experienced operator (TP) 
using dedicated software (Vitrea Advanced; Toshiba Systems) on axial views, with 
care taken to exclude calcium originating from the ascending aorta, left ventricular 
outflow tract, and coronary arteries (Pawade TA et al, 2018; Pawade TA et al, 2020). 
The calcium score was recorded in Agatston units. 
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Contrast-enhanced CT analysis was performed using an OsiriX workstation (OsiriX 
version 8.0.3 64-bit; OsiriX Imaging Software, Geneva, Switzerland). ECG-gated 
contrast-enhanced CT images were reconstructed in diastole. A multi-planar 
reconstruction was re-oriented into the exact short-axis (en face) plane of the aortic 
valve as described previously and, using the aortic valve annulus as the reference slice, 
resliced in 3-mm increments through the valve (Gurvitch et al, 2014; Achenbach S et 
al, 2012; Pawade TA et al, 2016). This slice thickness was selected to remain 
consistent with non-contrast CT calcium scoring. Blood pool contrast attenuation was 
sampled within a 2 cm2 circular region of interest positioned in the center of the lumen 
of the aortic root at the level of the sinotubular junction (Hounsfield Units, HU). Care 
was taken to exclude aortic wall calcifications. 
 
In the second part of the analysis, quantification of the aortic valve calcium volume 
and non-calcific leaflet volume was performed using SliceOmatic (Tomovision, 
Magog, Canada). Contrast-enhanced short-axis CT images of the valve were 
transferred to SliceOmatic as high dynamic range (HDR) files. The region-growing 
tool was used to select voxels within a defined range of attenuation values (HU) for 
valvular calcium and non-calcific leaflet thickening. The lower threshold for detection 
of calcium was determined as 3 standard deviations above the mean blood pool 
attenuation. For non-calcific leaflet thickening, a fixed lower threshold of 30 HU was 
employed to exclude artifacts (e.g. areas of photon starvation adjacent to dense 
calcification). The upper threshold for non-calcific valve thickening was calibrated to 
the mean blood pool attenuation according to an equation derived from analysis of a 
derivation cohort comprising 100 patient scans. Two independent observers titrated 
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the upper threshold for non-calcific leaflet thickening starting at 200 HU and adjusting 
by increments of 25 HU in either direction until the margins of the 3 aortic valve cusps 
were delineated without any highlighting of the blood pool. When this visually 
determined upper threshold (x) was plotted against the mean blood pool attenuation 
(y) in the derivation cohort, a strong linear relationship was identified (r2=0.902, 
p<0.001) with the equation: x = 41.46 + 0.42(y). Using these HU thresholds, areas of 
calcium and non-calcific leaflet thickening in the valve were assessed and quantified 
on co-axial en face views. Each adjacent 3-mm slice was assessed so that the whole 
volume of the valve was covered. Care was taken to avoid areas of calcification in the 
aorta and coronary arteries. This was easier to accomplish than on non-contrast CT-
AVC scans, given the superior anatomical detail provided by contrast CT and the 
ability to align with the true plane of the valve.  
 
Indexing to Aortic Annulus Area  
Calcific and non-calcific leaflet volumes were indexed to the annulus area determined 
by contrast-enhanced CT. This method is repeatable and widely used to size 
transcatheter aortic valves pre-procedure (Gurvitch et al, 2014; Achenbach S et al, 
2012). These indexed volumes for calcific and non-calcific valve thickening were then 
used for all subsequent comparisons and analyses.  
 
Reproducibility  
Measurements of calcific and non-calcific leaflet volumes were performed 
independently in 20 patients by two experienced operators (TC, JK) in order to assess 
inter-observer reproducibility. For this purpose non-calcific and calcific volumes were 
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not indexed to aortic valve area as the reproducibility of annular dimensions measured 
by CT angiography has been well described (Gurvitch et al, 2014; Achenbach S et al, 
2012). 
 
Fibro-Calcific Ratio and Fibro-Calcific Burden 
Using the contrast-enhanced indexed CT calcium volumes and the non-calcific leaflet 
volumes, we explored two novel imaging measures. The fibro-calcific ratio was 
derived by dividing the non-calcific by the calcific indexed leaflet volumes. A ratio 
>1.0 indicated a predominance of non-calcific (fibrotic) disease in the valve, whilst a 
ratio ≤1.0 indicated predominant calcification. The fibro-calcific burden was derived 
by addition of the indexed calcific and non-calcific leaflet volumes to provide an 
overall marker of disease burden. 
 
Validation of the Fibro-calcific Burden 
The fibro-calcific burden was validated as a marker of aortic stenosis severity in two 
ways.  First, the fibro-calcific burden was validated against ex vivo valve histology and 
valve weight using a separate patient population with severe aortic stenosis from 
Quebec, Canada. These subjects underwent contrast-enhanced, ECG-gated CT <3 
months prior to surgical aortic valve replacement. Image analysis with quantification 
of calcific and non-calcific leaflet volumes was performed as described above. Aortic 
valves were excised at the time of surgery and examined by a single pathologist who 
was blinded to the CT. The valve cusps and any accompanying small fragments were 
removed from 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid solution, placed on 
absorbing paper, and then weighed on laboratory scales with a tolerance of ±0.01 g. 
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Additionally, sections of three leaflet of the valves were sliced and then stained with 
Masson Trichrome and/or Verhoeff-Van Giesson staining to assess regions of fibrosis 
and calcification within the valve as well as other potential components such as 
thrombus or lipid. Areas of non-calcific leaflet thickening observed on the CT were 
targeted to assess the histological composition in these regions. 
 
Second, our study cohort findings were independently and externally validated in a 
further cohort of 39 patients with aortic stenosis (Université Laval, Quebec, Canada) 
who underwent Doppler echocardiography and ECG-gated contrast-enhanced CT 
angiography within the same episode of care (<3 months apart). Observers from 
Quebec (EG, MC) were initially trained in the image analysis methodology in 
Edinburgh before performing a local independent analysis on their validation cohort, 
with comparisons made between CT and echocardiography assessments of disease 
severity. Again, CT analysis was performed blinded to echocardiographic data.  
 
Statistics and Data Analysis 
Baseline characteristics are reported as number (percentages) for categorical variables 
and mean ± standard deviation or median [interquartile range] for continuous variables 
as appropriate. Where not normally distributed, continuous variables were log10 
transformed.  One-way analysis of variance was used to compare continuous data 
across multiple factors, with post-hoc analysis using the Bonferroni correction where 
appropriate. The Student’s t-test or Mann-Whitney U test were used to compare 
continuous outcomes between two independent groups depending on whether they 
were normally distributed. Two-tailed Pearson’s correlation (where data were 
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normally distributed) and Spearman’s rank correlation coefficient (where data were 
not normally distributed) were performed to assess the relationship between CT-AVC 
Agatston score, contrast CT calcium volume, non-calcific leaflet thickening volume 
and echocardiographic measures of aortic stenosis severity. Comparison of the 
strength of association between a variable and two linear predictors was made by 
applying Fisher’s Z transformation to the Pearson correlation coefficients. Statistical 
analysis was undertaken using IBM SPSS Statistics 23 and significance was taken at 






Baseline Characteristics of Study Population 
A total of 143 volunteers (20% female) with aortic stenosis (39 mild, 78 moderate, 26 
severe disease) attended for baseline study assessment. Participants were relatively 
elderly (age 72±8 years) with a high prevalence of treated hypertension (67%), known 
coronary artery disease (36%), type 2 diabetes mellitus (21%) and smoking habit 
(34%) (Table 3.1). Thirty-eight participants (50% female, age 65±8 years) without 





Annulus Area Measured by Contrast-Enhanced CT 
The area of the aortic valve annulus measured by CT across the study population was 
4.60 [4.01-5.30] cm2, with males having larger annular dimensions than females 
(males: 4.76 [4.21-5.44] versus females: 3.51 [3.19-4.17] cm2, p<0.001). There was a 
moderate correlation between measurements of annulus area by CT and LVOT area 
by echocardiography (r=0.68, p<0.001), although there was a tendency for 
echocardiography to underestimate the area when compared to CT (LVOT area by 
echocardiography: 3.14 [3.14-3.80] versus annulus area by CT: 4.62 [4.02-5.25] cm2, 
p<0.001).  
 
Aortic Valve Calcification 
In the control group, no aortic valve calcification was observed on either the contrast-
enhanced or non-contrast CT scans. In the aortic stenosis cohort, the median indexed 
aortic valve contrast-enhanced CT calcium volume was 75 [40-138] mm3/cm2 (Figure  
3.1). There was excellent inter-observer reproducibility (intraclass correlation 
coefficient [ICC] [average measures]: 0.95 (95% confidence interval [CI] 0.88 to 
0.98), p<0.001). Indexed contrast CT calcium volumes doubled with each increase in 
aortic stenosis severity class (mild: 42 [20-67] mm3/cm2, moderate: 80 [42-157] 
mm3/cm2 and severe: 154 [96-234] mm3/cm2) (Figure 3.2). Indexed contrast-enhanced 
CT calcium volumes correlated closely with non-contrast CT-AVC (r=0.86, p<0.001), 
with the two measures demonstrating similar moderate correlations with peak aortic-
jet velocity (r=0.57 and r=0.60 respectively, both p<0.001). Males displayed higher 
indexed calcium volumes on contrast-enhanced CT than females, an observation that 
persisted after adjusting for peak aortic-jet velocity (males: 26 [16-48] versus females: 
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9 [4-18] mm3/cm2/ms-1, p<0.001). In men, echocardiographic measures of aortic 
severity demonstrated a moderate correlation with indexed calcific CT volumes (peak 
aortic-jet velocity: r=0.52, p=0.001), whereas no correlation was observed in women 
(peak aortic-jet velocity: r=0.16, p=0.463; Table 3.2).  
 
Non-Calcific Valve Thickening  
In the control cohort, our novel image analysis approach detected the edge of the 
leaflets, providing a median non-calcific leaflet volume of 30 [20-43] mm3/cm2 with 
no gender difference (males: 27 [21-39] versus females: 33 [19-43] mm3/cm2, 
p=0.184). In patients with aortic stenosis, indexed non-calcific leaflet volumes were 
more than double those in the control cohort (79 [52-100] mm3/cm2, p<0.001) and 
similar to the measured indexed volumes of valvular calcium (79 [52-100] versus 75 
[40-138] mm3/cm2, p=0.209) (Figures 3.1 and 3.2). Quantification of indexed non-
calcific leaflet volume demonstrated excellent inter-observer reproducibility (ICC 
[average measures]: 1.00 (95% CI 0.99 to 1.00), p<0.001). There was a progressive 
increase in the indexed non-calcific leaflet volume with increasing aortic stenosis 
severity, although this was more gradual than for the indexed calcific volumes (mild: 
62 [42-88] mm3/cm2; moderate: 81 [56-111] mm3/cm2; and severe: 85 [64-106] 
mm3/cm2; r=0.22, p=0.012). Whilst only a weak correlation was observed between 
indexed non-calcific valve thickening and echocardiographic measurements in men, a 






Contrast-enhanced computed tomography in aortic stenosis: detection of valve 




Figure 3.1. Contrast-enhanced CT images in the en face plane of the aortic valve (A-
C) with calcium highlighted in green and non-calcific fibrotic leaflet thickening 
highlighted in red (D-F). The total fibro-calcific burden (mm3/cm2) and the fibro-




Calcific and Non-Calcific Aortic Valve Volumes. 
 
 
Figure 3.2. Scatter plot illustrating the close correlation between CT-AVC (Agatston 
Score) and contrast-enhanced CT calcific volume (A) (r=0.86, p<0.001). Tukey 
boxplot demonstrated a progressive increase in the indexed calcific volume with 
progressive aortic stenosis severity class (B), a comparison of the non-calcific volume 
in volunteers without aortic valve disease (control cohort) versus patients with aortic 
stenosis (C) and the indexed non-calcific leaflet volumes also increasing with aortic 




The ratio of the non-calcific to calcific leaflet volumes across the cohort of patients 
with aortic stenosis was 1.04 [0.48-1.79]. However, this fibro-calcific ratio varied 
depending on the severity of aortic stenosis. Fibrotic tissue predominated (1.33 [0.91-
2.4]) in patients with mild aortic stenosis, was similar to calcium in those with 
moderate stenosis (0.98 [0.47-1.78]) and played a more minor role in those with severe 
stenosis (0.53 [0.35-1.05]) (Figure 3.3). The fibro-calcific ratio also differed with 
respect to sex, with males exhibiting proportionally more calcific than non-calcific 
leaflet thickening and females demonstrating the reverse (males: 0.89 [0.45-1.54] 
versus females: 1.49 [0.82-5.74], p=0.001). This sex-difference remained after 
correcting for peak aortic-jet velocity (males: 0.26 [0.12-0.49] versus females: 0.31 
[0.13-0.61] ratio/ms-1, p=0.001). We did not demonstrate a statistical association 
between the fibro-calcific ratio and patient age (r=-0.10, p=0.248) though when 
patients were divided into quartiles according to age the youngest quartile did exhibit 
the highest ratio (quartile 1: 0.39 [0.25-0.84]; quartile 2: 0.23 [0.12-0.54]; quartile 3: 
0.29 [0.18-0.53]; quartile 4: 0.31 [0.13-0.61] ratio/ms-1, p=0.118). Similarly, we did 
not demonstrate a statistical difference in the ratio observed in patients with tricuspid 
or bicuspid valves after correcting for stenosis severity although there was an apparent 
tendency for a lower ratio in those with a bicuspid valve (0.31 [0.15-0.57] versus 0.11 






The Fibro-Calcific Ratio.  
 
 
Figure 3.3. Tukey boxplots of the fibro-calcific ratio grouped by aortic stenosis disease 
severity class (A), by sex (B), by quartiles according to age (quartile 1 being the 
youngest and quartile 4 the eldest) (C) and by cusp morphology (trileaflet versus 
bicuspid valves) (D). Note that the ratio decreases with progressive aortic stenosis 
severity class and is higher in women than men but does not demonstrate a clear 




Non-calcific and calcific leaflet volumes were combined and indexed to annulus area 
to produce the fibro-calcific burden as a marker of the total disease severity. The fibro-
calcific burden across the whole cohort was 172 [112-243] mm3/cm2 (compared to 30 
[20-43] mm3/cm2 in the control cohort; p<0.001) and there was a progressive increase 
in this burden with increasing aortic stenosis severity (mild: 110 [77-150] mm3/cm2; 
moderate: 191 [119-253] mm3/cm2; and severe: 230 [196-333] mm3/cm2; p<0.001) 
(Figure 3.4). The fibro-calcific burden demonstrated a strong correlation with all 
echocardiographic measures of aortic stenosis severity (peak aortic-jet velocity: r=0.71 
p<0.001), comparing favorably with traditional non-contrast CT-AVC assessments 
(r=0.60, p<0.001; Table 3.2). The fibro-calcific burden appeared to be of particular 
value in women, where it demonstrated a much closer association with hemodynamic 
echocardiographic assessments (peak aortic-jet velocity: r=0.77, p=0.001; mean 
gradient: r=0.85, p=0.001) than was observed for CT-AVC (peak aortic-jet velocity: 







Fibro-Calcific Burden (combined non-calcific and calcific leaflet volumes 
indexed to annulus area) and its association with aortic stenosis severity 




Figure 3.4. Tukey boxplots of the total fibro-calcific burden (mm3/cm2) comparing 
values in the control cohort without aortic valve disease versus the cohort with aortic 
stenosis (A) and grouped by aortic stenosis severity class (B). Scatter plots illustrating 
the correlation of aortic valve peak velocity with both non-contrast CT-AVC (r=0.51, 
p<0.001) (C) and the improved association with the fibro-calcific burden (r=0.71, 
p<0.001) (D) across the whole population. When women with aortic stenosis were 
selected, there was no significant association between peak velocity and CT-AVC 
(r=0.27, p=0.22) (E) but the fibro-calcific burden offered a strong positive correlation 
(r=0.77, p<0.001) (F), similar to that in the population as a whole.  
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FIGURE 3.5.  





Figure 3.5. Summary figure illustrating the comparison of the relative strengths and 
weakness of contrast and non-contrast computed tomography for the assessment of 
aortic stenosis disease burden and severity. The top patient example demonstrates 
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severe, predominantly calcific aortic stenosis with a corresponding high Agatston 
score. The calcium was distributed over multiple axial slices on CT-AVC and is more 
readily appreciated from the en face contrast-enhanced images. The middle example 
is of severe concordant aortic stenosis with mixed fibro-calcific disease but an 
Agatston score well below the threshold for severe disease. The bottom example 





External Validation of Fibro-Calcific Burden 
Twenty-five patients with severe aortic stenosis awaiting surgical aortic valve 
replacement underwent contrast-enhanced CT and subsequent analysis of the 
explanted aortic valve. There was a very strong correlation between the combined 
fibro-calcific burden and aortic valve weight (r=0.88, p<0.001). The valve weight 
demonstrated a closer (p=0.03) association with the combined fibro-calcific burden 
(r=0.87, p=0.002) than with CT-AVC alone (r=0.76, p=0.009). An interaction was 
observed between fibro-calcific burden and sex with respect to the prediction of valve 
weight, with a closer association between fibro-calcific burden and weight in women 
than in men (p=0.04). Finally, histological examination confirmed the presence of 
valve fibrosis in spatial correlation with areas of non-calcific leaflet thickening 
observed on CT (Figure 3.6). By contrast there was no thrombus or gross lipid 
deposition observed in these areas.  
 
In the external validation cohort, 39 patients (10 women and 29 men) (Table 3.3) 
underwent a contrast-enhanced ECG-gated CT and Doppler echocardiography. 
Correlations between the indexed calcific or non-calcific leaflet volumes and the mean 
gradient on echocardiography were similar to that observed in the original cohort 
(calcium volume: r=0.74, p<0.001; non-calcific volume: r=0.44, p=0.005). The 
correlation with echocardiographic assessments of aortic stenosis severity (mean 
gradient) was better for the fibro-calcific burden (r=0.78, p<0.001) than CT-AVC 
(p=0.005). Similar results were seen when peak aortic-jet velocity was used as the 








Figure 3.6. Case 1. A tricuspid aortic valve from a woman with a large amount of 
fibrosis (red) compared to calcification (green) on CT. Histology confirms a 
preponderance of fibrosis in the valve consistent with the CT findings with no clear 
 132 
evidence of valve thrombosis or lipid infiltration. Trichrome Masson staining: blue 
sections represent collagen; red/purple represents calcium.  
Case 2. A tricuspid aortic valve from a man with a small amount of fibrosis compared 
to calcification (from the 3 CT slices containing the aortic valve this one was the only 
one with significant fibrosis). This was again confirmed on histological analysis of the 
valve leaflet. Verhoeff-Van Giesson staining: Black represents elastic fibres, pink 
collagen fibres, and yellow calcium. 
Case 3. A bicuspid aortic valve from a man with both extensive fibrosis and 
calcification in the valve. Findings were again confirmed on histology with the spatial 
distribution of calcium and fibrosis on histology appearing similar to the calcific and 






For the first time, we describe a novel method of CT analysis that allows assessment 
of both valve calcification and non-calcific leaflet thickening (fibrosis) in patients with 
aortic stenosis (Figure 3.5). This has provided unique insights into the underlying 
pathophysiology of aortic stenosis, with fibrosis appearing to predominate in women 
and patients with mild stenosis, whilst calcification dominated in men and those with 
advanced severe disease. Moreover, we propose a novel anatomical measure of aortic 
stenosis severity, the fibro-calcific burden, that incorporates both fibrotic and calcific 
valve thickening. This novel summary measure demonstrates excellent agreement with 
echocardiographic assessments of hemodynamic disease severity and valve weight 
that were superior to CT-AVC alone. Given the widespread use of contrast CT in the 
assessment of patients with aortic stenosis (such as transcatheter aortic valve 
replacement planning), the fibro-calcific burden could be readily adopted into routine 
clinical practice, providing an alternative assessment of aortic stenosis severity for 
patients with uncertain disease severity.  
 
Discordant echocardiographic assessments of aortic stenosis severity are observed in 
around a third of patients (Clavel MA et al, 2013; Minners J et al, 2010), leading to 
diagnostic uncertainty about true disease severity. Non-contrast CT-AVC has emerged 
as an attractive alternative imaging approach in these patients providing an anatomic 
assessment of disease severity independent of flow that is now recommended by 
international guidelines (Baumgartner H et al, 2017). Sex-specific CT-AVC 
thresholds for severe aortic stenosis have been developed that may indirectly correct 
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for the increased valve fibrosis observed in women and which generally offer good 
diagnostic accuracy compared to echocardiography (area under the curve of ~0.90) 
(Pawade TA et al, 2018). However, as CT-AVC becomes more widely established, it 
is important to recognise that by ignoring valve fibrosis CT-AVC may in certain cases 
underestimate aortic stenosis severity. Indeed, reports have emerged in the literature 
of patients with concordant severe aortic stenosis yet low CT calcium scores, 
especially in young women (Shen M et al, 2016). Moreover, differentiation of valvular 
calcification from calcification of the aorta, left ventricular outflow tract, mitral valve 
annulus and coronary arteries can be challenging on axial non-contrast CT-AVC 
images. There is therefore a clear rationale for exploring alternative anatomic 
assessment of aortic stenosis. In particular, contrast-enhanced CT angiography offers 
a potential solution to each of these problems with the added advantage of current 
widespread use for transcatheter aortic valve replacement planning.  
 
Our study has several important strengths. First, we prospectively recruited patients 
across the spectrum of aortic stenosis severity as well as control subjects with normal 
aortic valves. Each participant underwent systematic multi-modality imaging 
assessments including ECG-gated non-contrast CT, contrast-enhanced CT and 
Doppler echocardiography with the rigor employed by a regulated double blind 
randomised controlled trial. The novel image analysis protocol here proposes the use 
of flexible thresholds for defining calcific and non-calcific valve thickening based 
upon contrast load at the sinotubular junction and makes use of approaches for finding 
the true aortic valve plane and sizing the aortic annulus that are well established in the 
transcatheter aortic valve replacement field. This has allowed the development of a 
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robust and reproducible method for quantifying both calcific and non-calcific valve 
thickening that has helped highlight the importance of fibrosis in the pathogenesis of 
aortic stenosis. Moreover, this study has established the fibro-calcific burden as a 
promising anatomic measure of aortic stenosis severity which we have validated 
against hemodynamic assessments on echocardiography, CT-AVC and ex vivo valve 
weights across two independent international patient cohorts.  
 
Progressive valve stiffening and narrowing in aortic stenosis occurs due to both 
fibrosis and calcification, although previous imaging approaches have focused almost 
exclusively on the latter (Dweck MR et al, 2012 a). Contrast-enhanced CT allows 
quantification of valvular calcium with a close association with CT-AVC, the current 
gold standard. However, we have also used contrast CT to measure the volume of non-
calcific valve thickening as a surrogate of fibrosis, allowing calculation of the fibro-
calcific ratio and providing an insight into the relative contributions of these 
pathological processes at different stages of disease. When examining the aortic 
stenosis cohort as a whole, the volumes of calcific and non-calcific valve thickening 
were similar (fibro-calcific ratio 1.04 [0.48-1.79]) highlighting the important 
contribution that fibrosis makes to the pathology of aortic stenosis. Here we make the 
assumption that non-calcific valve thickening represents valve fibrosis. We 
deliberately selected a lower boundary threshold of 30 HU to define non-calcific 
leaflet thickening since attenuation levels below this level may include thrombosis 
rather than fibrosis. Our assumptions are strongly supported by previous histological 
data demonstrating the predominance of fibrosis and calcification in aortic stenosis 
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(Yetkin E et al, 2009; Hinton RB et al, 2006), and are further confirmed by our own 
correlative ex vivo and histological assessments (Figure 3.6).  
 
The fibro-calcific ratio is not fixed but is instead highly variable. In mild aortic 
stenosis, fibrosis was the dominant finding, in moderate aortic stenosis there appeared 
to be a balanced contribution, while in severe disease calcification predominated. This 
suggests early disease begins with a fibrotic response that progressively calcifies 
leading to the development of hemodynamically significant disease. Interestingly, the 
fibro-calcific ratio also exhibited a clear sex discrepancy with calcification 
predominating in men (0.89 [0.45-1.54]) and fibrosis the predominant process in 
women (1.49 [0.82-5.74]). These observations have important clinical implications, 
indicating that the factors driving aortic stenosis progression both evolve with time 
and are different in men and women. The development of effective medical therapies 
will depend on understanding the mechanisms underlying these observations and 
potentially tailoring pharmacological interventions according to sex, disease severity 
and the predominant pathological processes observed on imaging.  
 
We explored the fibro-calcific burden as a novel anatomic measure of aortic stenosis 
severity. Differentiation of pathology in the valve from surrounding structures is easier 
than with CT-AVC, because contrast CT allows analysis on high-resolution images in 
the true plane of the valve. Reproducibility of measurements was therefore excellent. 
The fibrocalcific score was nearly 6-fold higher in patients with aortic stenosis 
compared to control subjects and increased steadily with progressive disease severity. 
Indeed, the fibro-calcific burden demonstrated a close association with 
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echocardiographic measurements of hemodynamic severity, outperforming CT-AVC. 
This was particularly true in women, in whom the CT-AVC demonstrated a 
disappointing association with peak aortic-jet velocity that improved considerably 
(similar to that observed in men) when using the fibro-calcific burden as the CT 
assessment. Similar findings were observed in an external independent validation 
cohort. Finally, we validated the CT fibro-calcific score against the valve weights of 
25 explanted valves from patients who had undergone CT imaging shortly before 
surgical aortic valve replacement. Once again, the fibro-calcific score demonstrated a 
closer association with valve weight than CT-AVC even though these patients all had 
severe stenosis, a stage of the disease where calcium predominates.  
 
The fibro-calcific burden holds major promise as an alternative anatomic assessment 
of aortic stenosis severity to complement echocardiography and CT calcium scoring. 
CT angiography is already widely performed in many centres, for example, as part of 
the routine pre-procedure assessment for transcatheter valve implantation and many 
clinicians have already developed corresponding expertise in reading these scans. 
There is therefore considerable potential for the fibro-calcific burden to be rapidly 
adopted into routine clinical practice within established patient pathways. However, 
further work is now required to validate the fibro-calcific burden in large patient 
populations, to establish its prognostic value and to provide robust thresholds that can 




We should acknowledge some limitations of our study. Our image analysis method is 
time consuming (~45 min) relying upon multiple steps and transfer of data between 
different software packages. An integrated software solution that can facilitate more 
rapid image analysis whilst maintaining accuracy and reproducibility would be 
welcome and help accelerate uptake of this approach. In addition, image analysis is 
challenging in scans at the upper and lower extremes of blood-pool contrast load and 
there is likely scope to refine how we calculate and administer intravenous iodinated 
contrast media and acquire the images. 
 
In conclusion, CT angiography allows robust and reproducible quantification of both 
valve leaflet fibrosis and calcification in patients with aortic stenosis. This has 
provided key pathophysiological insights, highlighting the importance of non-calcific 
valve thickening, particularly among women and patients with mild aortic stenosis. 
Moreover, the fibro-calcific burden provides a novel assessment of aortic stenosis 
severity that offers closer agreement with echocardiographic assessments and valve 
weight than CT-AVC. Further work is now required to validate the fibro-calcific 
burden, and to establish both its prognostic value and clear thresholds that can be used 
to differentiate severe from non-severe disease. This novel imaging method may 
provide an invaluable tool to confirm aortic stenosis severity in patients with 
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18F-Fluoride positron emission tomography (PET) and computed tomography (CT) 
can measure disease activity and progression in aortic stenosis. We aimed to optimise 
imaging methodology, analysis and scan-rescan reproducibility.  
 
Methods 
Fifteen patients with aortic stenosis underwent 18F-fluoride PET-CT on two occasions. 
We compared non-gated PET and non-contrast CT with a modified approach that 
incorporated contrast CT and ECG-gated PET. We explored a range of image analysis 
techniques including estimation of blood pool activity at differing vascular sites and a 
most-diseased segment (MDS) approach.   
 
Results 
Contrast-enhanced ECG-gated PET-CT provided superior spatial localization of 18F-
fluoride uptake that permitted localization to individual valve leaflets. Indeed, uptake 
was most commonly observed at sites of maximal mechanical stress, the leaflet tips 
and the commissures.  Scan-rescan reproducibility was markedly improved using 
enhanced analysis techniques leading to a reduction in variability from ±25% to 
<±10% (tissue-to-background MDS: mean value 1.55, difference 0.05, limits of 




Optimised 18F-fluoride PET-CT provides excellent spatial localization and scan-rescan 
reproducibility. It is estimated that a clinical trial powered at 95% would require a 
sample size of 46 patients to demonstrate a 10% reduction in 18F-Fluoride uptake 
(assuming an alpha error of probability of 0.05).  This technique holds major promise 
as a real-time marker of disease activity in aortic stenosis and is ready to be used as a 






Aortic stenosis is the most common form of valve disease in the western world and a 
major health care burden that is set to treble by 2050. However, we currently lack any 
disease-modifying therapies. Calcification appears to be the predominant pathological 
process driving disease progression leading to major interest in novel treatment 
strategies aimed at reducing calcification activity in the valve (Pawade TA et al, 2015). 
However, assessing the efficacy of new therapies requires large trials with prolonged 
follow-up to demonstrate an impact on disease progression and clinical end-points 
(Rossebo AB et al, 2008). A non-invasive imaging technique capable of measuring 
calcification activity in the valve would be highly desirable to assess treatment efficacy 
in phase 2 clinical trials.  
 
18F-Fluoride is a positron-emitting radiotracer that binds to regions of newly 
developing microcalcification beyond the resolution of computed tomography (Irkle 
A et al, 2015).  It is readily taken up by the valves of patients with aortic stenosis and 
on histology, correlates with markers of calcification activity (Dweck MR et al, 
2014)). Importantly this technique predicts disease progression both with respect to 
echocardiography and CT calcium scoring as well as adverse cardiovascular events 
(Dweck MR et al, 2014; Dweck MR et al, 2012 b; Jenkins WSA et al, 2014).  18F-
Fluoride positron emission tomography (PET) imaging therefore holds major promise 
as a marker of calcification activity in aortic stenosis and is an exploratory end-point 
in a randomised controlled trial of therapies targeting calcium metabolism 
(NCT02132026). Here, we sought to optimise 18F-fluoride PET scanning of the aortic 
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valve and to assess the scan-rescan reproducibility of this technique to inform its future 
application as a biomarker of calcification activity in clinical trials.  
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 4.3 METHODS 
 
Study Population 
Patients aged over 50 years with asymptomatic mild, moderate and severe calcific 
aortic stenosis were recruited from the Royal Infirmary of Edinburgh. Exclusion 
criteria included renal failure and women of childbearing potential, as detailed below.  
This study was approved by the Scottish Research and Ethics Committee and the 
Medicines and Healthcare products Regulatory Authority (MHRA) of the United 
Kingdom.  All patients gave written informed consent and research was performed in 
accordance with the Declaration of Helsinki. 
 
Inclusion Criteria 
Age > 50 years; peak aortic jet velocity > 2.5 m/s on Doppler echocardiography; grade 
2-4 calcification of the aortic valve on echocardiography. 
 
Exclusion Criteria 
Women of childbearing potential who are premenopausal, have not been sterilised or 
who are currently pregnant; women who are breastfeeding; renal failure (estimated 
glomerular filtration rate of <30 mL/min); inability to undergo scanning; allergy or 
contraindication to iodinated contrast; inability or unwilling to give informed consent; 
likelihood of non-compliance to treatment allocation or study protocol; anticipated or 
planned aortic valve surgery in the next 6 months; life expectancy less than 2 years; 
treatment for osteoporosis with bisphosphonates or denosumab; known allergy or 
intolerance to alendronate or denosumab, or any of their excipients; abnormalities of 
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the oesophagus or conditions, which delay oesophageal/gastric emptying; inability to 
sit or stand for at least 30 minutes; hypocalcaemia; regular calcium supplementation; 
dental extraction within 6 months; long term corticosteroid use; history of 
osteonecrosis of the jaw; poor dental hygiene.  
 
Initial Image Acquisition and Analysis  
Each patient underwent 18F-fluoride positron emission tomography (PET) and 
computed tomography (CT) scanning on two occasions less than 3 months apart. 
Patients were given 25 mg of oral metoprolol if their resting heart rate was >65 
beats/min before being administered 125 MBq of 18F-fluoride intravenously.  After 60 
min, patients were imaged with a hybrid PET and CT scanner (Biograph mCT, 
Siemens). Attenuation-correction CT scan was performed before acquisition of PET 
data in list mode using a single 30-min bed position centred on the valve in three-
dimensional mode. Finally, ECG-gated aortic valve CT calcium scoring and contrast-
enhanced CT angiography were performed in diastole and in held expiration.  
 
CT calcium scoring was performed by an experienced operator using dedicated 
software (Vitrea Advanced, Toshiba systems) on axial views, with care taken to 
exclude calcium originating from the ascending aorta, left ventricular outflow tract and 
coronary arteries. The calcium score was recorded in Agatston Units (AU).   
 
PET analysis was performed using an OsiriX workstation (OsiriX version 3.5.1 64-
bit; OsiriX Imaging Software, Geneva, Switzerland).  As previously reported, regions 
of interest were drawn around the perimeter of the valve on the fused non-gated PET 
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and non-contrast CT images (Dweck MR et al, 2012 b). These generated mean and 
maximum standard uptake values (SUV) for each slice. Averaging these values across 
the entire valve produced whole valve SUVmean and SUVmax values respectively. These 
SUV values were then corrected for blood pool activity to generate tissue-to-
background ratio (TBR): whole-valve I, and TBRmax. The blood pool uptake was 
determined using SUVmean values averaged from across ROIs drawn on 5 contiguous 
slices in the brachiocephalic vein. For consistency the most caudal ROI was positioned 
at the point where the innominate vein joined the brachiocephalic vein (Dweck MR et 
al, 2012 b). 
 
To optimise the spatial resolution and scan-rescan reproducibility of 18F-fluoride 
PET/CT imaging, we assessed different approaches to both image acquisition and 
image analysis.  
 
Optimisation of PET Image Acquisition 
Contrast CT of Aortic Valve 
Our original technique required the reorientation and co-registration of non-contrast 
CT images of the aortic valve. This technique posed several challenges, particularly 
with respect to getting into the true plane of the valve and accurately defining its 
perimeter. Moreover, the structure of individual leaflets was not visible on these scans 
precluding more detailed localization of 18F-fluoride uptake. Contrast CT offered 
potential solutions to these challenges given its superior anatomical detail and the well-
established methodology for finding the true plane of the valve (Litmanovich DE et 
al, 2014) (Figure 4.1). 
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ECG-Gated PET Data 
PET is susceptible to motion, limiting accurate co-registration and the spatial 
assessment of PET activity within the valve. As a solution, we employed 
electrocardiogram (ECG) gating of list mode PET data. These data were reconstructed 
into 4 gates at 25% intervals of the cardiac cycle. Only data acquired between 50 and 
75% of the RR interval were assessed because this period corresponds with diastole 
when cardiac motion is at a minimum. Given that three quarters of the PET data are 
therefore discarded, the bedtime was increased to 30 min in an attempt to preserve 
signal-to-noise.  
 
Optimisation of PET Image Analysis  
Measurement of Blood Pool Activity 
The stability of blood pool measurements in the SVC for 18F-fluoride based tracers has 
recently been questioned (Chen W et al, 2015) and we were concerned about variation 
in the measured blood-pool activity at different levels of the brachiocephalic vein.  We 
reasoned that this may be explained by the relatively small diameter of this vein 
rendering it susceptible to partial volume effects, amplified by the very low PET signal 
in surrounding lung tissue (especially in the cranial aspects of the brachiocephalic 
vein). We hypothesised that sampling blood-pool activity from the centre of the right 
atrium (a much larger structure) may improve the ease and accuracy with which these 
measurements could be made and the consequent scan-rescan reproducibility. Using 
the same co-registered PET and CT images of the heart, re-orientated to the plane of 
the valve, a 2-cm2 ROI was drawn in the centre of the right atrium at the level of the 
right coronary ostium and again in the same position one slice superiorly.  Averaging 
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the mean SUV for these two slices gave an alternative measure of blood-pool activity, 
which was used to correct valvular uptake measurements using two different 
approaches. First, we used the conventional method of dividing aortic valve SUV 
measurements by the blood-pool to generate TBR values. Secondly we subtracted the 
blood-pool value from the valvular uptake, to generate the corrected aortic valve SUV 
(cSUV) as described recently (Chen W et al, 2015).  
 
Most -diseased Segment and Whole Valve Approach 
One of the biggest difficulties in quantifying uptake in the valve is defining its limits 
in the z plane. To overcome this challenge, our original whole valve technique was 
compared to a ‘most-diseased segment’ (MDS) approach where the two contiguous 
slices with the highest SUV values (frequently in the centre of the valve) were 
averaged to generate SUVMDSmean, SUVMDSmax and corresponding TBR values. This is 
similar to the approach previously used for quantifying 18F-fluorodoexyglucose uptake 
in carotid and aortic atheroma (Fayad ZA et al, 2011).  
 
Spatial Resolution and Scan-Rescan Reproducibility 
The effect of our modifications on spatial resolution and scan-rescan reproducibility 
were then assessed in comparison with the original approach. First, we assessed the 
ability of the technique to localise increased 18F-fluoride activity to individual valve 
leaflets and their different regions. This was done visually using a standardised method 
for windowing the fused PET/CT images that incorporated the blood pool activity in 
RA as the minimum.  Kappa statistics were then used to quantify agreement as to the 
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presence or absence of increased 18F-fluoride uptake in individual leaflets between the 
baseline and repeat scans. 
 
Second, we determined the scan-rescan reproducibility of 18F-fluoride PET 
quantification in the valve using the various approaches. The paired scans for each 
patient were analysed by two experienced observers in a random order at least 2 weeks 
apart to minimise recall bias.  
 
Statistical Analysis  
Continuous variables were expressed as mean ± standard deviation. For normally 
distributed data, Student’s t-tests were used to assess differences between mean values.  
Data underwent logarithmic transformation where necessary.  To determine a 
relationship between continuous variables, the Pearson’s correlation coefficients were 
used. Scan-rescan, intra-observer and inter-observer reproducibility for both CT 
calcium scoring and PET uptake were analysed and presented using Bland-Altman 
analyses and intraclass correlation coefficients (ICC). Statistical significance was 






Fifteen patients (73±9 years, 67% male) had 2 scans within a 13-week period (13 
patients had repeat scanning within 8 weeks). Seven patients had mild aortic valve 
disease, 4 had moderate and 4 had severe aortic stenosis (Table 4.1).   There were no 
differences in 18F-fluoride doses between the two visits (123±8 and 125±4 MBq, 
P=0·49). The mean total radiation dose per patient for the two scans was 28.9±13 
mSV. 
 
Altered PET Acquisition and Image Quality 
Contrast CT imaging of the valve appeared to provide much clearer anatomical detail 
of the leaflets and valve structure compared to non-contrast CT (Figure 4.2). This made 
it technically easier to get into the true plane of the valve and allowed more accurate 
regions of interest to be drawn around its perimeter (Figure 4.1 and 4.2).  Co-
registration with ECG-gated PET data then allowed localization of 18F-fluoride uptake 
to individual leaflets and their different regions, which was previously impossible 
using non-contrast CT and non-gated PET. Most commonly increased activity was 
observed across all three coronary cusps (n=10), it involved two cusps in 4 patients, 
and was isolated to one cusp in just 1 patient. The non-coronary cusp was involved in 
all patients apart from that latter case.  Activity was most frequently observed at the 
valve commissures, and specifically at the points where the valve cusps meet the aortic 









Figure 4.1. Creation of planar en-face valve images using CT angiography was 
achieved as follows. First, the CT angiogram is reorientated to get into the approximate 
plane of the aortic valve by lining up the axial cross hair (purple in this example) using 
the images in the coronal (a) and sagittal planes (c).  This creates an approximate cross 
sectional image of the aortic valve in the axial frame (b).  Scrolling down in the axial 
frame, the centre of the crosshairs is then placed over the exact point at which the right 
coronary cusp disappears, identifying the base of that leaflet (d). Similarly, the base of 
the non-coronary cusp is identified and orthogonal planes adjusted so that the purple 
plane goes through the base of both these two cusps (d). Finally, the base of the left 
coronary cusp is found by rotation of the axial cross hairs so that first the cusp comes 
into view. The image is then slowly rotated in the opposite direction until the point 
where the leaflet first disappears (the base) is again found (f). This produces an en face 
image of the valve aligned with the base of all three leaflets (g). Adjacent 3-mm slices 
are then created in that plane and used for subsequent assessment. These slices are 
fused with the 18F-Fluoride PET images (h) and careful co-registration performed in 





Improved Localisation of PET Signal Within the Aortic Valve and its Leaflets. 
 
 
Figure 4.2. Paired non-gated, non-contrast  PET/CT scans (original approach: A-C, 
G-I) and gated, contrast-enhanced PET/CT images (final approach: D-F, J-L). Images 
demonstrate the typical distribution of the tracer uptake within the valve at sites of 
increased mechanical stress i.e. at the leaflet tips  (D-F) and at the commissures (J-L). 
  
 156 
There was good scan-rescan and intraobserver agreement as to the presence or absence 
of increased 18F-fluoride activity within individual valve cusps with an overall kappa 
statistics of 0.70 (95% CI 0.48 to 0.91). This agreement was excellent in the non- and 
right coronary cusps but was more difficult in the left coronary cusp perhaps due to 
adjacent uptake in the left main stem, aorta and other valve cusps (Tables 4.2 and 4.3).  
 
Effect of Altered Image Analysis on PET Reproducibility  
Interobserver and intra-observer reproducibility was excellent with no fixed or 
proportional biases for the various 18F-fluoride uptake measurements as previously 
reported. ICC values were all >0.95 (Dweck MR et al, 2012 b).  
 
The scan-rescan reproducibility of our original approach produced an error of 
approximately ±25% for each of the different SUV measurements (Table 4.4).  Scan 
re-scan reproducibility for TBR measurements were also disappointing with an error 
of ±60%.  
 
Blood pool measurements  
The poor reproducibility of the original TBR values compared to SUV suggested a 
problem with measuring blood-pool activity in the brachiocephalic vein. Indeed a step-
wise and non-physiological reduction in these blood pool measurements was observed 
on moving cranially up the axial slices away from the heart and into the lung. On 
average a 20% difference in values was observed between the top and bottom slices 
but this difference could be as high as 66%. By comparison blood-pool sampling from 
the right atrium was easier to perform, allowed larger regions of interest to be drawn  
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and was consistent, demonstrating a <1% difference in measurements acquired on 
adjacent slices (Figure 4.3).  Even with the new approach, variation remained in the 
18F-fluoride blood pool PET activity observed in different patients (blood pool SUV 
1.10±0.35).  
 
Sampling the blood pool in the right atrium led to a substantial improvement in the 
scan-rescan reproducibility of all our TBR measurements. Indeed after implementing 
this approach the reproducibility of our TBR values consistently outperformed those 
for SUV values with percentage errors of between 20 and 25% for both mean and 
maximum values. In contrast, the approach of subtracting the blood pool uptake from 
the tissue SUV to produce cSUV measures did not greatly improve reproducibility 
resulting in percentage errors of ±40% (Table 4.4).  
 
MDS Approach  
The MDS technique improved the technical ease of image analysis, removing the 
difficulty in deciding upon the upper and lower limits of the valve in the z plane. This 
translated into further improvements in scan-rescan reproducibility for mean TBR 
values. Indeed the percentage error for TBRMDSmean measurements was reduced to 
<10%. Similarly maximum values were optimised upon addition of the MDS approach 
(percentage errors TBRMDSmax ±18%) as were the SUV measurements (percentage 





Final Approach: Addition of Contrast-CT and ECG-gated PET  
After the addition of contrast CT and ECG-gated PET data, the reproducibility for our 
TBRMDSmean measurement remained excellent with a percentage error of <10% and an 
ICC value of 0.95 (Figure 4.4). This was the best performing measure of the different 
approaches tested and was again superior to the equivalent SUVMDSmean value 
(percentage error ±34%). It also outperformed the measurements quantifying 
maximum 18F-fluoride uptake in the valve, which were less reproducible after the 
addition of gated-PET and contrast-CT (percentage errors SUVMDSmax ±49% and 
TBRMDSmax ±36% respectively) (Table 4.4).  
 
Study Populations and Sample Sizes  
The excellent reproducibility of our valvular TBRMDSmax PET measurements means 
that relatively few patients would be required to demonstrate a reduction in 18F-
fluoride activity secondary to a drug intervention. Assuming 95% power and an alpha 
error probability of 0.05, we estimate that 46 patients in each arm would be required 
to demonstrate a 10% reduction in 18F-fluoride PET activity (TBRMDSmax), 16 patients 
would be required for a 20% reduction and 9 patients would be required for a 30% 




Scan-rescan and intra-observer reproducibility for presence or absence of 18F-
fluoride uptake.  
 






Scan 1a 1 2 1a 1 2 1a 1 2 
1 + + + + + + + + - 
2 + + + + + + + + + 
3 + + + - + + - + - 
4 + + + + + + + + + 
5 + + + + + + + + + 
6 + + + - - - - - - 
7 + + + + + + + + + 
8 - - - + + + + + + 
9 + + + + + + + + + 
10 + + + + + + + + + 
11 - - - + + + + + + 
12 + + - + + + - - - 
13 + + + + + + + + + 
14 + + + + + + + - + 
15 + + + + + + + + + 
 
Table 4.2. Presence or absence of 18F-Fluoride PET signal is denoted (+ and – 
respectively) for each individual valve leaflet.  The distribution of 18-Fluoride signal 
on scan 1 images (1a) were reassessed (1b) to assess intra-observer reproducibility and 
compared to scan 2 (2) to determine scan-rescan reproducibility. 
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TABLE 4.3.  
Kappa statistics for interobserver and scan-rescan agreement for 18F-Fluoride 
















0.15, 95% CI 
0.44 to 1.00) 
1.00 
(SE 0.00, 
95% CI 1.00 
to 1.00) 
0.63 
(SE 0.33, 95% 
CI -0.01 to 
1.00) 
0.58 
(SE 0.26, 95% 






0.16, 95% CI 
0.36 to 0.97) 
0.76 
(SE 0.22, 
95% CI 0.32 
to 1.00) 
1.00 
(SE 0.00, 95% 
CI 1.00 to 
1.00) 
0.44 
(SE 0.27, 95% 
CI -0.08 to 
0.97) 
 




Measuring Blood Pool Activity in the Brachiocephalic vein and the right atrium. 
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Figure 4.3. Regions of interest for measuring blood pool activity in the 
brachiocephalic vein (top) and right atrium (bottom) are shown in the en-face of the 
valve (left) and coronal (right) planes. Note that the right atrium is a much larger 
structure allowing for larger regions of interest with less potential for partial volume 
artifact problems related to poor registration. Tukey plot demonstrates mean SUV 
values for 5 contiguous slices from brachiocephalic (blue) and 2 from the right atrium 
(purple).  Note the variation in brachiocephalic vein measurements between those 






Scan-rescan Reproducibility for 18F-Fluoride PET quantification in the aortic 
valve with consequent sample size estimates. 
 
 
Figure 4.4. Bland Altman plots of scan-rescan reproducibility for TBRMDSmean 
measurements using the original image analysis and acquisition methods (left) and 
then using final method (right).  Percentage error for the final technique is less than 
±10%. Graph (below) showing sample size estimates needed to power clinical trials: 
95% power, assuming 2-sided significance and an alpha error of probability of 0.05. 
These data suggest relatively few patients would be required to demonstrate the effects 





In this study we have systematically investigated the acquisition and analysis of 18F-
fluoride PET imaging of the aortic valve. First, we have improved the spatial 
localization of tracer uptake using ECG-gated PET data and contrast CT imaging, so 
that activity can now be localised to individual leaflets and regions within those 
leaflets. This has demonstrated that calcification activity is most commonly observed 
at sites of maximal mechanical stress: in particular in regions of leaflet coaptation and 
at the commissures. Second, we have improved the scan-rescan reproducibility 
ultimately demonstrating excellent agreement statistics for repeat TBRMDSmean 
measurements in the valve (percentage error ±10%). This has important implications 
for application to future clinical trials, indicating that 18F-fluoride might provide a 
useful imaging end-point of drug efficacy, requiring relatively few patients in order to 
demonstrate reductions in valvular calcification activity.  
 
In this study we have modified our previous image acquisition protocol to include 
contrast-enhanced CT imaging of the aortic valve, thereby providing greater definition 
of the individual valve leaflets and their components. Moreover we have included 
ECG-gated PET data to reduce the effects of cardiac motion and more accurately 
localise the pattern of activity on to the valve. The combined effect of these changes 
has been to improve the spatial localization of PET activity within the valve, which 
after accurate 3-dimensional co-registration, is now possible within specific regions of 
individual leaflets. This has demonstrated that 18F-fluoride activity predominantly 
localises to sites of increased mechanical stress within the valve, supporting 
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mechanical injury as a key driver to the disease process. For example 18F-fluoride 
activity was observed at the tips of the valve leaflets exactly at the sites of leaflet 
coaptation during valve closure. Additionally uptake was observed at the valve 
commissures where mechanical stress is concentrated before being transferred to the 
aortic wall (Aikawa E et al, 2007; Deck JD et al, 1988). Whilst these findings need to 
be confirmed in larger studies, they here provide key insight into the triggers to 
calcification activity in aortic stenosis and the importance of mechanical injury. Recent 
data have indicated that the relationship between the valve calcium burden and 
hemodynamic obstruction is not perfect. The ability of PET to accurately localise 
calcification activity may be useful in trying to understand whether calcium formation 
at different sites of the valve have different hemodynamic impacts.   
 
We have modified our image analysis protocol, optimizing the scan-rescan 
reproducibility of 18F-fluoride imaging in the aortic valve using several different 
approaches. To date, it has been standard practice for 18F-fluorodeoxyglucose PET to 
measure the blood pool SUV in the brachiocephalic vein (Tawakol A et al, 2006). This 
has the benefit of avoiding contamination of myocardial 18F-fluorodeoxyglucose 
uptake that would overestimate the blood pool activity. However, this would not be 
the case for 18F-fluoride which has no background myocardial uptake. We therefore 
measured blood pool activity in both the right atrium and the brachiocephalic vein. 
Measurements in the right atrium are easily performed on the en face images of the 
valve and resulted in much more consistent blood-pool measurements. Moreover this 
approach led to a dramatic improvement in the scan-rescan reproducibility of our TBR 
measurements such that they then outperformed equivalent SUV measures. Thus it 
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appears important to correct for variations in background blood pool activity that can 
occur between scans perhaps due to minor changes in renal function, tracer dose and 
pharmacokinetics. We believe that sampling the blood-pool activity in the right atrium 
improved reproducibility because these measurements are less susceptible to the 
partial volume effects of adjacent lung tissue and because any minor inaccuracies in 
co-registration with the PET signal will not have a great impact.   
 
Chen et al recently surmised that subtracting the blood pool from tissue SUV would 
improve accuracy because blood activity appears to add to vascular wall activity due 
to spatial blurring of PET images (Chen W et al, 2015).  However our study findings 
did not support this and their approach produced lower TBR values thereby increasing 
the percentage error of our repeat measurements.  
 
Another major improvement in reproducibility was obtained using the most diseased 
segment (MDS) approach: measuring activity in the two hottest adjacent slices in the 
valve, rather than attempting to sample the entire valve. The major advantage of this 
technique is that it removes the considerable difficulty in deciding the limits and 
boundaries of the valve. Such uncertainty can lead to major differences in valve 
measurements because uptake is much lower at the extremes of the valve where the 
volume of tissue is small and inclusion of extraneous tissue will dilute down mean 
values.  
 
This is the first study to assess scan-rescan reproducibility for 18F-fluoride uptake in 
the aortic valve. This is important in order to validate this marker for serial 
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investigations as well as to estimate sample sizes for future clinical trials of novel 
therapeutic interventions. However we can now report TBRMDSmean measurements, 
made using our optimised image acquisition and analysis protocols, quantify valvular 
18F-fluoride activity with excellent reproducibility and less than a 10% percentage 
error. We have already shown that the TBRMDSmean can predict disease progression and 
clinical events in patients with aortic stenosis (Jenkins WSA et al, 2015). Our data 
now demonstrate that it is a robust end-point with which to detect reductions in 
calcification activity due to novel therapies.  We have also provided an estimate of the 
sample sizes required at different levels of estimated drug effects. As a result of the 
excellent scan-rescan reproducibility, PET imaging requires few subjects to show 
significant differences between groups: less than 50 patients in each group to detect a 
10% reduction in 18F-fluoride activity. However whilst these estimates provide a 
framework for minimum sample sizes, they should be interpreted with a degree of 
caution, because they assume a perfect agreement between changes in the TBRMDSmean 
signal and underlying changes in valve calcification activity. This may not be the case. 
Whilst previous studies have indicated that 18F-fluoride uptake correlates with 
histological markers of calcification activity and accurately predicts the progression in 
the CT calcium score, we currently lack data to show that 18F-fluoride is modifiable 
with drug therapy. Largely this is because no drug has yet demonstrated an ability to 
reduce disease activity in aortic stenosis and we lack reliable animal models of this 
condition. However the ability of medication directly targeting valve calcification 
activity to reduce aortic stenosis progression and the 18F-fluoride signal is the subject 
of an ongoing randomised control trial (NCT02132026) and we await the results with 
interest. 
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In this manuscript, “mean” measures of PET uptake demonstrated improved 
reproducibility compared to “maximum” measures. In particular ECG-gating of the 
PET data appeared to have a detrimental effect on the reproducibility of our maximum 
measures. Given that gating discards 75% of the PET data, and increases noise in the 
image, this is perhaps unsurprising for a technique that relies on a single voxel within 
an ROI.  It is possible that advanced image analysis approaches that models and 
corrects for both cardiac and respiratory motion without discarding any PET data 
would improve the reproducibility of TBRMDSmax measurements as has recently been 
described for coronary 18F-fluoride activity (Rubeaux M et al, 2015). This should be 
explored because it remains possible that TBRMDSmax values may be more sensitive to 
change and therefore better able to detect the effects of disease modifying therapies.   
 
In conclusion, we have optimised 18F-fluoride PET imaging in the aortic valve. 
Excellent localization of the PET signal within the aortic valve is now possible, with 
uptake observed in regions of maximal mechanical stress. Moreover quantification of 
valvular 18F-fluoride uptake is now possible with excellent scan-rescan 
reproducibility. 18F-Fluoride PET holds major promise as a method to better 
understand calcification activity in aortic stenosis and as a surrogate endpoint in 




18F-Fluoride is being increasingly used as a research tool to study vascular calcification 
activity, binding preferentially to regions of newly developing microcalcification 
beyond the resolution of CT (Irkle A et al, 2015). In aortic stenosis there is a close 
association between valvular 18F-fluoride uptake and calcification activity on 
histology (alkaline phosphatase staining), with the pattern of PET uptake ultimately 
predicting where new macroscopic deposits of calcium will develop on CT (Dweck 
MR et al, 2014).  Indeed baseline 18F-fluoride PET imaging is a good predictor of 
disease progression after both 1 and 2 years, as assessed aortic valve CT calcium score 
and Doppler echocardiography (Dweck MR et al, 2014; Jenkins WSA et al, 2015). 
18F-Fluoride PET therefore acts as a marker of disease activity in aortic stenosis with 
major potential to improve our understanding of the role of calcification in aortic 
stenosis. 18F-Fluoride is also being considered as an end-point in studies of novel 
therapies for this condition, because any reduction in calcification activity is likely to 
be detectable earlier than on standard measures of disease progression (e.g. 
echocardiography or CT calcium scoring which take at least 2 years to detect a 
difference) (Pawade TA et al, 2015). This would speed up phase 2 trials of new 
medication and reduce costs, potentially expediting the development of these much 
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There are an increasing number of people living with bioprosthetic heart valves, 
however, the pathophysiology of bioprosthetic valve degeneration is complex and 
poorly understood. Calcification is a key feature of failed bioprosthetic valves and 18F-




To investigate mechanisms of bioprosthetic valve degeneration and establish the 
histological correlates of 18F-fluoride binding in bioprosthetic valve tissue.  
 
Methods 
We examined 16 explanted degenerated bioprosthetic valves ex vivo using a unique 
combination of histopathology, 18F-fluoride micro-PET and CT.  
 
Results 
Calcification was the most prevalent pathological feature (in 87%), whilst thrombus 
(40%) and extension of pannus onto the cusps (47%) were other common findings in 
this series of degenerated valves. All valves exhibited 18F-fluoride uptake on PET, with 
a strong positive correlation between 18F-fluoride activity and calcium burden 
measured by CT (maximum standardised uptake value [SUV] versus total calcium 
volume: r=0.73, p=0.0031). 18F-Fluoride uptake was highest in regions of leaflet 
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calcification but was also present in regions where histology demonstrated organised 
thrombus, fibrosis and markers of matrix degradation. 
 
Conclusion 
Here we demonstrate that 18F-fluoride uptake is a consistent feature of bioprosthetic 
valve degeneration which correlates with calcification but also with other features of 
valve degeneration in the absence of calcium. 18F-Fluoride PET/CT therefore holds 
promise in the preclinical and clinical setting to help elucidate the pathophysiology of 
valve degeneration and assess the efficacy of developments in valve technology to 







The expansion in implantation of bioprosthetic heart valves over recent years reflects 
two key advantages of bioprosthetic over mechanical valves. First, bioprosthetic 
valves have low thrombogenicity and are not therefore associated with the requirement 
for longterm anticoagulation that is mandated with mechanical valves. Second, 
bioprosthetic valves can be crimped and mounted on an expandable stent for 
percutaneous transcatheter delivery or rapid surgical implantation. This feature has 
extended the availability of aortic valve intervention to high risk surgical candidates 
and those with specific technical contra-indications to cardiac surgery.  
 
Durability of Bioprosthetic Valves 
Since the emergence of bioprosthetic heart valves in the 1970s, technology has 
developed to overcome a variety of biomechanical problems ranging from premature 
tissue failure to stent fractures (Wheatley et al, 1987). Similarly, the performance and 
durability of xenograft tissue has incrementally improved with careful selection of 
porcine or bovine pericardial tissue, glutaraldehyde fixation to reduce antigenicity and 
increase tissue strength, and anti-mineralisation treatments. Nevertheless, the longterm 
durability of bioprosthetic aortic valves is finite and valve failure may result from 
structural valve degeneration, valve thrombosis or prosthetic valve infective 
endocarditis. Of these complications the most common mode of failure is structural 
valve degeneration, with actuarial estimates of reoperation for structural valve 
degeneration at 20 years ~46% in those under 60 years old at the time of implantation 
(Johnston DR et al, 2015).  
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Pathophysiology of Structural Valve Degeneration 
Structural valve degeneration is incompletely understood but postulated mechanisms 
include dystrophic calcification, injury resulting from adverse mechanical stress, 
immune reactivity, subclinical leaflet thrombosis, and an inflammatory process with 
similarities to atherosclerosis. Dystrophic calcification of bioprosthetic valves results 
from the devitalisation of cells during glutaraldehyde fixation, thereby providing a 
substrate for passive nucleation of calcium phosphate on the plasma membrane, 
cellular organelles and apoptotic bodies (Simionescu A et al, 2004). Calcium 
phosphate may also precipitate around the fibrous components of bioprosthetic valve 
tissue, such as the structural spaces around type 1 collagen called ‘hole zones’. These 
hole zones are usually shielded by proteoglycans, however, as these degrade and 
collagen is damaged by the effects of mechanical stress, oxidative stress and enzymatic 
activity, there is increased potential for calcification (Lovekamp JJ et al, 2006). Elastin 
is also degraded by mechanical injury and proteolysis, so offering another site for 
neocalcification (Simionescu A et al, 2004).  
 
Bioprosthetic valves lack the distinctive layers and regenerative properties of the 
native aortic valve, and are therefore more susceptible to adverse mechanical stress 
(Dalgliesh AJ et al, 2019). Mechanical load and calcification appear to be closely 
related, with calcium deposits often described at sites of peak mechanical stress at the 
leaflet margins and attachments to the valve frame. The cumulative effects of 
mechanical stress can result in delamination (e.g. cracking) of fibrous components, 
deterioration of the extracellular matrix with proteolysis and loss of 
glycosaminoglycans, and calcification of damaged collagen and elastin fibres. As 
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valve cusps become increasingly non-compliant, this exaggerates mechanical stress 
further and causes progressive structural degeneration (Sacks MS et al, 2015).  
 
Following implantation, prosthetic valves (both mechanical and bioprosthetic) trigger 
a foreign body reaction with infiltration of endothelial cells, myofibroblasts and 
immune cells (Teshima H et el, 2003). This is commonly initiated at sites where host 
and prosthetic material come into contact such as the suture line, leading to a 
fibrovascular tissue proliferation commonly referred to as pannus. There is evidence 
that increased expression of transforming growth factor ß (TGF- ß) and its type 1 
receptor by myofibroblasts are important in mediating the proliferation of pannus 
(Teshima H et el, 2003).  Though pannus formation may be protective against 
thrombosis and mechanical abrasion, overgrowth of pannus can be harmful by causing 
valve stenosis or regurgitation, and may also be a trigger for valve calcification.  
 
The immune reaction to bioprosthetic valve implantation is not fully understood but 
may be an important factor in structural degeneration. Infiltrates of immune cells are 
a common feature of explanted degenerated valves, as are high levels of IgM, IgG and 
C4d complement fragment (Nair V et al, 2012). Macrophages promote destruction of 
tissue by generating reactive oxidative species and calcium binding proteins such as 
osteopontin and osteonectin (New SE et al, 2013). In addition, high levels of 
macrophage-derived proteolytic enzymes, such as MMP-9 and plasminogen, are 
associated with phagocytosis and destruction of the extracellular matrix (Simionescu 
A et al, 1996 a). In animal studies, glutaraldehyde-treated xenogeneic implants suffer 
from more severe inflammation and tissue destruction then syngeneic implants and 
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there is a direct correlation between intensity of inflammation and severity of implant 
calcification (Manji RA et al, 2006). In further support of a causal immunological role, 
recipients of xenograft valves are found to have increased titres of antibodies to animal 
carbohydrates and animal proteins, including galactose-œ-1,3-galactose (œ-Gal), 
porcine albumin and type 4 collagen (Bloch O et al, 2011; Boër U et al, 2017). 
Xenograft valves also deteriorate more rapidly in younger subjects who are known to 
have greater immune reactivity whereas homografts which have lower 
immunogenicity are more durable (Bell D et al, 2019).   
 
There appear to be some similarities between native vascular atherosclerosis and 
features of degenerated bioprosthetic valves. For example, tissue from explanted 
valves exhibits lipid deposition, with oxidised low-density lipoprotein (LDL) and 
foam cells analogous to those seen in atherosclerosis (Simionescu A et al, 1996 b). 
Clinical studies reveal a correlation between the incidence of structural valve 
degeneration and features of adverse lipid metabolism, such as an increasing ratio of 
low-density to high-density lipoprotein cholesterol (Nsaibia MJ et al, 2016). The 
driver to lipid deposition in bioprosthetic valves is not well explained but it has been 
postulated that LDL may become entangled with glycosaminoglycans in leaflet tissue 
(Shetty R et al, 2009).   
 
Overt valve thrombosis is classified out with structural valve degeneration (Dvir et al, 
2018), however, there is evidence that subclinical leaflet thrombosis contributes to 
valve degeneration. This may be initiated by deposition of thrombogenic proteins such 
as fibrinogen, which has been found to be widely distributed in explanted valve tissue 
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(Sakaue T et al, 2018). Recurrent leaflet thrombosis may then trigger chronic 
inflammation, infiltration of leucocytes and ultimately provide a nidus for calcification 
(Sakaue T et al, 2018).  
 
Across the various pathways of bioprosthetic valve structural degeneration described 
here, calcification is a key common pathway and the most frequently identified 
histological feature of valve failure. Calcification is therefore an attractive target for 
investigative markers of disease progression. Micro-positron emission 
tomography/computed tomography (PET/CT) describes the use of a pre-clinical 
scanner for molecular or functional imaging of biochemical processes on a 
miniaturised scale. 18F-fluoride PET/CT has previously been utilised to identify micro-
calcification in native aortic stenosis and carotid artery atherosclerosis (Dweck MR et 
al, 2015; Irkle A et al, 2015). We therefore hypothesised that micro-18F-fluoride 
PET/CT could be used to study mechanisms of structural valve degeneration in 
explanted bioprosthetic valves, allowing correlation between high resolution imaging 
and histological analysis.  
 
PET/CT of Bioprosthetic Valves 
Micro-PET/CT imaging of bioprosthetic heart valves is a novel field and presents a 
number of technical challenges. Despite the excellent spatial resolution of modern pre-
clinical PET/CT, bioprosthetic valves are associated with a range of artefacts due to 
the radio-opaque and metal components of the prostheses. Compounding this, there 
are considerable differences in the composition of bioprosthetic valves. For example, 
the Edwards Lifesciences Perimount series is designed around a cobalt-chromium 
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alloy stent with stainless steel wire frame whilst the Medtronic Mosaic and Hancock 
series are built around a flexible acetyl homopolymer stent frame. CT artefacts 
particularly encountered during imaging of bioprosthetic valves include beam 
hardening, photon starvation and partial volume artefact.  
 
Beam hardening is the result of low energy photons being absorbed during passage of 
the X-ray beam through dense material, thereby increasing the mean energy of the 
beam and reducing the rate at which it is attenuated. If the X-rays pass through a dense 
cylindrical object then this can produce ‘cupping artefacts’, or if material in the 
scanned sample contains very heterogenous material then beam hardening varies with 
the tube position and can created dark bands and streak artefacts. The latter can occur 
with dense mineralised tissue, prosthetic material or contrast medium. Strategies for 
minimising beam hardening artefact include filtration with a metallic material to ‘pre-
harden’ the beam. In clinical scanners, phantoms can be used to calculate calibration 
corrections and iterative beam hardening correction algorithms can be applied.  
 
Photon starvation artefact is the effect of an X-ray beam passing through highly 
attenuating material, such that insufficient photons reach the detector in certain 
projections. The reconstruction process has the effect of further amplifying the 
artefact, producing horizontal streaks in the image. Increasing the tube current can be 
used to help address this problem, though at the expense of a higher radiation dose. 
Adaptive filtration techniques may also be used to help smooth these artefacts in 
clinical imaging.  
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Partial volume CT artefact occurs when a dense object in the periphery of the scanned 
volume partially protrudes into the x-ray beam in certain alignments of the beam but 
not others. The inconsistencies between different projections can result in shading 
artefacts appearing in the image. This may be mitigated by minimising the acquisition 
section width.  
 
Micro-PET is similarly subject to artefactual inaccuracies. First, partial volume effect 
arises when the size of a region or object is less than twice that of the full width at half 
maximum, a reflection of the upper limit of resolution of PET imaging. In this setting, 
the activity in the region of interest may be underestimated whilst activity in adjacent 
regions may appear to be artificially increased due to spill over. Second, CT 
attenuation correction (according to Hounsfield units) is routinely used in PET 
imaging to characterise tissue and apply a scale factor to the PET signal. This usually 
works well in clinical imaging, however, these algorithms tend to over-correct in the 
presence of high density material such as contrast agent or metallic objects. Artefact 
resulting from CT attenuation correction errors may therefore suggest high PET 
activity in regions where that is not the case. We planned to optimise our image 
acquisition protocol to minimise the impact of these potential artefacts and recognised 







Explanted degenerated bioprosthetic valves were obtained with written informed 
consent from patients undergoing redo-valve replacement surgery. Valves were 
weighed, photographed and their macroscopic features documented. Autoradiography 
and histological correlation were performed with one valve. All other valves were 
assessed by 18F-fluoride positron emission tomography (PET), micro-computed 
tomography (CT) and histological examination.  
 
Classification of Features of Structural Valve Degeneration 
Using a combination of visual examination, micro-CT and histology, pathological 
features of bioprosthetic valve degeneration were noted and classified according to 
published criteria (Table 5.1) (Butany J et al, 1992; Butany J et al, 2007; Schoen RJ 






As we were exploring the novel application of 18F-fluoride PET in the assessment of 
bioprosthetic valve degeneration, we first performed autoradiography to characterise 
the relationship between 18F-fluoride binding and histological markers of calcification 
in bioprosthetic valves. Non-decalcified valve tissue was cooled in dry ice and then 
sectioned using a cryostat (CM1520 Wetzlar, Germany). Sections for autoradiography 
were mounted on Superfrost slides (Gerhard Menzel, Braunschweig, Germany) before 
treatment with spray fixative. Sections were bathed in a solution of 18F-fluoride (1 
kBq/mL) for 60 min, and then rinsed with PBS. A freshly blanked phosphor screen 
was then placed over the slides and an overnight exposure was acquired. The screen 
was subsequently read using a FujiFilm FLA-5100 Fluorescent Image Analyser 
(Raytek Scientific Limited, Sheffield, UK). Sections adjacent to those used for 
autoradiography were examined for calcium orthophosphate using Von Kossa’s stain. 
These were manually registered and assessed for co-localisation with 18F-fluoride 
uptake.  
 
18F-Fluoride Positron Emission Tomography and Computed Tomography 
Explanted bioprosthetic valves were preserved in 10% w/v buffered formalin 
phosphate (Fisher Chemical SF100-20) after explantation. Prior to imaging, valves 
were rinsed in phosphate-buffered saline (PBS) then incubated in 20 mL of 100 
kBq/mL 18F-fluoride (target activity 2 MBq) for 20 min at 20o Celsius. Valves were 
rinsed in PBS on a further 2 occasions before being mounted in a plastic universal 
container for scanning. PET data were acquired over a 30 min bed time using 1:5 
coincidence mode. A micro-CT was acquired (full semi-circular full trajectory, 
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maximum field of view, 720 projections, 70 kVp, exposure 450 ms and 1:4 binning) 
for attenuation correction and anatomical co-registration. PET data were reconstructed 
using Mediso’s iterative Tera-Tomo 3D algorithm and the following settings: 4 
iterations, 6 subsets, full detector model, normal regularization, spike filter on, voxel 
size 0.6 mm, 400-600 keV energy window.  
 
Optimisation of Image Acquisition 
As this constitutes the first reported use of 18F-fluoride micro-PET/CT in the 
assessment of bioprosthetic valves, a series of scans using variations in acquisition 
parameters and scanning mediums were undertaken to determine an optimal approach. 
The CT tube voltage was adjusted and a subjective assessment was made of image 
quality. Images of a unused control valve (Edwards Lifesciences 25mm Perimount) 
were acquired by independently varying tube voltage (35, 50 and 70 kVp) and 
exposure time (300ms and 450ms). It was determined that a tube voltage of 70 kVp 
with 450ms exposure provided the best image quality by minimising beam hardening 
artefact from the high density material in the valve.  
 
Different scanning mediums were also investigated. The control valve was scanned 
immersed in PBS, in varying concentrations of iodinated contrast medium (10%, 20% 
and 50%), and without liquid scanning medium. From subjective assessment, there 
was some reduction in CT beam hardening artefact when using higher concentrations 
of contrast medium, however, this also resulted in anatomical detail being obscured 
and a reduced ability to detect tissue calcification. There was concern that scanning 
without liquid medium may result in tissue damage, however, this ultimately provided 
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Analysis of PET/CT was performed using PMOD (PMOD Technologies, Switzerland) 
and OsiriX (OsiriX version 8.0.3 64-bit; OsiriX Imaging Software, Geneva, 
Switzerland). A bespoke tool was used to measure calcium volume in the valve cusps, 
taking care to exclude calcification of the sewing ring and the valve ring itself. The 
micro-PET and CT series were reorientated and fused. 18F-Fluoride uptake in the valve 
cusps by various methods including the whole valve mean, the most diseased segment 
mean, and the maximum standardised uptake values (SUV).  
 
Histological Validation 
To characterise the pathophysiology underlying the imaging observations made in 
these investigations, bioprosthetic valve tissue underwent histological examination. 
These analyses were performed by collaborating groups at the University of British 
Columbia (Vancouver, Canada) and the CVPath Institute (Gaithersburg, Maryland, 
USA).  
 
In patients undergoing redo-valve replacement surgery, the bioprosthetic valve was 
excised at the time of surgery and the integrity of the valve structure was preserved. 
Explanted valve specimens were fixed in 10% w/v buffered formalin phosphate 
(Fisher Chemical SF100-20) pending histological analysis. Heavily calcified samples 
were treated with fixative decalcifier to facilitate sectioning (Fisher Chemical, Cal-Ex 
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II, CS511-1D). Leaflets were detached from the base of the valve and marked with 
tissue dye to maintain orientation. Each leaflet was processed then sectioned into 2-4 
mm sections and embedded in paraffin sequentially to yield 7-8 tissue cross-sections 
per leaflet. Paraffin sections were used for histology. Sections were stained for 
architecture (haematoxylin and eosin, Movat pentachrome), calcium phosphate (von 
Kossa), thrombus and fibrosis (Movat Pentachrome). Visual assessment was 
performed and reported by experienced pathologists.  
 
Tissue Staining Protocols 
Haematoxylin and Eosin 
Eosin is an acidic dye which stains basic structures pink, such as cytoplasm or 
extracellular fibres. Haematoxylin is a basic dye which stains acidic structures, such 
as nuclei, a purple-blue colour. Tissue sections were deparaffinised using heat and 
immersion in xylene. Sections were then hydrated by passing through decreasing 
concentrations of alcohol before firstly being stained with haematoxylin for 3-5 min. 
Sections were washed under running water for several minutes, treated in 1% 
hydrochloric acid alcohol, washed, treated in ammonia and then washed again prior to 
staining with eosin for 10 minutes. Finally, tissue sections were washed in running 
water, dehydrated in increasing concentrations of alcohol, cleared in xylene and 
mounted in mounting media ready for microscopy.  
 
Movat Pentachrome  
This is a five-colour stain which highlights the constituents of connective tissue, with 
nuclei and elastin staining black, collagen staining yellow, mucin staining blue, fibrin 
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staining bright red and muscle staining red. Tissue sections were deparaffinised and 
hydrated as above. Tissue was subject to a Bouins mordant, heated in a microwave 
and rested for 10 min. After washing in cold running water, sections were treated in 
sodium thiosulphate for 5 min then again washed and stained with 1% Alcian Blue for 
20 min. After a wash, sections were placed in preheated alkaline alcohol for 10 min, 
again rinsed then treated in Movat’s Weigerts for 1 hour. A further wash was followed 
by treatment in Crocein scarlet/acid fuchsin for 1 minute, a rinse, treatment in 5% 
phosphotungstic acid for 5 minutes, transfer to 1% acetic acid for 5 min, a rinse, 
dehydration in increasing concentrations of alcohol and then treatment in alcoholic 
saffron for 20 min. A final rinse with 2 changes was performed in 100% ethanol before 
clearing in xylene and mounting in mounting media for microscopy.  
 
Von Kossa  
Silver ions bind phosphate ions and undergo photochemical degradation to visualise 
silver deposits as a metallic silver colour on microscopy. Tissue sections were 
deparaffinised and hydrated as above, then immersed in 5% aqueous silver nitrate. 
Sections were then exposed to ultraviolet light for 20 min, washed in distilled wated 
then treated with 2% sodium thiosulphate for 2 min. After rinsing, sections were 
counter-stained with 1% neutral red for 2 min. They were then dehydrated in alcohol, 






Explanted Degenerated Bioprosthetic Valves  
Sixteen explanted bioprosthetic valves were obtained for ex vivo investigation. These 
comprised porcine and bovine pericardial stented valves of a variety of models 
produced by four different manufacturers (Table 5.2). One bovine pericardial valve 
was investigated by 18F-fluoride autoradiography and histopathology. The other fifteen 
valves were assessed by macroscopic inspection, micro-computed tomography (CT), 
18F-fluoride positron emission tomography (PET) and histopathology. Features of 
bioprosthetic valve degeneration were documented including cusp tears and 
perforations, valve frame distortion, cusp calcification, fibrosis and thrombus 
formation. Calcium volume was measured by CT and 18F-fluoride tracer uptake was 
quantified by PET. Morphological findings were graded according to published 







A bovine pericardial stented aortic valve (Edward’s Lifesciences Perimount) was 
explanted during repeat aortic valve replacement surgery for symptomatic severe 
prosthetic valve stenosis. Diffuse nodular calcification of the valve cusps was visible 
on gross assessment. On autoradiography, binding of 18F-fluoride to valve tissue was 
found to co-localise with visually apparent calcification and evidence of structural 




FIGURE 5.1.  




Figure 5.1. A. Photograph of an explanted bovine pericardial bioprosthetic aortic 
valve with a large calcific nodule close to a commissural attachment (red arrow) B. 
Tissue sections from the valve cusps with a large calcific nodule on section 5 C. 
Autoradiography of corresponding tissue sections (1-5) demonstrating 18F-fluoride 
uptake in all samples, with the highest signal in section 5 D. Von Kossa stain 




Calcification was often presumed on visual inspection, though this alone did not offer 
a reliable indication of the presence of calcification and in 2 notable cases it was not 
substantiated by findings from CT or histology (valves 4 and 12). CT detected cusp 
calcification in 13 valves (87%) and histology identified cusp calcification in 11 valves 
(73%), all of which had calcium clearly apparent on CT. CT therefore appeared to 
offer greater sensitivity for the detection of tissue calcification than histology. Tissue 
histology revealed a typical pattern of intrinsic cusp calcification, with calcium 
aggregates developing in the central region of the cusp and ultimately penetrating the 
cusp surface in severe cases (e.g. valves 1, 5, 6, 8, 9, 10, 11 and 15). 18F-Fluoride 
uptake assessed by micro-PET correlated spatially with calcification seen on CT and 
histology, and was associated with the highest tracer activity when compared to 
healthy cusp tissue and other features of tissue degeneration (e.g. valves 1, 5, 6, 8, 9, 
10, 11, 15).  
 
Pannus 
Pannus had a characteristic appearance, typically covering the valve sewing ring in a 
circumferential pattern and extending to a variable degree over the surfaces of the 
valve cusps. Pannus was a universal finding (100%) affecting the valve sewing ring 
and involved the valve cusps in 7 out of 15 cases (47%). In severe cases, there was 
significant encroachment causing restricted cusp mobility and cusp retraction (e.g. 
valves 9 and 10). This could be a mechanism of valve stenosis and/or valve 
incompetence. CT was able to differentiate between regions of calcific and non-
calcific cusp thickening, and in several cases identified calcium deposits within 
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regions of mature pannus (e.g. valves 8, 9 and 14). Histology samples from regions of 
pannus confirmed fibrous cusp thickening, with and without associated calcification. 
18F-Fluoride PET uptake was increased in regions of pannus affecting both the valve 
sewing ring and cusps, even in the absence of calcification, (e.g. valves 1, 4, 9, 12, 13). 
This advocates pannus as a potential driving factor in bioprosthetic valve calcification.  
 
Thrombus 
Thrombus was also a prevalent finding, identified by histology in 6 out of 15 valves 
(40%). When present it tended to be minor and localised (grade 1 in 3 cases, grade 2 
in 3 cases), and was unlikely to account for significant valve dysfunction. In 2 cases 
thrombus was seen in association with more significant cusp thickening and increased 
18F-fluoride uptake, both in the absence of cusp calcification (e.g. valve 1, cusp 2) and 
presence of cusp calcification (e.g. valve 15, cusp 1).  
 
18F-Fluoride Positron Emission Tomography   
Increased uptake of 18F-fluoride was frequently seen co-localising to the rim of pannus 
covering the valve sewing ring, to regions of fibrotic cusp thickening (e.g. valve 9, 
cusp 3), and to regions where histology identified organised thrombus in the absence 
of calcification (e.g. valve 1, cusp 2). The areas of highest tracer uptake correlated with 
CT and histological evidence of calcification. Valve cusp 18F-fluoride activity was 
quantified and found to correlate with calcium volume as measured by CT (maximum 
standardised uptake value [SUV] versus total calcium volume: r=0.73, p=0.0031) 




Description of Individual Valve Findings  
 
Valve 1  (Figure 5.3)  
Description 
Medtronic Mosaic stented porcine valve.  
Macroscopic Assessment 
Valve weight is 3.8g. A visible layer of pannus is seen over the ventricular surface of 
the valve ring but not encroaching on the cusps (grade 1 pannus). There is increased 
folding of cusp tissue, a large oval tear in the central region of cusp 3 and adjacent to 
this is thinned and friable cusp tissue with multiple fenestrations (type IV tear). There 
is calcification apparent at the base of cusp 3 and at the commissural attachments.  
Computed Tomography 
There is increased radio-opacity of the cusps consistent with fibrous thickening and 
partial folding. Calcification is seen at the base and at both commissures of cusp 3. 
Histopathology 
In all 3 cusps there is evidence of expansion of the central collagen-proteoglycan 
layer and organising thrombus on both surfaces (grade 2B thrombus). In cusp 3, 
there is calcification on the aortic surface near the commissure adjacent to cusp 2 
(grade 3 calcification). 
18F-Fluoride Positron Emission Tomography 
There is mildly increased 18F-fluoride activity corresponding to pannus over the 
ventricular surface of the valve ring and stent posts. There is high tracer activity in 
cusp 3 at the commissure adjacent to cusp 2, co-localising to calcification noted on CT 
and histology. There is also a region of high uptake near the free edge in cusp 2, where 
calcification was not apparent and histology showed organising thrombus.  
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Valve 2  (Figure 5.4)  
Description 
Carpentier-Edwards’ stented porcine valve.  
Macroscopic Assessment 
Valve weight is 3.7g. There is a layer of pannus over the ventricular surface of the 
valve ring which does not extend on to the cusps (grade 1 pannus). Cusp 1 appears thin 
and friable, with a tear near the commissure with cusp 3 (type II tear). There is mild 
stent creep with inward distortion of the stent post between cusps 1 and 3. From the 
aortic aspect, there is apparent calcification of cusp 3 near the commissure adjacent to 
cusp 1.   
Computed Tomography 
There is increased radio-opacity of the leaflets consistent with fibrous thickening and 
partial folding. Calcification is demonstrated at the base of cusp 3 and the 
commissure adjacent to leaflet 1.   
Histopathology 
In all cusps there is mild fibrous thickening and mild expansion of the central collagen-
proteoglycan layer near the free edge. There is no evidence of thrombus. There is no 
calcification identified in cusps 1 and 2, however, in cusp 3 there is focal calcification 
at the basal region of the section (grade 2 calcification).  
18F-Fluoride Positron Emission Tomography 
There is mildly increased 18F-fluoride activity corresponding to pannus on the 
ventricular surface of the valve ring. There is extensive activity in the region of the 
commissure between cusps 1 and 3, correlating with the calcification noted on CT and 
histology.  
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Valve 3  (Figure 5.5)  
Description 
Carpentier-Edwards’ stented porcine valve.  
Macroscopic Assessment 
Valve weight is 4.3g. There is pannus extending over the ventricular surface of the 
valve ring, predominantly beneath cusp 2 (grade 1 pannus). There is a small circular 
perforation in the body of cusp 2, a linear tear extending from the free edge of cusp 1, 
and a fenestrated perforation in the body of cusp 3 (type IV tear). There is mild stent 
creep with inward distortion of the stent posts on either side of cusp 1 and some 
elliptical deformation of the valve frame. A very large calcific nodule is apparent in 
the body of cusp 3, penetrating both surfaces.  
Computed Tomography 
Confirms severe calcification of cusp 3 with a large calcific nodule and further 
calcification around the commissural region, adjacent to cusp 1.  
Histopathology 
Tissue sections from cusps 1 and 2 demonstrate mild fibrous thickening and mild 
expansion of the central collagen-proteoglycan layer due to fluid insudation resulting 
in separation of collagen fibres. Cusp 3 exhibits severe nodular calcification erupting 
through both surfaces of the cusp, extending from the base to mid region of the leaflet 
(grade 4 calcification). There is no evidence of thrombus (grade 0 thrombus).  
18F-Fluoride Positron Emission Tomography 
There is mildly increased 18F-fluoride activity corresponding to pannus covering the 
ventricular surface of the sewing ring. There is high tracer uptake in cusp 3, co-
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localising to the large calcific nodule in the body of the cusp, calcification seen at the 
commissure with cusp 1, and also mid leaflet at the free edge adjacent to cusp 2.  
 
Valve 4  (Figure 5.6)  
Description 
Carpentier-Edwards’ Perimount stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 3.6g. There is mild pannus extending over the ventricular surface of 
the valve ring and over the stent post between cusps 2 and 3 (grade 1 pannus). There 
is a small linear tear in cusp 1 at the stent post attachment adjacent to cusp 2 (type 1).  
Computed Tomography 
There are regions of increased radio-opacity representing fibrous thickening, most 
apparent in the region of the commissure between cusps 1 and 2. There is no evidence 
of calcification.  
Histopathology 
Tissue sections from all 3 cusps show fibrous thickening with fluid insudation and 
separation of collagen fibres. These changes are most marked in towards the basal 
region of cusps 1 and 2. There is no evidence of thrombus.  
18F-Fluoride Positron Emission Tomography 
There is mildly increased 18F-fluoride activity corresponding to the layer of pannus 
seen over the ventricular surface of the valve ring and extending over the stent post 
between cusps 2 and 3. There is also mild diffuse tracer activity in all 3 valve leaflets, 
highest in cusp 2.  
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Valve 5  (Figure 5.7)  
Description 
Carpentier Edward’s stented porcine valve.  
Macroscopic Assessment 
Valve weight is 5.4g. There is a mild layer of pannus over the ventricular surface of 
the valve ring (grade 1 pannus). All cusps are severely disrupted with diffuse nodular 
calcification visible on both aortic and ventricular surfaces. There is a linear tear in the 
body of cusp 3 parallel to the sewing ring (type 2 tear) and a tear extending from the 
free edge of cusp 2 (type 1 tear).  
Computed Tomography 
This illustrates severe nodular calcification of all 3 cusps 
Histopathology 
Tissue sections from all 3 cusps shows full thickness intrinsic calcification extending 
the full length of the cusp (grade 4 calcification). There is no evidence of thrombus 
(grade 0).  
18F-Fluoride Positron Emission Tomography 
There is very high 18F-fluoride activity in all 3 cusps correlating with regions of 
calcification seen on CT.  
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Valve 6  (Figure 5.8)  
Description 
Sorin Mitroflow stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 2.0g. There is mild pannus over the inner ventricular surface of the 
sewing ring beneath cusp 3 (grade 1 pannus). All cusps appear thickened with reduced 
mobility. There is a tear in both cusps 2 and 3 extending from the commissure region 
(type 1 tear) where there is visible extensive calcification penetrating the aortic 
surface. There is a further small tear in cusp 1 at the commissure with cusp 2, also 
associated with macroscopic calcification.  
Computed Tomography 
Imaging demonstrates diffuse fibrous thickening and severe calcification, which is 
predominantly located at the commissures and free edge in all 3 cusps.  
Histopathology 
Sections show mild fibrous thickening secondary to fluid insudation. There is full 
thickness intrinsic calcification seen in all 3 cusps, which extends the full length of the 
cusps near the commissures (grade 4 calcification). There is no evidence of thrombus 
(grade 0).  
18F-Fluoride Positron Emission Tomography 
There is very high tracer uptake in all 3 cusps co-localising to regions of tissue 
calcification, particularly at the commissures and in the body of cusps 1 and 3.  
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Valve 7  (Figure 5.9)  
Description 
Carpentier Edward’s stented porcine valve.  
Macroscopic Assessment 
Valve weight is 4.2g. There is a layer of pannus extending over the ventricular surface 
of the valve ring and encroaching on cusps 1 and 3 (grade 2 pannus). Pannus also 
covers the outer fabric surface of the stent posts but does not affect the aortic surface 
of the valve cusps. There is a small tear in the free edge of cusp 1, near the commissure 
adjacent to cusp 2 (type 1 tear). There appears to be nodular calcification in this region 
of cusp 1, near the commissure with cusp 2. There is discolouration in the basal region 
of cusp 2, seen from both the aortic and ventricular aspect, which suggests the presence 
of thrombus.  
Computed Tomography 
CT demonstrates extensive calcification in cusp 1 and affecting the region of the 
commissure in both cusps 1 and 2.  
Histopathology 
Tissue sections show calcification of cusp 1 (seen on Movat pentachrome sections but 
not von Kossa), and organised thrombus on the surface of cusps 1 and 2 (grade 1A).  
There are regions of fibrous leaflet thickening.  
18F-Fluoride Positron Emission Tomography 
There is increased 18F-fluoride activity in all 3 cusps correlating with regions of 
calcification seen on CT, with the major focus of tracer uptake in cusp 1.  
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Valve 8  (Figure 5.10)  
Description 
St Jude Trifecta stented porcine pericardial valve.  
Macroscopic Assessment 
Valve weight is 5.0g. There is severe circumferential pannus covering the ventricular 
surface of the sewing ring and extending onto the ventricular surface of all 3 cusps 
(grade 3 pannus). All cusps appear thickened. There are small tears in cusp 1 and 3 at 
the commissures with cusp 2  (type 1 tear). There is extensive macroscopic 
calcification penetrating the aortic surface of cusps 1 and 3 (grade 4 calcification) and 
the mobility of cusp 1 is severely restricted.  
Computed Tomography 
Imaging demonstrates calcification associated with the pannus on the ventricular 
surface of cusp 1. There is severe calcification at all commissure regions and in the 
body of both cusp 1 and 3.  
Histopathology 
Sections show distorted leaflet architecture with full thickness intrinsic calcification 
erupting through both surfaces in cusp 1 and cusp 3 (grade 4 calcification). There is 
no evidence of thrombus (grade 0).  
18F-Fluoride Positron Emission Tomography 
There is increased tracer activity which co-localises to the regions of leaflet 
calcification seen macroscopically and on CT, but also to the thick rim of pannus 




Valve 9  (Figure 5.11)  
Description 
Carpentier-Edwards’ Perimount stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 6.0g. The valve cusps appear mildly thickened. There is severe pannus 
formation on the aortic surface of all 3 cusps. This extends along the base of each cusp 
parallel to the valve ring, and cusp 3 is retracted with restricted mobility (grade 4 
pannus). There is no significant pannus formation over the ventricular surface of the 
valve. Cusps are intact with no sign of perforation or tear.  
Computed Tomography 
There is increased opacification consistent with fibrous leaflet thickening at the base 
of the cusps. Cusp 1 and cusp 2 are diffusely calcified, with calcification seen co-
localising to the region of fibrous pannus at the base of cusp 2.  
Histopathology 
Tissue sections demonstrate intrinsic calcification within cusp 1 (grade 4 
calcification), whilst calcium is not illustrated in the sections from cusp 2. There is no 
significant fibrosis or thrombus (grade 0) in evidence.  
18F-Fluoride Positron Emission Tomography 
There is increased 18F-fluoride activity in all 3 cusps spatially correlating with regions 
of fibrous thickening (pannus) and calcification. In cusp 3, high tracer uptake 
corresponds to fibrous thickening in the absence of calcification.  
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Valve 10  (Figure 5.12)  
Description 
Carpentier Edward’s Perimount stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 6.0g. There is severe pannus formation on the aortic surface of the 
cusp 3, covering the valve sewing ring, a stent post, and extending over the cusp. There 
is cusp thickening and retraction with reduced mobility (grade 4 pannus). Nodules of 
calcification are macroscopically apparent in each cusp and there is dark red 
discolouration at the base of cusps 1 and 2 in suggestive of possibly thrombus.  
Computed Tomography 
CT demonstrates thickening of all 3 cusps, which is particularly marked in cusp 3. 
There is diffuse calcification of all 3 cusps.  
Histopathology 
Von Kossa staining reveals intrinsic calcification of all 3 cusps, penetrating through 
both leaflet surfaces (grade 4 calcification). There is fibrous thickening of all 3 cusps, 
with the most severe changes affecting cusp 3. Organised thrombus is evident on all 3 
cusps (grade 1 thrombus).  
18F-Fluoride Positron Emission Tomography 
There is high uptake of 18F-fluoride in all 3 cusps, and around the periphery of the 
valve sewing ring where there is macroscopic evidence of pannus overgrowth.   
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Valve 11  (Figure 5.13)  
Description 
Carpentier Edward’s Perimount stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 7.6g. There are large calcific nodules penetrating the aortic and 
ventricular surfaces of cusp 1 and cusp 2 (grade 4 calcification). There is a linear tear 
of the free edge of cusp 1, adjacent to cusp 2 (type 1 tear). There is some elliptical 
deformation of the valve frame. There is a patch of dark red discolouration on the 
ventricular surface at the base of cusp 3 and 1, suspicious for possible thrombus. There 
is minor pannus formation which is restricted to the ventricular surface of the valve 
sewing ring (grade 1 pannus).  
Computed Tomography 
CT illustrates areas of leaflet thickening and diffuse calcification of all 3 cusps, in 
particular with calcification around the valve commissures.  
Histopathology 
There is widespread intrinsic leaflet calcification of all 3 cusps, which is most severe 
in the tissue sections from cusp 1 where calcific deposits penetrate both surfaces. 
There appears to be a large papillary thrombus at the base of cusp 3 (grade 2/3 
thrombus).  
18F-Fluoride Positron Emission Tomography 
There is very high binding of 18F-fluoride in all 3 cusps, particularly co-localising to 
regions of calcification around the commissures. There is mild uptake in the region of 
the thrombus identified at the base of cusp 3.  
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Valve 12  (Figure 5.14)  
Description 
Carpentier Edward’s Perimount stented bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 3.1g. The valve cusps appear mildly thickened. Cusps are intact with 
no sign of perforation or tear. There is a circumferential rim of pannus around the 
ventricular surface of the valve ring with limited extension onto the ventricular surface 
of all 3 cusps. There is pannus reaching around the outer margin of the sewing ring 
onto the aortic surface of the base of cusp 3, again with limited extension onto the cusp 
but no apparent restriction of cusp mobility (grade 2 pannus). There is a patch of 
thickening in the body of cusp 1, however, no definite calcification is evident.  
Computed Tomography 
There is an isolated small fibrotic nodule in the free edge of cusp 3. There is diffuse 
calcification within the circumferential rim of subvalvular pannus without involving 
the cusps.  
Histopathology 
Histology shows loss of collagen architecture and fragmentation in cusp 1, cusp 
thickening with fibrosis and organised thrombus on the surface of leaflet 2, and fibrosis 
at the base of leaflet 3. There is no evidence of cusp calcification on micro-CT or 
histology (grade 0 calcification).  
18F-Fluoride Positron Emission Tomography 
There is increased 18F-fluoride uptake in the valve cusps around the commissural 
regions and at the base of cusp 3 co-localising to the region of pannus extending onto 
 209 
the cusp. There is extensive 18F-fluoride uptake correlating with the rim of subvalvular 
pannus encircling the valve ring.   
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Valve 13  (Figure 5.15)  
Description 
Sorin Mitroflow bovine pericardial valve.  
Macroscopic Assessment 
Valve weight is 4.9g. All 3 cusps appear grossly thickened. There are tears in cusps 2 
and 3 at the commissural attachment (type 2 tear). There is a patch of dark red 
discolouration in the body of cups 1 suggesting possible thrombus. There is a nodular 
texture to the cusp surface but no macroscopically evident calcification penetrating 
either cusp surface. There is mild pannus formation over the outer surface of the stent 
posts but this does not encroach the cusps (grade 1 pannus).  
Computed Tomography 
All cusps are markedly thickened. There is severe diffuse calcification of cusps 1 and 
3 (grade 4 calcification). There is no calcification apparent in cusp 2 but there is severe 
non-calcific thickening in the body of the cusp.  
Histopathology 
Von Kossa staining does not demonstrate tissue calcification as clearly seen on micro-
CT. There is evidence of fibrosis , fluid insudation and disruption of collagen 
architecture resulting in severe thickening of all 3 cusps. There is organised thrombus 
on the aortic surface at the base of cusp 1 and 3 (grade 1A).   
18F-Fluoride Positron Emission Tomography 
There is very high uptake of 18F-fluoride in the valve cusps. The highest regions of 
activity correspond with aggregates of calcium in cusps 1 and 3. There is also 
significant 18F-fluoride uptake in the body and at the base of cusp 2 in the absence of 
calcification.  
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Valve 14  (Figure 5.16)  
Description 
Carpentier Edward’s stented porcine valve.  
Macroscopic Assessment 
Valve weight is 3.4g. There is a tear in the free edge of cusp 3 and an oval tear in the 
body of cusp 2 (type 3 tear). There is very severe pannus formation encircling the valve 
ring and extending onto all 3 cusps on both the aortic and ventricular surfaces, such 
that cusp mobility is restricted (grade 4 pannus). There is no visible calcification.  
Computed Tomography 
There is increased opacification consistent with fibrous leaflet thickening at the base 
of the cusps. There is a calcific nodule within the pannus covering the ventricular 
surface of cusp 1 (grade 3 calcification) and further small flecks of calcium at the base 
of cusp 3 and at the commissure between cusps 2 and 3.  
Histopathology 
Histology demonstrates regions of fibrosis with leaflet thickening in all 3 cusps. No 
calcification is seen in the sections sampled. There is no evidence of thrombus (grade 
0).  
18F-Fluoride Positron Emission Tomography 
There is increased 18F-fluoride uptake correlating with the circumferential pattern of 
pannus overgrowth and with a focus of high uptake co-localising to the calcification 
at the base of cusp 1 noted on micro-CT.   
  
 212 
Valve 15  (Figure 5.17)  
Description 
Medtronic Hancock stented porcine valve.  
Macroscopic Assessment 
Valve weight is 6.7g. There are linear tears along the free edge of each cusp (type 1 
tears). There are calcific nodules penetrating the aortic surface of cups 1 and just 
beneath the surface of cusp 3. There is a thin, translucent layer of pannus covering the 
fabric sewing ring with mild extension onto the valve cusps. There is cusp thickening 
with a dark red discolouration on the ventricular surface at the base of cusp 1 
suspicious for thrombus.  
Computed Tomography 
There is a very long calcific nodule in cusp 1 extending the length of the free edge 
from the commissure to the leaflet tip, adjacent to cusp 2. There are further small 
calcium deposits near the base of cusp 2, and extending from both free margins of cusp 
3.   
Histopathology 
Von Kossa staining identifies intrinsic calcification of all 3 cusps, with the most severe 
changes in cusp 1 where calcium penetrates the surface (grade 4 calcification). There 
is fibrous thickening in all cusps and organised thrombus at the base of cusp 1 (grade 
2).  
18F-Fluoride Positron Emission Tomography 
There is increased 18F-fluoride activity in all 3 cusps correlating with regions of 
calcification, and highest where a large calcific nodule is noted in cusp 1. There is also 
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18F-fluoride uptake associated with regions of non-calcific leaflet thickening at the 
base of the 3 valve cusps.
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FIGURE 5.3.  
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FIGURE 5.4.  
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FIGURE 5.6.  
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FIGURE 5.7.  
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FIGURE 5.8.  
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FIGURE 5.9.  
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FIGURE 5.11.  
 
 223 
FIGURE 5.12.  
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FIGURE 5.13.  
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FIGURE 5.14.  
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FIGURE 5.15.  
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In this study we describe the features of structural valve degeneration in a series of 
explanted bioprosthetic heart valves by combining a detailed assessment of 
morphological characteristics with tissue histology, micro-computed tomography 
(CT) and 18F-fluoride positron emission tomography (PET). We document the 
prevalence of leaflet calcification, fibrosis and thrombus, and use unique insights from 
PET/CT to help elucidate the mechanisms of bioprosthetic valve degeneration. In 
particular,18F-fluoride PET detects nascent calcification and our findings reinforce the 
central role of calcification in the development of valve degeneration whilst also 
suggesting upstream triggers.  
 
Explanted valves displayed clear macroscopic features of degeneration, with 
distortions of the valve frame, gross leaflet thickening or fragility, and cusp tears in 12 
of 15 valves. Calcification was a dominant feature (in 13 of 15 valves) and micro-CT 
offered excellent sensitivity for the detection of calcium, superior to either direct visual 
inspection or tissue histology. The geographical distribution of calcium was readily 
appreciated by CT and showed a predilection for the leaflet commissures, which are 
recognised to be areas affected by high mechanical stress. This supports the important 
function of adverse mechanical stress in driving valve degeneration. On a microscopic 
level, tissue histology illustrated a particular pattern of mineralisation in bioprosthetic 
valves with intrinsic calcium deposition in the central regions of the cusp which 
propagate outwards and ultimately penetrate the surface. This observation is consistent 
with the theory of dystrophic calcification whereby devitalised cells and damaged 
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collagen and elastin structures serve as a nucleation sites for calcium phosphate within 
the cusp tissue.  
 
Pannus was another prevalent feature in our series of bioprosthetic valves, with a 
distinctive translucent appearance which was easily recognisable on visual inspection.  
Pannus is a proliferation of fibrovascular tissue triggered by the host response to 
foreign material and typically manifests at the anastomosis of the valve sewing ring to 
the native annulus. In our study, pannus was universally found at least partly covering 
the sewing ring and encroached onto the cusps in around half of valves (7 of 15). 
Severe (grade 4) pannus was identified in 2 cases in which there was severe restriction 
or retraction of one or more cusps, and this was likely to be the major cause of valve 
dysfunction. In cases of pannus extending onto the valve cusps, cusp thickening was 
evident from micro-CT and often in a circumferential pattern around the base of the 
valve cusps. In several instances CT identified calcium deposition within the fibrotic 
tissue and histology provided corroborating evidence of an association between 
pannus and leaflet calcification. Our findings suggest that limited pannus growth is an 
essentially normal finding in bioprosthetic valve implants, and when present to a 
limited degree it may provide a protective covering which reduces thrombogenicity 
and adds tensile strength. However, more aggressive pannus overgrowth appears to 
provide a substrate for calcification, thereby leading to progressive structural valve 
degeneration, or may be a primary cause of valve failure.  
 
Other features were less clearly discernible from macroscopic inspection and CT 
imaging but were detected on histological examination. These included organised 
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thrombus (in 6 of 15 valves) and features of tissue degradation such as loss of collagen 
structure, expansion of the proteoglycan layer and fluid insudation. Where present, 
leaflet thrombus was too limited in extent to cause haemodynamic valve dysfunction 
but did colocalise with regions of cusp thickening on CT and, in one instance, was 
associated with leaflet calcification on CT. This implies that leaflet thrombosis may 
more often be a subclinical event perpetuating progressive structural degeneration 
rather than a primary cause of valve obstruction and failure.  
 
In our investigation of 18F-fluoride as a marker of bioprosthetic valve degeneration, 
we first performed autoradiography and histological staining to confirm the binding of 
18F-fluoride to regions of calcium phosphate deposition in bioprosthetic valve tissue. 
We then used micro-PET/CT to examine 18F-fluoride uptake in the explanted valves, 
demonstrating variable degrees of uptake in all of the valves. The highest 18F-fluoride 
signal was observed to colocalise with regions of leaflet calcification and there was a 
positive correlation between total valve calcium volume quantified by CT and 
maximum 18F-fluoride activity measured by PET. However, 18F-fluoride activity also 
spatially correlated with other histological findings including fibrosis, thrombus and 
features of tissue degradation such as disruption of collagen architecture, even in the 
absence of calcium. These observations promote the theory of leaflet calcification as 
a final common response to bioprosthetic valve injury. In addition, it has been 
suggested that 18F-fluoride may have the potential to bind matrix metalloproteinases 
which are upregulated and implicated in bioprosthesis tissue degradation (Simionescu 
A et al, 1996 b; Kato MT et al, J Den Res 2014).  
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Our study has several key strengths. First, given the scarcity and challenge of obtaining 
sixteen well-preserved explanted degenerated bioprosthetic valves, this represents a 
robust sample size from which we have been able to study a range of the most widely 
used stented xenograft valve models. Second, we combine high quality tissue histology 
performed in expert hands with the novel application of preclinical PET and CT 
imaging. Whilst micro-CT provides high resolution anatomical detail, 18F-fluoride 
PET offers complementary functional information about calcification activity and 
therefore allows us to theorise about the mechanistic pathways leading to valve 
degeneration. Our multimodal imaging approach is particularly well suited to the study 
of bioprosthetic valves in which calcium typically aggregates in the deeper layers of 
cusp tissue such that degeneration is well advanced before calcification is apparent on 
the valve surface.  
 
Our study also has a number of limitations. Though comparable in size to many 
published series, we would ideally wish to expand our sample size to strengthen the 
applicability of our observations. In addition, CT imaging of prosthetic valves is 
afflicted by artefact, principally beam hardening and photon starvation artefact, 
resulting from the dense materials used in manufacture of the valve frame. This in turn 
influences the CT attenuation correction applied to PET data, with the consequence 
that there may sometimes appear to be increased PET signal in regions affected by 
such artefact. We have optimised our scanning protocol to minimise this impact, whilst 




In conclusion, 18F-fluoride PET has been successfully used to assess calcification 
activity and predict disease progression in a range of cardiovascular pathology 
including coronary heart disease, stroke, abdominal aortic aneurysms and aortic 
stenosis (Joshi NV et al; Forsythe RF et al; Vesey A et al; Dweck et al). We now 
extend these observations to bioprosthetic valves ex vivo and confirm that 18F-fluoride 
localises to regions of developing leaflet calcification on histology and high-resolution 
micro-PET/CT. Interestingly, a minority of bioprosthetic valves appear to degenerate 
without histological evidence of calcification. In these cases, there was also increased 
18F-fluoride activity which correlated with histological features including organised 
thrombus, fibrosis (pannus), gross leaflet thickening, fluid insudation and disruption 
of normal collagen architecture. These findings suggest that subclinical leaflet 
thrombosis, fibrosis and matrix degradation may all be potential upstream triggers of 
a calcific response. This is consistent with the theory of calcification being the final 
common consequence of various mechanisms of bioprosthetic valve injury and a major 
driver towards valve dysfunction, causing progressive cusp stiffness and obstruction 
as well as leaflet fragility and tears. We therefore propose that 18F-fluoride PET/CT 
imaging may provide an informative marker of bioprosthetic valve degeneration 
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Bioprosthetic aortic valve degeneration is increasingly common, often unheralded and 
can have catastrophic consequences.  
 
Objectives 
To assess whether 18F-fluoride positron emission tomography (PET) – computed 




Explanted degenerate bioprosthetic valves were examined ex-vivo. Patients with 
bioprosthetic aortic valves were recruited into two cohorts with and without prosthetic 
valve dysfunction and underwent in-vivo contrast-enhanced CT angiography, 18F-
fluoride PET, and serial echocardiography during 2 years of follow-up.  
 
Results 
All degenerate bioprosthetic valves displayed 18F-fluoride PET uptake that co-
localised with tissue degeneration on histology. In 71 patients without known 
bioprosthesis dysfunction, 14 had abnormal leaflet pathology on CT and 24 
demonstrated 18F-fluoride PET uptake (target-to-background ratio 1.55 [1.44-1.88]). 
Patients with increased 18F-fluoride uptake exhibited more rapid deterioration in valve 
function compared to those without (annualised change in peak transvalvular velocity: 
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0.30 [0.13-0.61] versus 0.01 [-0.05-0.16] ms-1/year, p<0.001). Indeed 18F-Fluoride 
uptake correlated with deterioration in all the conventional echocardiographic 
measures of valve function assessed (e.g. change in peak velocity, r=0.72; p<0.001). 
Each of the 10 patients who developed new overt bioprosthesis dysfunction during 
follow-up had evidence of 18F-fluoride uptake at baseline (target-to-background ratio 
1.89 [1.46-2.59]). On multivariable analysis, 18F-fluoride uptake was the only 
independent predictor of future bioprosthetic dysfunction.  
 
Conclusion 
18F-Fluoride PET-CT identifies subclinical bioprosthetic valve degeneration, 
providing powerful prediction of subsequent valvular dysfunction and highlighting 
patients at risk of valve failure. This technique holds major promise in the diagnosis 





The implantation of bioprosthetic heart valves is increasing rapidly due to patient 
preference, the increasing prevalence of valve disease in an ageing population, and the 
emergence of transcatheter aortic valve implantation (Iung B et al, 2011; Nkomo VT 
et al, 2006; Brown JM et al, 2009; Brennan JM et al, 2017). In the United States, 
90,000 surgical aortic valve replacements are performed annually, with over three-
quarters incorporating bioprosthetic valves (Brown JM et al, 2009). In addition, over 
80,000 transcatheter aortic valve implantation procedures have been performed since 
Food and Drug Administration approval in 2011 (Brennan JM et al, 2017). Given the 
finite lifespan of these valves and the rapid expansion of the population of patients 
requiring regular surveillance, bioprosthetic valve degeneration will become a major 
cause of cardiovascular morbidity and healthcare burden over the coming decades.  
 
The pathophysiology of bioprosthetic valve degeneration is poorly understood. Whilst 
calcification appears to contribute to both progressive valve narrowing and leaflet 
tears, non-invasive methods for detecting this process have been lacking, and the 
triggers of valve degeneration and calcification are unknown (Pibarot P et al, 2009; 
Singhal P et al, 2013; Rodriguez-Gabella T et al, 2017). Current standard of care relies 
on serial echocardiography and clinical assessment aimed at detecting the valve 
dysfunction that occurs only towards the end stages of the degeneration process. 
Unfortunately, many patients present in extremis with unheralded valve failure due to 
rapid onset valvular obstruction or regurgitation, with repeat operation a high-risk 
undertaking. Indeed, emergency repeat aortic valve replacement surgery is associated 
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with a mortality of 22.6% compared to 1.4% for elective repeat surgery (Vogt PR et 
al, 2000). Detection of bioprosthetic valve degeneration is therefore highly desirable 
allowing at-risk patients to be identified early, offered close tailored monitoring, and 
optimised timing of repeat elective intervention, thereby avoiding potentially 
catastrophic valve failure.  
 
18F-Fluoride positron emission tomography (PET) has recently been used to image 
tissue calcification activity in a range of cardiovascular diseases (Dweck MR et al, 
2012 A; Forsythe RO et al, 2018; Joshi NV et al, 2014; Vesey AT et al, 2017). 18F-
Fluoride preferentially binds to areas of developing microcalcification indicative of 
tissue degeneration that precede the macrocalcification detectable by computed 
tomography (CT) (Irkle A et al, 2015; Dweck MR et al, 2014); Jenkins WS et al, 
2014). Given that calcification is one of the key pathological process underlying 
bioprosthetic valve degeneration, we hypothesised that increased 18F-fluoride uptake 
would identify prosthetic valve degeneration and predict subsequent deterioration in 




Ex-vivo Assessment of Degenerated Bioprosthetic Aortic Valves 
Explanted degenerated aortic valve bioprostheses were obtained with written consent 
from patients undergoing repeat surgical aortic valve replacement for bioprosthetic 
valve failure. Valves were weighed, photographed and their macroscopic features 
documented. Ex-vivo micro-PET-CT was performed with a nano-PET-CT scanner 
(Mediso, Hungary) and X-ray microtomograph (Brucher, Belgium) before undergoing 
histological evaluation.  
 
Clinical Study Design and Population 
Patients over 40 years who had undergone previous surgical aortic valve replacement 
using a bioprosthetic valve were prospectively recruited into a single-centre cohort 
study according to defined inclusion and exclusion criteria as below (Figure 6.3). 
Participants were recruited if they were under routine clinical review and had (a) 
known evidence of bioprosthetic valve failure on echocardiography and had been 
referred for repeat aortic valve intervention, or (b) no known evidence of valve 
dysfunction or degeneration (Lancellotti P et al, 2016; Zoghbi WA et al, 2009). 
Written informed consent was obtained from all participants. The study 
(www.clinicaltrials.gov, NCT02304276) was conducted in accordance with the 
Declaration of Helsinki and was approved by an NHS Scotland Research Ethics 




Study Eligibility Criteria for Patient Selection 
Inclusion Criteria 
Ability to give informed consent; over 40 years of age; Cohort 1: patients with a 
surgically implanted bioprosthetic aortic valve who are due to undergo redo-aortic 
valve surgery or valve-in-valve transcatheter valve implantation for bioprosthetic 
valve failure; Cohort 2: patients with a surgically implanted bioprosthetic aortic valve, 
implanted 1 month, 2 years, 5 years or 10 years prior to study recruitment and without 
known evidence of valve dysfunction or degeneration.  
 
Exclusion Criteria 
Inability to give informed consent; pregnancy; breastfeeding; claustrophobia; allergy 
to iodinated contrast; liver failure; chronic kidney disease (with estimated glomerular 
filtration rate <30 mL/min/1.73m2); Paget’s disease; metastatic malignancy; inability 
to tolerate the supine position. 
 
Study Assessments and Data Collection 
All participants underwent baseline clinical assessment including Doppler and two-
dimensional echocardiography, non-contrast CT calcium scoring, contrast-enhanced 
CT angiography and in-vivo 18F-fluoride PET. Participants were invited to return 
annually for 2 years for repeat clinical assessments and echocardiography to assess 
changes in bioprosthesis performance. Definitions of bioprosthetic degeneration and 
dysfunction vary but in this study, we used definitions from both contemporary 
international guideline criteria (Lancellotti P et al, 2016; Zoghbi WA et al, 2009) and 
a recent expert consensus statement (Dvir D et al, 2018). Bioprosthetic valve failure 
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was defined as the development of severe haemodynamic valve dysfunction combined 
with patient symptoms, the need for redo valve intervention or valve-related death 
(Capodanno D et al, 2017). Patients were followed up for the development of valve 
failure beyond the 2 year time frame using electronic patient record data.  
 
Echocardiography 
Two-dimensional and Doppler echocardiography was performed at baseline and 
annually for 2 years by a single experienced and British Society of Echocardiography-
accredited echocardiographer using a single echocardiography scanner (Affiniti 70, 
Philips Healthcare) according to a standardised protocol. Aortic valve Doppler 
measurements were routinely assessed from the apex, suprasternal notch and right 
sternal edge and used to measure the peak velocity through the valve, the mean 
gradient and the Doppler velocity index (DVI).  Mean values were taken from 3 
measurements when subjects were in sinus rhythm and from 5 measurements if atrial 
fibrillation was present. Bioprosthetic valve regurgitation was graded as mild, 
moderate or severe according to guideline recommendation on the basis of visual 
appraisal of colour Doppler images, measurement of pressure half-time (ms) and 
assessment for aortic flow reversal in diastole (Lancellotti P et al, 2016; Zoghbi WA 
et al, 2009). In cohort 2, all 71 patients completed baseline and 1 year 
echocardiographic assessments, with 67 completing the 2 year visit. Measurements of 
relevant continuous variables were assessed as an annualised change during the 
follow-up period. 
 
Defining Bioprosthetic Degeneration and Dysfunction  
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Prosthetic valve dysfunction was adjudicated based upon European Association of 
Cardiovascular Imaging/Inter-American Society of Echocardiography/Brazilian 
Department of Cardiovascular Imaging and American Society of Echocardiography 
guidelines (Lancellotti P et al, 2016; Zoghbi WA et al, 2009) using the following 
criteria: Doppler velocity index (DVI) <0.29 and either peak velocity >3 I or mean 
gradient >20 mmHg (i.e. valve dysfunction suggested by one flow-independent 
parameter and one flow-dependent parameter), prosthetic regurgitation of at least 
moderate severity or an increase in mean gradient >10 mmHg. 
 
We also investigated an alternative definition of bioprosthetic valve degeneration and 
dysfunction proposed in a recent expert consensus statement: stage 1 characterised by 
morphological abnormality (detected on echocardiography or computed tomography) 
in the absence of haemodynamic changes; stage 2 characterised by the presence of 
either moderate valve obstruction, moderate regurgitation or both; stage 3 
characterised by the presence of either severe valve obstruction or regurgitation (Dvir 
D et al, 2018). Central to this definition of structural valve degeneration is a 
deterioration in function over time, for example, new valve obstruction should be 
accompanied by a change in mean gradient >10mmHg associated with a decrease in 
Doppler velocity index and effective orifice area. Valve failure was defined as the 
development of severe stenosis or regurgitation resulting in the development of patient 
symptoms and/or the need for redo valve intervention (Brennan JM et al, 2017). 
 
Positron Emission Tomography and Computed Tomography 
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Subjects were given 25 mg of oral metoprolol if their resting heart rate was >65 
beats/min in the absence of any contraindication. A target dose of 125 MBq 18F-
fluoride was administered intravenously, with an effective radiation dose of 3 mSv.  
After 60 min, participants were imaged on a hybrid 128-detector array positron 
emission tomography and computed tomography (PET-CT) scanner (Biograph mCT, 
Siemens, Erlangen, Germany). Pharmacokinetic modelling has demonstrated that this 
timing provides excellent vascular tissue contrast resolution (Irkle A et al, 2015). A 
low-dose attenuation correction CT scan was performed (120 kV, 50 mAs; 5/3 mm), 
followed by acquisition of PET data in list mode, using a single 30-min bed position 
centred on the valve in 3-dimensional mode. Finally, ECG-gated aortic valve CT 
calcium scoring and contrast-enhanced CT angiography were performed in diastole 




Static PET-CT images were reconstructed with correction applied for attenuation, dead 
time, scatter and random coincidences, using an optimised iterative reconstruction 
algorithm (ultra-HD; TrueX + TOF, matrix 200, zoom 1; Gaussian filter). Analyses 
were performed using an OsiriX workstation (OsiriX version 8.0.3 64-bit; OsiriX 
Imaging Software, Geneva, Switzerland). ECG-gated contrast-enhanced CT images 
were reconstructed in diastole using 1-mm slices. For this purpose, ECG-gating of list 
mode PET data was used to reconstruct at 25% intervals of the cardiac cycle with 
diastolic data determined as that acquired between 50 and 75% of the R-R interval. 
PET and CT reconstructions were carefully co-registered in all 3 planes using the 2-D 
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orthogonal tool (Figure 6.1). Key points of reference were the sternum, vertebrae, 
blood-pool in the left ventricle (based upon the high 18F-fluoride activity in the blood 
relative to the surrounding myocardium), the ascending aorta and the aortic arch.  
Fused PET and contrast-enhanced CT images were reoriented to provide en face 
images of the bioprosthetic valve with corresponding long-axis views. Images were 
analysed by two experienced PET/CT observers (TC, MRD). Using pre-specified 
criteria, CT scans were adjudicated to be abnormal if there was pannus 
(circumferential low-attenuation [non-calcific] material with radial thickness ≥2 mm 
and encroachment on the valve cusps) (Lancellotti P et al, 2016; Makkar RR et al, 
2015), non-calcific leaflet thickening (focal areas of low attenuation [30-200 
Hounsfield Units] cusp thickening ≥2 mm visualised in at least 2 planes) (Makkar RR 
et al, 2015; Pache G et al, 2016), or leaflet calcification (calcium >500 HU localised 
to valve cusp in at least 2 planes) (Fujita B et al, 2016). Leaflet calcification was further 
sub-divided into spotty calcification if maximum diameter <3 mm and large 
calcification if maximum diameter ≥3 mm (Motoyama S et al, 2007). PET scans were 
adjudicated to be abnormal if increased 18F-fluoride uptake (target-to background ratio 
>1.3) originating in the valve cusps was observed in both en face and long-axis views. 
18F-fluoride uptake originating from the sewing ring or the aortic wall was not 




FIGURE 6.1.  
Methodology for co-registration of positron emission tomography and contrast 




Figure 6.1. Careful alignment of the positron emission tomography (PET) activity in 
the cardiac blood pool with the contrast-enhanced computed tomography (CT) images 
is performed in 3 planes (left). This is possible because of the high 18F-fluoride activity 
in the blood pool compared to the myocardium.  Subsequently PET activity in the 
ascending aorta and aortic arch (center) is aligned with the CT and final refinement of 
co-registration is performed according to landmarks around the bioprosthetic aortic 
valve such as the coronary arteries and mitral valve annulus. Hybrid images are then 
re-orientated to provide en face images of the bioprosthetic valve with corresponding 
perpendicular long-axis images. Finally, the PET windowing is adjusted to the point 
below which blood pool activity in the aorta is visible to assess uptake in the valve 
leaflets.  
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Quantification of 18F-Fluoride Uptake in Bioprosthetic Valve Leaflets 
To quantify 18F-fluoride uptake, a circular (area 1-cm2) region of interest (ROI) was 
drawn around the area of maximal uptake originating in the valve cusps on the 
reorientated co-registered PET-CT images, employing a ‘most diseased segment’ 
(MDS) approach (Pawade TA et al, 2016). Where there was no visible uptake in the 
valve cusps, a 1-cm2 circular ROI was drawn in the center of the valve.  Mean and 
maximum standardised uptake values (SUV) were extracted from these ROIs and 
corrected for blood-pool activity measured in the right atrium (2-cm2 ROIs, axial 
slices, at the level of the right coronary ostium) to calculate the target-to-background 
ratio (TBR) (Pawade TA et al, 2016). Mean TBR values using the MDS approach 
(TBR) were used as the principal comparator in the outcome analysis in keeping with 
data from native aortic valve 18F-fluoride PET studies, although results for all PET 
measurements are presented (Dweck et al, 2014; Pawade TA et al, 2016). The 
TBR>1.3 threshold was pre-selected based upon previous vascular 18F-fluoride studies 
and was supported by the threshold defining the upper tertile of bioprosthetic valve 
18F-fluoride activity observed in this study (Joshi NV et al, 2014).  
 
Micro Positron Emission Tomography and Computed Tomography 
Explanted bioprosthetic valves were incubated with 2 MBq 18F-fluoride for 20 min 
and PET data were acquired over a 30-min bed time using 1:5 coincidence mode.  
Micro CT was then acquired (semi-circular full trajectory, maximum field of view, 
720 projections, 70 kVp, exposure 300 ms and 1:1 binning) for attenuation correction 
and anatomical registration. PET data were reconstructed using Mediso’s iterative 
Tera-Tomo 3D algorithm and the following settings: 4 iterations, 6 subsets, full 
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detector model, normal regularization, spike filter on, voxel size 0.6 mm, 400-600 keV 
energy window. Analysis was performed using PMOD (PMOD Technologies, 
Switzerland) and OsiriX (OsiriX version 8.0.3 64-bit; OsiriX Imaging Software, 
Geneva, Switzerland) to quantify calcium volume and 18F-fluoride activity.  
 
Histopathology 
Explanted bioprosthetic valve specimens were fixed in 10% w/v buffered formalin 
phosphate (Fisher Chemical SF100-20) pending histological analysis. Heavily 
calcified samples were treated with fixative decalcifier to facilitate sectioning (Fisher 
Chemical, Cal-Ex II, CS511-1D). Leaflets were detached from the base of the valve 
frame and marked with tissue dye fixed with acetic acid to maintain orientation. Each 
leaflet was processed then sectioned into 2-4 mm sections and embedded in paraffin 
sequentially to yield 7-8 tissue cross-sections per leaflet. Paraffin sections (4 µm) were 
used for histology. Tissue was sectioned and stained for architecture (hematoxylin and 
eosin), calcium phosphate (von Kossa), thrombus and fibrosis (Movat Pentachrome).  
 
Statistics and Data Analysis 
Baseline characteristics are reported as number (percentages) for categorical variables 
and mean ± standard deviation or median [interquartile range] for continuous variables 
depending on whether variables were normally distributed. Categorical data were 
compared using chi-squared or Fisher’s exact tests. Continuous variables were log-
transformed [logN(x+1) for positive values and -logN(-x+1) for negative values] where 
not normally distributed. The point-biserial correlation coefficient was used to 
measure the strength and direction of the association between one dichotomous 
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variable and one continuous variable. One-way ANOVA was used to compare 
continuous data across multiple factors, with post-hoc analysis using the Bonferonni 
test where appropriate. The Student’s t-test or Mann-Whitney U test were used to 
compare continuous outcomes between two independent groups depending on whether 
they were normally distributed. The Student’s t-test or Wilcoxon signed-rank test were 
employed to compare paired variables. Two-tailed Pearson’s correlation analysis was 
performed to investigate the relationship between 18F-fluoride uptake and 
echocardiographic measures of valve function. Multivariable analysis was performed 
to assess the predictors of deterioration in bioprosthetic valve dysfunction (annualised 
change in peak velocity after 2 years). Statistical analysis was undertaken using IBM 






Explanted Degenerate Bioprosthetic Aortic Valves  
Fifteen failed explanted bioprosthetic aortic valves were obtained for ex vivo 
investigation. Micro-CT detected leaflet calcification in 13 valves, which was 
confirmed on histology. In contrast, all 15 valves demonstrated 18F-fluoride leaflet 
uptake that correlated with a range of histological markers of bioprosthetic tissue 
degeneration. In particular, 18F-fluoride activity detected both micro and macrocalcific 
deposits within the valve leaflets that co-localised predominantly with regions of 
pannus (fibrous thickening) and thrombus on histology. However, 18F-fluoride uptake 
was additionally observed in the absence of calcification on histology at sites of leaflet 
thickening, fluid insudation and disrupted collagen architecture (Figure 6.2).  
 
Clinical Cohort Study Population  
Eighty participants were recruited to the clinical cohort study and underwent in vivo 
PET-CT imaging, although 2 patients were unable to complete the baseline scan 
(claustrophobia) and were excluded (Figure 6.3). The remaining 78 patients were 75 
±7 years old with a high prevalence of coronary artery disease and associated risk 
factors (Table 6.1), and a range of bioprosthetic valve models (Table 6.2 and 6.3).  
  
Patients with Suspected Bioprosthetic Valve Failure 
Seven participants were recruited to the cohort with suspected bioprosthetic valve 
failure. One subject proceeded to repeat surgical aortic valve replacement, 5 underwent 
valve-in-valve transcatheter valve implantation, and 1 subject was deemed to have 
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severe patient-prosthesis mismatch according to guideline criteria and therefore not 
considered to have valve failure (Lancellotti P et al, 2016; Zoghbi WA et al, 2009). 
All 6 subjects with confirmed bioprosthetic valve failure demonstrated abnormalities 
on both CT and 18F-fluoride PET studies. CT revealed evidence of leaflet calcification 
in all patients (spotty calcification n=3, large calcification n=3) and less commonly 
non-calcific leaflet thickening (n=2), circumferential pannus (n=1) and distorted 
leaflet morphology (n=1). Increased 18F-fluoride PET leaflet uptake was observed in 
the bioprosthetic valves of all these patients, and TBR values were nearly 3 times 
higher than in patients without known valvular dysfunction (2.91 [1.75-4.09] versus 
1.12 [1.04-1.51], p<0.001). In the one patient with severe patient-prosthesis mismatch, 




FIGURE 6.2.  
Ex-vivo degenerated bioprosthetic aortic valves: macroscopic appearances, 




Figure 6.2. Row A. Macroscopic appearances of failed and explanted bioprosthetic 
valves. Row B Computed tomography en face images of the valves. Row C Positron 
emission tomography (PET) en face images demonstrating increased 18F-fluoride 
uptake in all valves. Row D. Histology staining of sections taken from valve leaflet as 
indicated, with von Kossa (top row, calcium appears black), Movat Pentachrome 
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(bottom row valves 1 & 4) and haematoxylin & eosin (bottom row valves 2 & 3). All 
4 bioprostheses demonstrate increased 18F-fluoride uptake in the valve leaflets. In 
Valve 1 this uptake corresponds to gross leaflet calcification observed 
macroscopically and on CT images with confirmation on histology (extensive black 
staining). In Valve 2 increased 18F-fluoride uptake is observed in association with 
fibrotic leaflet thickening and pannus (red arrows) with associated calcification (black 
arrows) observed macroscopically and on CT with confirmation on histology. In Valve 
3 increased 18F-fluoride uptake is observed at the site of valve leaflet thrombus (red 
arrow) observed macroscopically at the base of leaflet 1, with confirmation of 
thrombus (red arrow) and co-localised calcification (black arrow) on histology. In 
Valve 4 extensive 18F-fluoride uptake is observed in the absence of calcification on 
CT and histology but instead in areas of leaflet thickening, marked fluid insudation 
and disrupted collagen architecture.  
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FIGURE 6.3.  
CONSORT flow diagram of study recruitment, allocation, follow-up and 
analysis. 
 
Figure 6.3. Flow diagram illustrating prospective study recruitment and allocation to 
pre-defined cross-sectional groups (Cohort 1: patients with suspected bioprosthetic 
valve failure, Cohort 2: patients under clinical review without evidence of valve 
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dysfunction or degeneration grouped by time from valve implantation), follow-up and 









Patients Without Known Bioprosthetic Valve Dysfunction 
In the 71 patients without known bioprosthetic valve dysfunction, surgical aortic valve 
replacement had been conducted 1 month (n=9), 2 years (n=22), 5 years (n=20), and 
>10 years (n=20) previously. The function of these different aged valves was generally 
within normal limits at baseline (peak velocity 2.76±0.52 ms-1, mean gradient 
16.4±7.0 mmHg) (Table 6.1).  
 
Contrast-enhanced CT images were not interpretable in 8 (11%) patients due to motion 
degradation and metallic blooming artefact from the valve struts. Fourteen (19%) 
subjects had 1 or more leaflet abnormalities on CT: spotty calcification (n=5), non-
calcific leaflet thickening (n=5), and pannus (n=7) (Figure 6.4).  
 
PET scans were interpretable in all patients. Increased 18F-fluoride uptake was more 
common than abnormalities on CT and was seen in 24 (34%) patients (TBR 1.55 [1.44-
1.88]; Figure 6.4). Similar to the ex-vivo findings increased 18F-fluoride uptake co-
localised with areas of spotty calcification, non-calcific leaflet thickening (suggestive 
of thrombus) and pannus observed on the CT, but was also observed remote from CT 





FIGURE 6.4.    
In-vivo 18F-fluoride positron emission tomography and computed tomography 
imaging of patients with bioprosthetic aortic valves. 
 
Figure 6.4. Baseline computed tomography (CT, left) and 18F-fluoride positron 
emission tomography (PET, right) images from patients with bioprosthetic aortic 
valves. En face CT images of aortic bioprosthetic valves showing spotty calcification 
and large calcification (top left panel), circumferential pannus (bottom left panel) and 
non-calcific leaflet thickening (top right panel) (all abnormalities identified by red 
arrows). Hybrid en face PET/CT images in the same patients: increased bioprosthetic 
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18F-fluoride activity (red/yellow areas) is observed in each patient co-localizing with 
the CT abnormalities. 18F-fluoride activity was also commonly observed remote from 
leaflet changes on CT (bottom right panel). Target-to-background (TBR) values are 




Prediction of Bioprosthetic Valve Dysfunction  
Sixty-seven of the patients without established valve degeneration at baseline 
underwent repeat echocardiography at 2 years and demonstrated increased peak 
velocities compared to baseline (2.87 [2.52-3.13] versus 2.73 [2.38-3.07] I, p=0.002). 
There was no association between hemodynamic progression and either the type or the 
age of the bioprosthesis (Table 6.4).  
 
The 14 patients with abnormal CT findings appeared to demonstrate deterioration in 
bioprosthetic valve function after 2 years, but there was no statistical difference in 
disease progression compared to patients with a normal CT (change in peak velocity: 
0.25 [-0.06 to 0.57] versus 0.10 [-0.04 to 0.31] I, p=0.232).  
 
By contrast the 24 patients with increased 18F-fluoride uptake at baseline demonstrated 
clear evidence of deteriorating bioprosthesis function after 2 years, whilst patients 
without uptake displayed no change in valve function (change in peak velocity: 0.30 
[0.13 to 0.61] versus 0.01 [-0.05 to 0.16] I/year, p<0.001). Similarly, patients in the 
highest tertile of 18F-fluoride uptake demonstrated greater disease progression than 
patients in the lower 2 tertiles (annualised change in valve peak velocity; tertile 1: 0.14 
[0.05 to 0.30] versus tertiles 2 and 3: 0.01 [-0.02 to 0.10] I/year, p=0.006; Figure 6.5). 
The 4 patients with new or worsening prosthetic valve regurgitation during follow-up 
were amongst those in tertile 1. Moreover, bbaseline 18F-fluoride uptake correlated 
strongly with echocardiographic measures of hemodynamic progression regardless of 





FIGURE 6.5.  
Tertile analysis according to 18F-fluoride PET uptake demonstrating tissue-to-
background (TBR) values across the tertiles and relationship with change in 
valve function during follow-up. 
 
Figure 6.5. A. Box-plot illustrating the spread of 18F-fluoride tissue-to-background 
(TBR) values when grouped into tertiles. Dashed red line represents TBR 1.3 which 
was the cut off for the top tertile and also the threshold for discriminating increased 
uptake. B. Box-plot demonstrating haemodynamic progression (measured by the 
change in peak valve velocity between baseline and 2-year follow-up) when patients 
were grouped by tertile according to 18F-fluoride TBR values. Patients in tertile 1 
(TBR >1.3) exhibited more rapid haemodynamic progression than those in the lower 
tertiles. The 4 patients with new or worsening prosthetic valve regurgitation during 
follow-up were also all amongst those in tertile 1. 
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Based upon international guideline criteria, 10 patients developed new bioprosthetic 
valve dysfunction during follow-up 2 with valve regurgitation, 6 with valve stenosis 
and 2 with mixed dysfunction (Lancellotti P et al, 2016; Zoghbi WA et al, 2009). 
Median time from valve implantation to their assessment in the study was 7.5 [5-10] 
years. Of these patients, 5 had an abnormal baseline CT while all 10 patients had 
increased 18F-fluoride uptake (TBR 1.89 [1.46-2.59]) and this included the 7 patients 
with the highest TBR values in the cohort. Two proceeded to urgent valve re-
intervention and another died of valve failure. Using the alternative criteria suggested 
by the recent international consensus statement (Dvir D et al, 2018), 16 patients met 
the definition of structural valve degeneration, 15 of whom demonstrated increased 
18F-fluoride uptake (TBR 1.54 [1.38-1.96] versus 1.08 [1.02-1.19], p<0.001). Seven 
patients fulfilled criteria for stage 2 or 3 structural valve degeneration, signifying the 
development of valve dysfunction, and they all exhibited increased baseline 18F-
fluoride uptake (TBR 1.89 [1.47-3.15]; Figure 6.6). Moreover 18F-fluoride activity 
increased in a step-wise fashion across these progressive stages of structural 
degeneration (TBR; no degeneration: 1.08 [1.02-1.19], stage 1: 1.48 [1.34-1.64], stage 
2: 1.72 [1.42-1.94], stage 3: 4.23 [3.15-5.36], post-hoc linear trend: p<0.001; Figure 
6.6). Two patients developed overt bioprosthetic valve failure during 2-year follow-up 
and a further 2 patients developed valve failure on subsequent follow-up, all 
demonstrating high intensity 18F-fluoride uptake (TBR 2.57 [1.96-3.70]) (Figure 6.7) 
(Capodanno D et al, 2017).  
 
On univariable analysis, the only predictors of deterioration in bioprosthetic valve 
function (annualised change in bioprosthetic valve peak velocity) were current 
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smoking habit (p=0.047) and 18F-fluoride PET uptake, irrespective of whether the 
latter was considered as a categorical or continuous variable (both p<0.001) (Table 4). 
On multivariable analysis incorporating age, sex, duration of valve implantation, 
baseline peak prosthetic valve velocity and CT findings, 18F-fluoride uptake emerged 
as the only predictor of deterioration in bioprosthetic valve function (unstandardised 
coefficient 0.79 (95% CI 0.62-0.96), p<0.001; Figure 6.6 and Table 6.5).  
 
Irrespective of the definition used, similar results were observed when the 
development of bioprosthetic valve dysfunction was considered as a categorical, with 
baseline 18F-fluoride uptake emerging each time as an independent predictor on 
multivariable analyses (international guideline criteria: unstandardised coefficient 
7.57 [standard error 2.66], p=0.004; expert consensus statement: unstandardised 
coefficient 6.81 [standard error 2.92], p=0.02; Table 6.6A and 6.6B) (Lancellotti P et 
al, 2016; Zoghbi WA et al, 2009; Dvir D et al, 2018). Summary of effective radiation 




FIGURE 6.6.  
Baseline 18F-fluoride positron emission tomography uptake predicts subsequent 
deterioration in bioprosthetic valve function after 2 years.  
 
 
Figure 6.6. A. A strong correlation was observed between baseline 18F-fluoride uptake 
in the bioprosthetic valves (target-to-background ratio; TBR) and subsequent 
progression in prosthetic valve peak velocity (log transformation applied; r=0.72, 
p<0.001). Red dots signify patients who developed new prosthetic valve regurgitation 
during follow up. B. 18F-Fluoride uptake (perforated red line represents threshold for 
increased 18F-fluoride uptake; TBR 1.3) in patients with different stages of structural 
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valve degeneration (normal: no structural or functional valve changes; stage 1 
structural degeneration with morphological abnormalities but no changes in 
haemodynamic function; stage 2 deterioration in valve function; stage 3 rapid 
deterioration in valve function19) demonstrating incrementally higher uptake values 
with increasing severity of structural valve degeneration.  
C & D. Forest plots of unstandardised coefficients (95% confidence intervals) from a 
multivariable linear regression analysis predicting change in bioprosthetic valve 
function (annualised change in peak velocity) during follow-up. When examining all 
relevant baseline characteristics, 18F-Fluoride uptake was the only independent 
predictor of haemodynamic deterioration in valve function when used both as a 




FIGURE 6.7.  
Case illustrations: baseline 18F-fluoride positron emission tomography and 
computed tomography predict imminent failure of bioprosthetic function. 
 
Figure 6.7. Cases 1-4 illustrate the utility of 18F-fluoride positron emission 
tomography (PET) and computed tomography (CT) in the prediction of deteriorating 
valve performance. None of the patients had known bioprosthetic degeneration at 
baseline. En face contrast-enhanced CT images (top row) demonstrate non-calcific 
leaflet thickening in case 1, but no clear structural CT changes in the remaining cases. 
Hybrid 18F-fluoride PET-CT images (middle row) demonstrate high intensity 18F-
fluoride activity in all the valves (TBR values in white italics). Doppler 
echocardiographic assessments of bioprosthetic valve function after follow-up 
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(bottom row). In each case new valve dysfunction has developed with progression to 
severe obstruction in cases 1, 2 & 3 and new moderate/severe eccentric regurgitation 
in case 4 (pressure half time 316 ms with holodiastolic flow reversal in aorta). Patient 
1 died from valve related heart failure, patient 2 required redo-surgical valve 








6.5 DISCUSSION  
 
In this multi-modality prospective imaging study, we have identified 18F-fluoride PET-
CT as the first non-invasive technique capable of detecting early bioprosthetic valve 
degeneration and predicting future valve dysfunction.  We provide extensive 
validation of the technique against state-of-the-art ex vivo imaging and histology. This 
consistently demonstrated increased 18F-fluoride uptake in each of the failed 
bioprosthetic aortic valves examined, with PET activity co-localising to areas of 
calcification, pannus, thrombus and disrupted tissue architecture on histology. When 
applied to patients in the clinical setting, 18F-fluoride PET identified early valve 
degeneration beyond the resolution of conventional assessments and predicted the 
development of new valvular dysfunction and overt valve failure within the 2-year 
follow-up period. Indeed, 18F-fluoride uptake was an independent predictor of 
deteriorating bioprosthetic valve performance, outperforming all other variables 
including valve type and age, echocardiographic and CT findings. 18F-Fluoride PET-
CT therefore provides a readily applicable measure of valve degeneration with the 
potential to transform how we monitor and treat the expanding population of patients 
living with bioprosthetic valves.  
 
Our study has several major strengths. This is a comprehensive multimodal imaging 
study using ultrasound, CT and PET in patients with bioprosthetic aortic valves of 
varying implant ages. Uniquely, we have been able to correlate imaging findings with 
state-of-the-art ex vivo imaging and histological characterization of explanted valves, 
enabling us to validate our imaging technique and provide novel insights into the 
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pathogenesis of bioprosthetic valve degeneration. Moreover, our systematic 
prospective study design has allowed us to confirm the utility of baseline 18F-fluoride 
PET in identifying patients at risk of developing future bioprosthetic dysfunction and 
overt valve failure.  
 
A Clinical Challenge 
Whilst bioprosthetic valves offer important advantages over mechanical valves, they 
have only limited durability (Forountan F et al, 2016; Bloomfield P et al, 1991). 
Indeed, bioprosthetic valve degeneration has become a major clinical issue with the 
growing rate of bioprosthetic valve implantation and improved long-term patient 
survival. Although international guidelines recommend serial echocardiography for 
the detection of bioprosthetic degeneration, visualization of the valve is often poor due 
to acoustic artefacts from the prosthesis, limiting its sensitivity (Lancellotti P et al, 
2016; Zoghbi WA et al, 2009). This means that valve degeneration is frequently well 
advanced before clinically overt valve dysfunction is apparent. Moreover, valve 
obstruction often evolves rapidly, whilst the catastrophic development of valvular 
regurgitation due to leaflet tears is frequently unheralded and unpredictable. Novel 
techniques capable of detecting the earlier stages of valve degeneration and allowing 
personalised and better planned management strategies for patients with bioprosthetic 
valves are therefore highly desirable.  
 
Insights into the Mechanism of Bioprosthetic Valve Degeneration 
We and others have used 18F-fluoride PET to assess cardiovascular calcification 
activity and tissue degeneration in a range of conditions including coronary heart 
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disease, stroke, abdominal aortic aneurysms and aortic stenosis (Dweck MR et al, 2012 
A; Forsythe RO et al, 2018; Joshi NV et al, 2014; Vesey AT et al, 2017). We now 
extend these observations to bioprosthetic valves and confirm that 18F-fluoride 
localises to regions of developing leaflet calcification on histology and high-resolution 
micro-PET-CT imaging. Calcification is believed to be the final common response to 
bioprosthetic valve injury and a major driver towards valve dysfunction, causing both 
progressive cusp stiffness and obstruction as well as leaflet fragility and tears. In this 
study, all bioprosthetic valves with established degeneration and valve failure 
demonstrated increased 18F-fluoride uptake. Moreover, in both our ex vivo and in vivo 
studies, we observed a close spatial interaction of calcification with both leaflet 
thrombosis and pannus, suggesting these may be potential upstream triggers. In 
contrast, a minority of bioprosthetic valves appear to degenerate without any 
histological evidence of calcification. In these cases, the remarkable histological 
features were gross leaflet thickening, fluid insudation and disruption of normal 
collagen architecture. Interestingly, these valves also exhibited high levels of 18F-
fluoride uptake. We hypothesise that upregulation of matrix metalloproteinases may 
be implicated in the degradation of bioprosthetic leaflet tissue and that these proteins 
have the potential to bind 18F-fluoride (Simionescu A et al, 1996 A; Kato MT et al, 
2014). Further investigation of the mechanism of uptake is required.  
 
Recent reports have described focal non-calcific leaflet thickening as a marker of 
thrombus formation (Makkar RR et al, 2015; Chakravarty T et al, 2017). Whilst these 
areas can cause acute valve obstruction, more commonly they do not result in any 
immediate hemodynamic disturbance, leading some to question their clinical 
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relevance. In our study, we also observed low-attenuation non-calcific leaflet 
thickening on CT suggestive of non-obstructive thrombus, that was associated with 
both increased 18F-fluoride activity and delayed deterioration in valve performance 
over the following 2 years. Similar findings were observed in explanted valves where 
areas of thrombus co-localised with calcium on Von Kossa staining and exhibited 
increased 18F-fluoride PET activity. This raises the hypothesis that bioprosthetic valve 
thrombosis may act as one potential trigger to valve degeneration that might be 
prevented with prompt detection and anticoagulation. Interestingly, recent 
observational data have suggested that bioprosthetic durability may be enhanced by 
concomitant anticoagulation therapy (Del Trigo M et al, 2018).  
 
Clinical Implications 
Our findings have several major implications for clinical practice. Firstly, in addition 
to micro and macrocalcification, 18F-fluoride PET-CT can identify a range of 
degenerative processes including fibrosis, thrombosis and leaflet degradation with 
disrupted collagen architecture and fluid insudation. This has provided important 
insights into the pathogenesis of bioprosthetic valve failure and highlights potential 
targets for novel therapies aimed at improving valve durability. Secondly, 18F-fluoride 
PET can detect and quantify the early stages of valvular degeneration and identify 
patients otherwise thought to have normal valves but who are in fact at high-risk of 
subsequent valve failure. Given the high mortality associated with emergency repeat 
valve replacement (Vogt PR et al, 2000), these patients are likely to benefit from both 
close tailored surveillance and early elective intervention before the onset of abrupt 
valve failure. Conversely patients without PET uptake, who here demonstrated very 
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stable valve function during follow-up, could undergo less intensive surveillance. Our 
data suggests that 5 years post-implantation may be an appropriate stage at which to 
offer a PET-CT and guide follow-up, with further studies needed. Third, 18F-fluoride 
PET-CT appears of value in determining the presence of valvular degeneration in cases 
where the diagnosis and clinical management is uncertain, for example in patients with 
suspected patient-prosthesis mismatch. Finally, 18F-fluoride PET-CT provides a 
readily applicable measure of valve durability that may prove useful in assessing novel 
prosthetic designs such as transcatheter valves before these are extended into younger 
and healthier patient populations.  
 
Limitations 
It was initially envisaged that serial CT calcium scoring of bioprosthetic aortic valves 
would also provide a marker of valve degeneration. However, in our hands we 
observed major artefact related to motion and the stent struts that precluded detailed 
analysis of CT calcium scores. Leaflet pathology was instead more successfully 
identified by contrast-enhanced CT, where superior anatomical detail allowed 
differentiation between pannus ingrowth, thrombosis or calcification, although a 
minority of scans still could not be accurately adjudicated.  Alongside the robust 
information provided by 18F-fluoride PET this is an important advantage of the hybrid 
PET/CT technique.   
 
Although our study population is relatively large compared to other cardiovascular 
PET studies, external validation in a larger study population with longer follow-up 
would be welcome. Future studies may wish to investigate 18F-fluoride activity in 
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novel bioprostheses, in particular aortic and mitral transcatheter valves, as well as 
assessing whether the bioprosthetic 18F-fluoride signal is modifiable with adjuvant 
therapies, such as anticoagulation in patients with associated thrombus or drugs that 
modify calcium metabolism (e.g. bisphosphonates, denosumab).  
 
Conclusions 
In conclusion, 18F-fluoride PET-CT detects early bioprosthetic valve degeneration, 
providing powerful prediction of subsequent deterioration in valve performance and 
highlighting patients at imminent risk of valve failure. This novel imaging approach 
has the potential to transform our understanding of bioprosthetic valve failure and the 







CONCLUSIONS AND FUTURE DIRECTIONS 
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7.1 SUMMARY OF FINDINGS  
 
Prior to manifesting at an advanced stage, valvular heart disease has often been 
asymptomatic and undetected over a prolonged period. The early pathophysiological 
processes are not well understood and, accordingly, we lack effective therapies to 
reduce or reverse disease progression until surgery or transcatheter intervention is 
indicated for symptomatic severe valve disease.  The chronicity of degenerative valve 
disease, with slow subclinical progression over many years, poses a significant 
challenge for the detection and understanding of early disease (when treatment targets 
may be most readily modified), and for ascertaining the short and longterm treatment 
effects of medical therapies. Clinical trials of novel therapies therefore require large 
numbers of patients subject to prolonged follow-up at considerable expense.  
 
CT and PET respectively offer high resolution anatomical detail and real-time 
quantification of biological processes in vivo. There has consequently been growing 
interest in these modalities for the assessment of cardiovascular disease. In this thesis, 
we investigate novel approaches to cardiac CT and PET to illuminate our 
understanding of disease mechanisms and improve diagnostic accuracy in both native 
aortic valve stenosis and bioprosthetic valve degeneration. We also propose hybrid 
18F-fluoride PET/CT as a method of assessing disease activity in both of these 
conditions, that may provide an early marker of therapeutic response in future studies.  
 
Our comprehensive multimodality imaging approach combined echocardiography, 
cardiac CT and PET, and results were validated with ex vivo imaging and 
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histopathology. From our investigations, we conclude that contrast-enhanced CT 
angiography can be used to quantify non-calcific leaflet thickening as a surrogate of 
fibrosis in aortic stenosis, that fibrosis is an important pathological feature, and that 
the combined fibrocalcific burden holds promise as a tool to improve diagnostic 
accuracy (chapter 3). Furthermore, we demonstrate that 18F-fluoride PET/CT is an 
accurate and reproducible technique for the quantification and localisation of 
calcification activity in aortic stenosis (chapter 4). Finally, we use ex vivo 18F-fluoride 
PET/CT and histology to elucidate the importance of calcification as a common final 
pathway in bioprosthetic valve degeneration (chapter 5), then show that 18F-fluoride 
PET/CT can be used in patients with bioprosthetic aortic valves to detect early valve 
degeneration, predict the development of valve dysfunction and identify those at risk 








7.2 CT angiography detects calcification and fibrosis of the aortic 
valve and provide insights into the contribution of fibrosis and 
calcification in the pathogenesis of aortic stenosis.  
 
International guidelines recommend non-contrast CT calcium scoring of the aortic 
valve (CT-AVC) as an additional method of assessing aortic stenosis severity when 
echocardiographic measurements are discordant (Baumgartner H et al, 2015). 
However, CT-AVC offers limited detail about valve morphology and the anatomical 
distribution of calcium in the valve and surrounding structures. Moreover, it 
demonstrates only moderate associations with hemodynamic severity by 
echocardiography and women consistently demonstrate lower calcium burden for a 
given degree of valvular stenosis. CT-AVC is unable to account for valve fibrosis, an 
important contributor to valve stenosis, and may therefore misclassify disease severity, 
particularly in young women and those with bicuspid aortic valves (Shen M et al, 
2016; Simard L et al, 2016).  
 
In this thesis, we developed a novel approach to CT angiography that allows 
assessment of both valve calcification and non-calcific leaflet thickening (a surrogate 
for valve fibrosis) in patients with aortic stenosis. In total, 143 volunteers with varying 
degrees of aortic stenosis underwent echocardiography, CT-AVC and CT angiography 
as part of a randomised controlled trial. CT angiography was able to quantify valve 
non-calcific and calcific leaflet volumes with excellent inter-observer reproducibility, 
and we demonstrated that non-calcific leaflet volumes in the aortic stenosis cohort 
were more than double those in a sex-matched control group. Our innovative technique 
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provided unique insights into the pathophysiology of aortic stenosis, with fibrosis 
appearing to predominate in women and patients with mild stenosis, whilst 
calcification dominated in men and those with severe stenosis. Moreover, we proposed 
a novel anatomical measure of aortic stenosis severity, the fibro-calcific burden, that 
incorporated both fibrotic and calcific valve thickening. This summary measure 
demonstrated excellent agreement with echocardiographic assessments of 
hemodynamic disease severity and ex vivo valve weight that were superior to CT-AVC 
alone. We were able to reproduce similar findings in an independent external cohort 
and were also able to validate imaging markers of valve fibrosis with tissue histology 
from explanted valves.   
 
By way of limitations, the technique was relatively time consuming and became less 
accurate at the upper and lower extremes of blood pool contrast attenuation. 
Furthermore, the limited proportion of women (~20%) in the study population 
necessitates that further investigation be performed in a larger cohort.  
 
In conclusion, CT angiography allowed robust and reproducible quantification of both 
valve leaflet fibrosis and calcification in patients with aortic stenosis. Our observations 
indicate that the factors driving aortic stenosis progression both evolve with time and 
are different in men and women. Moreover, the fibro-calcific burden provides a novel 
assessment of aortic stenosis severity potentially offering closer agreement with 
echocardiographic assessments than CT-AVC. Further work is now required to 
validate the fibro-calcific burden, and to establish both diagnostic thresholds for 
severity and its prognostic value. CT angiography is already widely performed in many 
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centres and may, in future, provide a valuable tool to confirm aortic stenosis severity 




7.3 18F-Fluoride PET/CT can be established as an accurate and 
reproducible technique to assess disease activity in aortic stenosis.  
 
In this thesis, we continued our investigation of non-invasive imaging methods in the 
assessment of native aortic valve stenosis.  18F-Fluoride binds preferentially to regions 
of newly developing microcalcification, and 18F-fluoride PET/CT has been shown to 
measure disease activity and predict progression in aortic stenosis (Jenkins WSA et al, 
2015). Here we studied the acquisition and analysis of 18F-fluoride PET/CT.  
 
A total of 15 volunteers with varying degrees of aortic stenosis underwent CT aortic 
valve calcium scoring, CT angiography and 18F-fluoride PET on two separate 
occasions, no more than 3 months apart. Prior investigations of PET/CT had been 
performed using non-contrast CT and PET without ECG gating. We first improved the 
spatial localisation of tracer uptake by using contrast-enhanced CT imaging and ECG-
gated PET data, such that activity could be localised to regions within individual 
leaflets. This demonstrated that calcification activity is most commonly observed at 
sites of high mechanical stress, for example, at the valve commissures and regions of 
leaflet coaptation.  
 
Second, we improved the scan-rescan reproducibility of aortic valve 18F-fluoride 
PET/CT, achieving excellent agreement statistics for measurement of the TBRMDSmean. 
This was accomplished by sampling and correcting for background blood pool activity 
in the right atrium, rather than the brachiocephalic vein as had been done in previous 
investigations, where measurements were less susceptible to error from partial 
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voluming effect and inaccuracies in PET/CT co-registration. Another improvement 
was achieved by using the most diseased segment (MDS) approach: measuring activity 
in the two adjacent slices with the highest uptake, rather than quantifying uptake in the 
whole valve. The key advantage of this was to remove the challenge of determining 
the boundaries of the valve. The resulting improved reproducibility (<±10%) makes 
18F-fluoride a potentially attractive biomarker of efficacy in future clinical trials, 
requiring relatively few patients to demonstrate reductions in valvular calcification 
activity. Inter-observer reproducibility was also excellent using the modified 
approach.  
 
In conclusion, we optimised 18F-fluoride PET/CT imaging of the aortic valve to offer 
accurate spatial resolution, excellent scan-rescan and inter-observer reproducibility. 
18F-Fluoride PET/CT holds promise as a method to better understand calcification 
activity in aortic stenosis and as a surrogate endpoint to assess efficacy of novel 




7.4 Assessment of degenerated bioprosthetic valves with micro-18F-
fluoride PET/CT and correlating histology will provide novel insight 
about the mechanisms of bioprosthetic valve degeneration.  
 
Degeneration of bioprosthetic valves is an increasingly relevant clinical problem as a 
result of the increasing incidence of aortic stenosis in our ageing population, expansion 
in the availability of transcatheter valve implantation, and the increased life 
expectancy of people with prosthetic valves. Despite advances in valve production, 
bioprosthetic valves have limited durability and calcification is one of the dominant 
features of valve failure. Nonetheless, the pathogenesis of bioprosthetic valve 
degeneration is complex and incompletely understood.  
 
In this thesis, we investigated the pathogenesis of bioprosthetic valve degeneration in 
a series of 16 explanted degenerated bioprosthetic valves. We documented 
morphological findings, performed micro-18F-fluoride PET/CT and tissue histology.  
 
Calcification was a central feature of degenerated valves (found in 88%) and was best 
appreciated by CT. The spatial distribution of calcium showed a predilection for leaflet 
commissures and free margins, regions recognised to be affected by high mechanical 
stress. Histology revealed a pattern of intrinsic calcium deposition in the deep layers 
of the cusp, propagating outwards and ultimately penetrating the surface. Pannus was 
another prevalent feature, universally present over the sewing ring and extending onto 
the valve cusps in 47%. Severe pannus was likely to be the cause of valve failure in 2 




pannus overgrowth may be a substrate for calcification. Other features detected on 
histology included organised thrombus (in 40%) and markers of tissue degradation 
such as loss of collagen structure, fluid insudation and expansion of the proteoglycan 
layer.  
 
We validated 18F-fluoride as a marker of calcium phosphate deposition in bioprosthetic 
valve tissue by correlating autoradiography and histological staining. We then used 
18F-fluoride PET/CT to demonstrate significant 18F-fluoride binding in all the 
explanted valves. The highest 18F-fluoride signal colocalised with regions of 
calcification and there was a positive correlation between calcium volume quantified 
by CT and 18F-fluoride activity measured by PET. 18F-Fluoride signal also correlated 
with histological evidence of fibrosis, thrombus and features of tissue degradation such 
as disruption of collagen architecture.  
 
In conclusion, we confirmed that calcification is a central finding in degenerated 
bioprosthetic valves, whilst fibrosis (pannus), thrombus and degradation of structural 
components are other common features. We discovered that 18F-fluoride localises to 
regions of calcification on histology but also to a lesser extent these other features of 
degeneration, suggesting these may be upstream triggers. This substantiates the theory 
of leaflet calcification as the final common response to various mechanisms of 







7.5 18F-Fluoride PET/CT can be applied to the assessment of 
bioprosthetic aortic valves to detect and predict structural valve 
degeneration. 
 
Although international guidelines recommend serial echocardiography for the 
detection of bioprosthetic degeneration,(16,17) visualisation of the valve is often poor 
due to acoustic artefacts from the prosthesis, limiting its sensitivity. This means that 
valve degeneration is frequently well advanced before it is clinically apparent. 
Moreover, valve obstruction often evolves rapidly, whilst valvular regurgitation due 
to leaflet tears is frequently unheralded and catastrophic. Novel techniques capable of 
detecting the earlier stages of valve degeneration are therefore highly desirable.  
 
Having established the utility of pre-clinical 18F-fluoride PET/CT in the investigation 
of bioprosthetic valve degeneration ex vivo, we went on to perform the first prospective 
observational cohort study of 18F-fluoride PET/CT in patients with bioprosthetic aortic 
valves. A total of 80 volunteers were recruited into two cohorts, with and without 
prosthetic valve dysfunction, and underwent contrast-enhanced CT angiography, 18F-
fluoride PET, and serial echocardiography during 2 years of follow-up.  
 
In patients with echocardiographic evidence of severe prosthetic valve dysfunction, all 
exhibited abnormalities on CT (e.g. calcification, hypoattenuation leaflet thickening) 
and very high uptake of 18F-fluoride. In patients without echocardiographic evidence 
of prosthetic valve dysfunction, 20% had abnormal leaflet pathology on CT and 34% 




demonstrated more rapid deterioration in valve function compared to those without. 
Indeed 18F-fluoride uptake correlated with deterioration in all echocardiographic 
measures of valve function. Each of the 10 patients who developed new bioprosthesis 
dysfunction during follow-up had evidence of increased 18F-fluoride uptake at 
baseline. On multivariable analysis, 18F-fluoride uptake was the only independent 
predictor of future bioprosthetic dysfunction.  
 
In other important findings, we investigated aortic valve calcium scoring as a method 
with which to monitor disease progression in bioprosthetic valve degeneration. 
However, we observed significant artefact related to motion and the dense materials 
present in prosthetic valves which precluded reliable analysis. Alternatively, a very 
small minority of contrast-enhanced CT scans were of suboptimal quality such that 
they could not be accurately adjudicated and, in combination with reliable data from 
18F-fluoride PET, this was an advantage of hybrid PET/CT.  
 
In conclusion, 18F-Fluoride PET-CT identified subclinical bioprosthetic valve 
degeneration beyond the capability of conventional assessments, provided powerful 
prediction of subsequent valve dysfunction and highlighted patients at risk of 
imminent valve failure. Although further investigation is required, this novel imaging 
approach has the potential to transform our understanding of bioprosthetic valve 





7.6 FUTURE DIRECTIONS 
 
The work in this thesis presents a number of opportunities for further investigations to 
reinforce and develop the role of cardiac PET/CT in the assessment of native and 
bioprosthetic valve disease.  
 
A combined assessment of fibrosis and calcification may offer incremental diagnostic 
benefit over established imaging modalities in aortic stenosis. However, further work 
is now required to validate the fibro-calcific burden in a larger patient population, to 
establish its prognostic value and to provide robust thresholds that can be used in 
clinical practice to identify patients with severe and non-severe aortic stenosis. In 
addition, the image analysis method used in our study is time consuming and 
fragmented across several different software tools. Work is therefore underway to 
refine the image analysis with a bespoke integrated software solution that can facilitate 
more rapid processing whilst maintaining accuracy and reproducibility. This will 
accelerate potential uptake in the clinical setting.  
 
The study population that contributed the data used in chapters 3 and 4 was part of a 
randomised controlled trial of anti-calcific therapies, alendronate and denosumab, in 
the treatment of aortic stenosis (SALTIRE 2, NCT02132026) that is due to report in 
the near future. On the basis of our investigations in chapter 4 establishing the accuracy 
and reproducibility of aortic valve 18F-fluoride PET/CT, 18F-fluoride uptake has been 
incorporated as a surrogate endpoint of therapeutic effectiveness in this trial. This will 





In chapter 4, it was noted that ECG-gating of PET data had a detrimental effect on the 
reproducibility of maximum measures of 18F-fluoride uptake. The future development 
of advanced image processing that corrects for both cardiac and respiratory motion 
without discarding PET data may improve the reproducibility of maximum uptake 
measurements, which may then be more sensitive to change than mean measurements 
and better able to detect the effects of disease modifying therapies.  
 
Projects are underway to expand the investigation of PET/CT in bioprosthetic valve 
disease, as described in chapters 5 and 6. This work includes a planned extension of 
the cohort study undertaken in chapter 6 which will allow comparison of imaging 
findings and clinical outcomes in patients who have received transcatheter aortic valve 
replacement with patients who have received surgically implanted bioprosthetic 
valves. Although the population in our clinical cohort study in chapter 6 is relatively 
large compared to other cardiovascular PET studies, external validation in a larger 
study population with longer follow-up would also be welcome. Thereafter, it would 
be interesting to explore whether the 8F-fluoride signal in bioprosthetic valves is 
modifiable with developments in valve technology designed to reduce potential for 
calcification, or with the use of anti-calcific or anticoagulant therapies. Finally, our 
observations on the prevalence and possible causative role of subclinical leaflet 
thrombosis in bioprosthetic valve degeneration have prompted the recent 
commencement of an observational study of novel thrombus PET tracer 18F-GP1, 
which binds to glycoprotein IIb/IIIa receptors on activated platelets, in patients with 




evolve into a tool for improved detection of valve thrombosis and for evaluating the 








The investigations described in this thesis support the exciting future role of non-
invasive cardiovascular imaging, with potential to illuminate our understanding of 
disease processes and to improve the care we deliver to patients. In the setting of 
valvular heart disease, clinicians are almost entirely reliant upon non-invasive methods 
of assessment. The novel imaging techniques we describe might add significantly to 
current practice by combining anatomical and functional information to promote more 
individually tailored approaches to clinical care. In particular, functional molecular 
imaging offers great promise as an early indicator of disease-modifying intervention 
and there is abundant potential for development of new PET tracers. Here we have 
established a robust methodology with which 18F-fluoride PET/CT can now be 
employed as a biomarker of aortic stenosis in large clinical trials and demonstrated a 
role in the assessment of bioprosthetic valves, to which it is perhaps uniquely well 
suited. Further work is now required to ensure that these advances ultimately translate 
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THE 18F-FAABULOUS STUDY 
 
18F-FLUORIDE ASSESSMENT OF AORTIC BIOPROSTHESES 
DURABILITY AND OUTCOMES 
 
You are being invited to take part in a research study. Before you decide whether or 
not to participate, it is important that you understand why the research is being done 
and what it will involve. Please read the following information carefully and discuss it 
with others if you wish.  
 
If there is anything that is not clear or if there are questions you would like to ask then 
please contact us for further information. Alternatively, you can also contact Dr 
Cruden, who is not directly involved in this study but who can give you independent 
advice. He can be contacted via the Royal Infirmary of Edinburgh switchboard on 
0131 536 1000 by asking for his secretary. 
 
What is the purpose of the study? 
Narrowing of the main outlet valve of the heart (aortic stenosis) is the most common 
form of heart valve disease in the western world and replacing this valve is the most 
frequently performed heart valve operation. The majority of replacement valves are 
made from animal tissue with the benefit that, unlike metal valves, they do not require 
blood-thinning treatment afterwards. Recently, procedures have developed to replace 
the aortic valve using a key-hole technique, thereby avoiding the need for open heart 
surgery. However, whilst we know that traditional surgical tissue valves last on 
average between 10 and 15 years we do not know how long the new key-hole valves 
will endure. 
 
The main purpose of this study is therefore to use a special type of scan called “PET-
CT” to investigate what happens to these tissue valves (both surgical and key-hole). 
This scan can measure the activity of “calcification” which causes hardening and 
chalkiness of the valve and is the main way in which such valves fail. We believe that 
these scans will predict how long the different types of replacement valve are likely to 
last and potentially to predict when, and in whom, they will need replaced.  
 
Why have I been invited? 
You have been invited to take part in this research because you previously had a 
tissue heart valve replacement and are being considered for a repeat valve 
replacement operation. 
 
Do I have to take part? 
No. It is entirely up to you to decide whether or not to take part. If you do decide to 
take part, you are still free to withdraw at any time without having to give a reason. A 
decision not to take part or to withdraw at a later stage will not affect the standard of 





What will happen to me if I take part? 
You have been provided with this information sheet and will be given at least 24 hours 
to read it over before being contacted by a member of the research team. They will 
give you an opportunity to ask any questions that you might have and ask if you wish 
to participate in the study. If you agree to take part, we will arrange a date close to 
your operation for you to attend the Clinical Research Facility at the Royal Infirmary 
of Edinburgh.  
 
At this visit, we will again discuss the study to ensure that you understand eveything 
and will ask for your written consent.  As part of a general assessment, we will ask 
about your symptoms, undertake a full examination of your heart, record an electrical 
tracing of your heart and take some blood tests (~60ml = 4 tablespoons of blood will 
be taken). This volume of blood will allow for a range of immediate tests to be 
performed and also provide samples for storage which will be valuable in future 
research studies.  
 
We will then arrange for you to have a PET-CT scan of the heart, to take place during 
the same visit wherever possible. The PET-CT scan provides detailed images of the 
heart and will require injection of a special tracer about 60 minutes before the scan 
via a plastic tube (cannula) in one of your veins. This special tracer called 
radiolabelled 18F-fluoride is radioactive and highlights areas of active calcium 
formation in the heart. It has been used in humans for 40 years with no major harmful 
effects. Prior to the scan you may also require a medicine called metoprolol or 
verapamil in order to slow your heart rate. Slowing your heart rate will improve the 
quality of images obtained and minimise the dose of radiation which is required for 
the scan. This will be prescribed by an experienced doctor after considering your 
personal medical history and any possible interactions with medications which you 
already take. This medication may need to be taken as a tablet for several days prior 
to the scan and as an injection through the cannula at the time of the scan. During the 
PET-CT there will be a further injection of an iodine-based contrast “dye” via the 
cannula in your arm in order to obtain more detailed information from the images. 
 
The process of taking consent is likely to take 30 minutes, the clinical assessment will 
take 30 minutes and the PET-CT will take 90 minutes, starting with injection of the 
tracer 60 minutes prior to the scan. We therefore estimate that your initial visit to 
hospital will take around 2 hours 30 mins. 
 
The second stage of your involvement in the study will be at the time of your operation. 
The surgeon will remove your existing replacement heart valve before implanting a 
new replacement valve. The existing heart valve is normally thrown away but we will 
keep it and perform detailed analysis on it. This will not affect your operation in any 
way. 
 
What happens to the blood and tissue samples that are taken? 
Some blood and tissue samples will be taken for immediate tests and other samples 
will be retained in an anonymised fashion to be frozen and stored so that further tests 
may be performed in the future. We will store these samples for a maximum of 10 
years after which time they will be destroyed in accordance with standard NHS 
Lothian procedure. 
 




You will be contributing to our understanding of the disease process that affects aortic 
valve replacements.  The information that we gather will help us to evaluate which 
valve replacement options are most effective and particularly to compare the durability 
of new techniques with traditional approaches. This study is the first of its kind to use 
such imaging technology and, depending on the results obtained, this technology may 
become a valuable tool for identifying patients at risk of needing further treatment and 
for testing new treatments. 
 
 
What are the possible disadvantages and risks of taking part? 
A PET-CT scan is a routine medical procedure and is itself associated with very few 
side effects. The most important side effects are exposure to ionising radiation and 
potential reaction to the contrast dye.  We have a well-developed protocol for PET-
CT imaging that minimises radiation exposure and have clear procedures for 
managing contrast reactions.  
 
The exact amount of radiation used during this type of scan varies but is 
approximately 7 times the amount that you would normally receive in a year from 
natural background sources of radiation. The lifetime risk of developing a cancer from 
the extra radiation in this scan is small: 1 in 1200. To put this number in context, in 
the average population 1 in 4 people develop cancer during their lifetime. Therefore 
your risk would increase from 300 in 1200 to 301 in 1200. If you are female and there 
is a possibility that you are pregnant then we will ask to perform a pregnancy test. 
Radiation can cause damage to babies in the womb so we need to ensure that no 
scans are performed on pregnant women.  
 
There is a low risk of harmful effects on the kidneys or developing an allergic reaction 
from the contrast dye used in the PET-CT scan. The risk from contrast exposure in 
this study will be minimised by excluding patients who have significant kidney disease 
or a history of allergic reactions to contrast dye. If you feel unwell after the scan or 
have any concerns then you should contact a member of the research team on the 
number provided or contact 999 in the unlikely event of an emergency.  
 
The use of medication to slow the heart rate of patients prior to a PET-CT scan is a 
well established procedure which improves the quality of images and minimises the 
dose of radiation required. Such medication will only be prescribed if it is required and 
by an experienced doctor after reviewing your medical history and current list of 
medication. The medications which may be used are called metoprolol and verapamil. 
Metoprolol belongs to a family of drugs called ‘beta-blockers’ and potential side effects 
include cold hands/feet, fatigue, erectile dysfunction, a reduction in your blood 
pressure and making you feel breathless.  These effects are all reversible upon 
stopping the medication. We would avoid giving metoprolol to anybody with a history 
of asthma, airway spasm, a slow heart rate or acute symptoms of heart failure. 
Verapamil belongs to a family of drugs called ‘calcium channel-blockers’ with potential 
side effects including constipation, nausea, headache, ankle swelling and a reduction 
in blood pressure. Similarly, these effects are all reversible upon stoping the 
medication and we would avoid giving verapamil to anybody with a history of a slow 
heart rate or acute symptoms of heart failure. You may be asked to take one of these 
medications for a number of days prior to your scan, in which case you will be provided 
with clearly labelled medication and instructions on how and when it should be taken. 
More commonly, metoprolol or verapamil is given to patients immediately prior to the 
scan as an injection via a plastic tube in one of the veins and this will be under the 




medication or concerns about side effects then please contact a member of the 
research team.  
 
Finally, participating in the study will require that you devote some time to 
consultations and scans. We will endeavour to make these as time-efficient and 
convenient for you as possible. We are also happy to reimburse reasonable travel 
expenses incurred whilst travelling to study visits - please ask a member of the 
research team about this. 
 
 
What if something abnormal is found in my scans or other tests?  
As part of this study we will obtain images of your chest, focusing on your heart. After 
your scan, a specialist will examine these pictures (this will not be done on the day of 
your study). There is a small possibility that we will identify unexpected or unrelated 
changes in the heart or other chest organs. You should be aware that because our 
pictures are taken for a specific research purpose, not all abnormalities that might be 
detected by other CT or PET scans are necessarily seen.  On rare occasions, we 
might find an abnormality that is significant and which should be investigated further. 
Similarly, we will be performing blood tests that may identify unexpected abnormalities 
that could require additional follow-up or treatment.  If we find such a significant 
abnormality from the scan or blood tests then we will inform you and contact your GP 
in order to organise appropriate ongoing care.   
 
Although a significant abnormality is unlikely, you should be aware that if such an 
abnormality is detected then this may have consequences for your treatment. In 
addition, important incidental findings may have implications for your existing and 
future insurance policies (such as increased insurance premiums or difficulty 
arranging cover) and we would strongly advise that you consult your insurance 
provider in such an event.  
 
What happens if I lose the capacity to make decisions? 
If you should lose the capacity to make decisions, we would retain and make use of 
identifiable information and tissue which had already been collected but there would 
be no further participation in the study. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be 
kept strictly confidential and there are laws which safeguard your privacy at every 
stage. Your participation in the study will be recorded in your medical notes. Any 
information about you that leaves the NHS or University will have your name and 
address removed so that you cannot be recognised from it.  
 
Will my GP be informed? 
As long as you agree, we will let your GP know about your participation in the study. 
If any incidental findings are picked up during our tests then these will be reported to 
your GP to consider further tests or review as appropriate.  
 
What will happen to the results of the research study?  
Once we have completed the study and analysed the results, we will submit a paper for 
publication in one of the scientific journals. The results may also be presented at scientific 




who are interested, we will notify you of any publications arising from this research and 
provide you with periodic updates in a newsletter via post or email.  
 
Who is organising the study? 
The study is being organised through the University of Edinburgh in collaboration with 
Papworth Hospital, Cambridge and Bichat University Hospital, Paris. The British Heart 
Foundation is funding the research. Your doctors will not be paid for including you in 
this study. 
 
Who has reviewed the study? 
An NHS Research Ethics Committee has reviewed and approved the study. 
 
Contact for further information 
If you have any questions about the study then please contact Dr Tim Cartlidge via 
telephone on 07732973884 or e-mail at timothy.cartlidge@nhs.net or Dr Marc Dweck 
(Chief Investigator) at marc.dweck@ed.ac.uk.  
 
If you would like to discuss this study with an independent party then please contact 
Dr Cruden, Consultant Cardiologist, who is not directly involved with the study and 
can offer independent advice. Please contact him via his secretary through the Royal 
Infirmary switchboard on 0131 536 1000. 
 
 
If you wish to make a complaint about the study please contact NHS Lothian. 
NHS Lothian Complaints Team 
2nd Floor, Waverley Gate 
2-4 Waterloo Place 
Edinburgh, EH1 3EG 












Volunteer Information Sheet 
  
Cohorts 2 and 3 
 
 
THE 18F-FAABULOUS STUDY 
 
18F-FLUORIDE ASSESSMENT OF AORTIC BIOPROSTHESES 
DURABILITY AND OUTCOMES 
 
 
You are being invited to take part in a research study. Before you decide whether or 
not to participate, it is important that you understand why the research is being done 
and what it will involve. Please read the following information carefully and discuss it 
with others if you wish.  
 
If there is anything that is not clear or if there are questions you would like to ask then 
please contact us for further information. Alternatively, you can also contact Dr 
Cruden, who is not directly involved in this study but who can give you independent 
advice. He can be contacted via the Royal Infirmary of Edinburgh switchboard on 
0131 536 1000 by asking for his secretary. 
 
What is the purpose of the study? 
Narrowing of the main outlet valve of the heart (aortic stenosis) is the most common 
form of heart valve disease in the western world and replacing this valve is the most 
frequently performed heart valve operation. The majority of replacement valves are 
made from animal tissue with the benefit that, unlike metal valves, they do not require 
blood-thinning treatment afterwards. Recently, procedures have developed to replace 
the aortic valve using a key-hole technique, thereby avoiding the need for open heart 
surgery. However, whilst we know that traditional surgical tissue valves last on 
average between 10 and 15 years we do not know how long the new key-hole valves 
will endure. 
 
The main purpose of this study is therefore to use a special type of scan called “PET-
CT” to investigate what happens to these tissue valves (both surgical and key-hole). 
This scan can measure the activity of “calcification” which causes hardening and 
chalkiness of the valve and is the main way in which such valves fail. We believe that 
these scans will predict how long the different types of replacement valve are likely to 
last and potentially to predict when, and in whom, they will need replaced.  
 
Why have I been invited? 
You have been invited to take part in this research because you have a tissue heart 
valve replacement. 
 
Do I have to take part? 
No. It is entirely up to you to decide whether or not to take part. If you do decide to 
take part, you are still free to withdraw at any time without having to give a reason. A 
decision not to take part or to withdraw at a later stage will not affect the standard of 






What will happen to me if I take part? 
You have been provided with this information sheet and will be given at least 24 hours 
to read it over before being contacted by a member of the research team. We will give 
you an opportunity to ask any questions that you might have and ask if you wish to 
participate in the study. If you agree to take part, we will arrange a date for you to 
attend the Clinical Research Facility at the Royal Infirmary of Edinburgh.  
 
At this visit, we will again discuss the study to ensure that you understand eveything 
and will ask for your written consent.  As part of a general assessment, we will ask 
about your symptoms, undertake a full examination of your heart, record an electrical 
tracing of your heart (ECG) and take some blood tests (~60ml = 4 tablespoons of 
blood will be taken). This volume of blood will allow for a range of immediate tests to 
be performed and provide samples for storage which will be valuable in future 
research studies. We will also arrange an ultrasound scan of the heart called an 
echocardiogram.  
 
We will then organise for you to have a PET-CT scan of the heart,  to take place 
during the same visit wherever possible. The PET-CT scan provides detailed images 
of the heart and will require injection of a special tracer about 60 minutes before the 
scan via a plastic tube (cannula) in one of your veins. This special tracer called 
radiolabelled 18F-fluoride is radioactive and highlights areas of active calcium 
formation in the heart. It has been used in humans for 40 years with no major harmful 
effects. Prior to the scan you may also require a medicine called metoprolol or 
verapamil in order to slow your heart rate. Slowing your heart rate will improve the 
quality of images obtained and minimise the dose of radiation which is required for 
the scan. This will be prescribed by an experienced doctor after considering your 
personal medical history and any possible interactions with medications which you 
already take. This medication may need to be taken as a tablet for several days prior 
to the scan and as an injection through the cannula at the time of the scan. During the 
PET-CT there will be a further injection of an iodine-based contrast “dye” via the 
cannula in your arm in order to obtain more detailed information from the images. 
 
The process of taking consent, the clinical assessment and echocardiogram is likely 
to take 90 minutes in total and the PET-CT will take a further 90 minutes, starting from 
injection of the tracer 60 minutes prior to the scan. We therefore estimate that your 
initial visit to hospital will take around 3 hours in total.   
 
After the initial study visit, we will then ask you to return to the Royal Infirmary of 
Edinburgh for follow-up at 1 year and 2 years. This will again involve asking about 
your symptoms, undertaking an examination of your heart, recording an ECG, 
performing an echocardiogram and taking further blood samples. These visits will take 
around 90 minutes each. The 2 year follow-up visit will be combined with a repeat CT 
scan to acquire pictures of your replacement heart valve for comparison with the 
baseline images. The CT scan will take around 30 minutes and will again involve 
injection of an iodine-based contrast “dye” via a cannula in your arm. 
 
Thereafter, follow-up will be conducted via a brief telephone consultation annually at 
3, 4 and 5 years. As part of the study, if you encounter any health complications 
relating to your replacement heart valve then your hospital team will share this 
information with the research team. 
 




Some blood is taken for immediate tests. Any samples obtained from you will be 
retained in an anonymised fashion and will then be frozen and stored so that further 
tests may be performed in the future. We will store these samples for a maximum of 
10 years after which time they will be destroyed in accordance with standard NHS 
Lothian procedure. 
 
What are the possible disadvantages and risks of taking part? 
PET-CT scans are routine medical procedures and are associated with very few side 
effects. The most important side effects are exposure to ionising radiation and 
potential reaction to the contrast dye.  We have a well-developed protocol for PET-
CT imaging that minimises radiation exposure and have clear procedures for 
managing contrast reactions.  
 
The exact amount of radiation used during this type of scan varies but is 
approximately 9 times the amount that you would normally receive in a year from 
natural background sources of radiation. The lifetime risk of developing a cancer from 
the extra radiation in this scan is 1 in 625. To put this number in context, in the average 
population 1 in 4 people develop cancer during their lifetime. Therefore your risk 
would increase from 250 in 1000 to 252 in 1000. If you are female and there is a 
possibility that you are pregnant then we will ask to perform a pregnancy test. 
Radiation can cause damage to babies in the womb so we need to ensure that no 
scans are performed on pregnant women.  
 
There is a low risk of harmful effects on the kidneys or developing an allergic reaction 
from the contrast dye used in the PET-CT scan. The risk from contrast exposure in 
this study will be minimised by excluding patients who have significant kidney disease 
or a history of allergic reactions to contrast dye. If you feel unwell after the scan or 
have any concerns then you should contact a member of the research team on the 
number provided or contact 999 in the unlikely event of an emergency.  
 
The use of medication to slow the heart rate of patients prior to a PET-CT scan is a 
well-established procedure which improves the quality of images and minimises the 
dose of radiation required. Such medication will only be prescribed if it is required and 
by an experienced doctor after reviewing your medical history and current list of 
medication. The medications which may be used are called metoprolol and verapamil. 
Metoprolol belongs to a family of drugs called ‘beta-blockers’ and potential side effects 
include cold hands/feet, fatigue, erectile dysfunction, a reduction in your blood 
pressure and making you feel breathless.  These effects are all reversible upon 
stopping the medication. We would avoid giving metoprolol to anybody with a history 
of asthma, airway spasm, a slow heart rate or acute symptoms of heart failure. 
Verapamil belongs to a family of drugs called ‘calcium channel-blockers’ with potential 
side effects including constipation, nausea, headache, ankle swelling and a reduction 
in blood pressure. Similarly, these effects are all reversible upon stoping the 
medication and we would avoid giving verapamil to anybody with a history of a slow 
heart rate or acute symptoms of heart failure. You may be asked to take one of these 
medications for a number of days prior to your scan, in which case you will be provided 
with clearly labelled medication and instructions on how and when it should be taken. 
More commonly, metoprolol or verapamil is given to patients immediately prior to the 
scan as an injection via a plastic tube in one of the veins and this will be under the 
direct supervision of an experienced doctor. If you have any questions about the 
medication or concerns about side effects then please contact a member of the 





Finally, participating in the study will require that you devote some time to 
consultations and scans. We will endeavour to make these as time-efficient and 
convenient for you as possible. We are also happy to reimburse reasonable travel 
expenses incurred whilst travelling to study visits - please ask a member of the 
research team about this. 
 
What if something abnormal is found in my scans or other tests?  
As part of this study we will obtain images of your chest, focusing on your heart. After 
your scan, a specialist will examine these pictures (this will not be done on the day of 
your study). There is a small possibility that we will identify unexpected or unrelated 
changes in the heart or other chest organs. You should be aware that because our 
pictures are taken for a specific research purpose, not all abnormalities that might be 
detected by other CT or PET scans are necessarily seen.  On rare occasions, we 
might find an abnormality that is significant and which should be investigated further. 
Similarly, we will be performing blood tests that may identify unexpected abnormalities 
that could require additional follow-up or treatment.  If we find such a significant 
abnormality from the scan or blood tests then we will inform you and contact your GP 
in order to organise appropriate ongoing care.   
 
Although a significant abnormality is unlikely, you should be aware that if such an 
abnormality is detected then this may have consequences for your treatment. In 
addition, important incidental findings may have implications for your existing and 
future insurance policies (such as increased insurance premiums or difficulty 
arranging cover) and we would strongly advise that you consult your insurance 
provider in such an event.  
 
What happens if I lose the capacity to make decisions? 
If you should lose the capacity to make decisions, we would retain and make use of 
identifiable information and tissue which had already been collected but there would 
be no further participation in the study. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be 
kept strictly confidential and there are laws which safeguard your privacy at every 
stage. Your participation in the study will be recorded in your medical notes. Any 
information about you that leaves the NHS or University will have your name and 
address removed so that you cannot be recognised from it.  
 
Will my GP be informed? 
As long as you agree, we will let your GP know about your participation in the study. 
If any incidental findings are picked up during our tests then these will be reported to 
your GP to consider further tests or review as appropriate.  
 
What will happen to the results of the research study?  
Once we have completed the study and analysed the results, we will submit a paper for 
publication in one of the scientific journals. The results may also be presented at scientific 
meetings but you will not be identifiable in any published or presented results.  For those 
patients who are interested, we will notify you of any publications arising from this 
research and provide you with periodic updates in a newsletter via post or email.  
 




The study is being organised through the University of Edinburgh in collaboration with 
Papworth Hospital, Cambridge and Bichat University Hospital, Paris. The British Heart 
Foundation is funding the research. Your doctors will not be paid for including you in 
this study. 
 
Who has reviewed the study? 
An NHS Research Ethics Committee has reviewed and approved the study. 
 
Contact for further information 
If you have any questions about the study then please contact Dr Tim Cartlidge via 
telephone on 07732973884 or e-mail at timothy.cartlidge@nhs.net or Dr Marc Dweck 
(Chief Investigator) at marc.dweck@ed.ac.uk.  
 
If you would like to discuss this study with an independent party then please contact 
Dr Cruden, Consultant Cardiologist, who is not directly involved with the study and 
can offer independent advice. Please contact him via his secretary through the Royal 
Infirmary switchboard on 0131 536 1000. 
 
 
If you wish to make a complaint about the study please contact NHS Lothian. 
NHS Lothian Complaints Team 
2nd Floor, Waverley Gate 
2-4 Waterloo Place 
Edinburgh, EH1 3EG 













    
Patient Name: 
Patient DoB: 
Patient Identification Number for this trial: 
CONSENT FORM 
 
THE 18F-FAABULOUS STUDY 
 
18F-FLUORIDE ASSESSMENT OF AORTIC BIOPROSTHESES 




Name of Researchers: Dr Marc R. Dweck and Professor David E. Newby 
 
Please initial all boxes  
1. I confirm that I have read and understand the information sheet dated 15/09/14 
(Cohort 1) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.  
2. I agree to participate, understand that my participation is voluntary and that I 
am free to withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that this will not influence the medical treatment that is planned for 
me in any way. 
4. I understand that the PET CT scan performed will be associated with exposure 
to a dose of radiation. 
5. I understand that the PET CT scan will require the administration of contrast 
agent and a radioactive tracer. 





7. I understand that anonymised blood samples and heart valve tissue will be 
stored (under NHS Lothian's Tissue Governance Standards) for analysis as part 
of this study. 
8. I understand that anonymised blood samples and heart valve tissue will be 
stored (under NHS Lothian’s Tissue Governance Standards) for potential use 
in future research studies which will be subject to further ethical approval. 
9. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from the regulatory authorities 
and from the Sponsors (NHS Lothian and The University of Edinburgh) where 
it is relevant to my taking part in this research. I give permission for those 
individuals to have access to my records. 
10. I agree to my GP being informed of my participation in the study, and that he or 
she will be informed of any incidental findings of clinical significance arising from 
my participation in the study. 
11. I agree to the further use of identifiable data/tissue in the event of a loss of 




            
Name of Participant  Date    Signature 
                                
 
            
Name of Person   Date    Signature  







    
Patient Name: 
Patient DoB: 
Patient Identification Number for this trial: 
CONSENT FORM 
THE 18F-FAABULOUS STUDY 
 
18F-FLUORIDE ASSESSMENT OF AORTIC BIOPROSTHESES 
DURABILITY AND OUTCOMES 
 
 
Cohorts 2 and 3 
 
Name of Researchers: Dr Marc R. Dweck and Professor David E. Newby 
 
Please initial all boxes  
12. I confirm that I have read and understand the information sheet dated 01/12/14 
(Cohorts 2 and 3) for the above study.  I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily.  
13. I agree to participate, understand that my participation is voluntary and that I 
am free to withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
14. I understand that this will not influence the medical treatment that is planned for 
me in any way. 
15. I understand that the PET CT and CT scans performed will be associated with 
exposure to a dose of radiation. 
16. I understand that the PET CT scan will require the administration of a contrast 
agent and a radioactive tracer. 





18. I understand that anonymised blood samples will be stored (under NHS 
Lothian's Tissue Governance Standards) for analysis as part of this study. 
19. I understand that anonymised blood samples will be stored (under NHS 
Lothian’s Tissue Governance Standards) for potential use in future research 
studies which will be subject to further ethical approval. 
20. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from the regulatory authorities 
and from the Sponsors (NHS Lothian and The University of Edinburgh) where 
it is relevant to my taking part in this research. I give permission for those 
individuals to have access to my records. 
21. I agree to my GP being informed of my participation in the study, and that he or 
she will be informed of any incidental findings of clinical significance arising from 
my participation in the study. 
22. I agree to the further use of identifiable data/tissue in the event of a loss of 





            
Name of Participant  Date    Signature 
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Dr Marc Dweck 
BHF Centre for Cardiovascular Science 
Queen's Medical Research Institute 
47 Little France Crescent 
Edinburgh 
EH16 4TJ 
Date 24 September 2014 
Your Ref  
Our Ref  
 
Enquiries to:   Sandra Wyllie 
Extension:      35473  





Dear Dr Dweck  
 
Study title: 18F-Fluoride Assessment of Aortic Bioprostheses 
Durability and Outcomes 
REC reference: 14/SS/1049 
IRAS project ID: 147780 
 
Thank you for your letter of 19 September 2014, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this opinion letter.  Should you wish to provide a substitute contact point, require further 
information, or wish to make a request to postpone publication, please contact the REC 
Manager, Mrs Sandra Wyllie, sandra.wyllie@nhslothian.scot.nhs.uk. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised, subject to the conditions specified below. 
 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved 
in the study in accordance with NHS research governance arrangements. 
 
